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Currently, infallible cancer treatment has not been achieved. Doxorubicin (DOX), an active 
anticancer drug, initiates the apoptotic signaling pathway by intercalating topoisomerase-II, 
resulting in DNA replication disorder and producing reactive oxygen species that can damage 
DNA and activate cell death receptors. However, long-term DOX administration is always 
accompanied with serious multidrug resistance (MDR) and adverse side-effects. Therefore, 
delivery systems for DOX and gene drug, such as miRNA-21 inhibitor (miR-21i) which 
mitigates MDR, have been developed to reduce side-effects caused by non-selective cellular 
uptake of co-drugs in the absence of suitable delivery systems. However, difficulties in 
designing delivery systems for different types of drugs to achieve both high therapeutic efficacy 
and low side-effects have been reported.  
In this thesis, various biodegradable and biocompatible smart microgels are developed for 
DOX and gene co-delivery to achieve maximal anticancer performance and minimal side-
effects. The microgel delivery carriers are prepared by crosslinking biocompatible low 
molecular weight polyethyleneimine (PEI800) using glutathione-cleavable diselenide 
crosslinkers. To the carriers, DOX is conjugated via various intracellular microenvironment 
sensitive linkers, and genes are electrostatically loaded to glutathione-cleavable 
polyethyleneimine. Finally, anionic hyaluronic acid (HA) surface coating is able to inhibit 
serum protein adsorption during blood circulation and promote HA receptor-mediated 
endocytosis for selective metastatic cancer cells. The hydrodynamic sizes of resulting nano-
drugs at 100–200 nm allow prolonged circulation. The developed nano-drugs degrade into less 
than 10 nm fragments in the glutathione-rich cytosol of cancer cells by cleaving diselenide 
crosslinkers, allowing intensive gene release and complete urinary excretion. Real-time tracks 
of release profiles are developed using fluorescence quenching technique. 
xix 
 
On the other hand, to eliminate premature release, DOX is conjugated to microgel carriers 
through various linkers for efficiently controlled spatiotemporal release in cancer lysosomes, 
such as acid-responsive hydrazone linkers, glutathione-cleavable diselenide linkers and 
enzyme-cleavable peptide linkers. The system comprising of DOX with a hydrazone bond 
demonstrates 4.4-fold higher in vitro anticancer performance on MDA-MB-231 cell line than 
free DOX. The nano-drug system of miR-21i and conjugated DOX via hydrazone and 
diselenide dual bonds completely surpasses DOX premature leakage in physiological condition 
and results in a high survival rate of over 95 % for HEK293T kidney cell line at a DOX 
concentration of 2.5 µg mL−1, but it reveals 3.2-fold increase in therapeutic effect on the 
multidrug-resistant cancer cell line of MDA-MB-231-R12w compared with free DOX. To 
simplify DOX loading process, diselenide crosslinkers can be used for both microgel synthesis 
and DOX conjugation to produce a simultaneous release system of gene and DOX in cytosol. 
The introduction of ATP aptamer to the miR-21i and DOX co-delivery system further increases 
intracellular DOX accumulation in MDA-MD-231-R12w cells with 4.2-fold higher anticancer 
performance than free DOX but with low cytotoxicity to healthy cells. To achieve sequential 
release, the nano-drug system of miR-21i and conjugated DOX with a caspase-3-cleavable 
DEVDC peptide linker enables the step release of miR-21i followed by DOX. Compared with 
free DOX, this systems demonstrates a 7.3-fold increase in anticancer effect on MDA-MB-
231-R24w and negligible side effects.  
In summary, we have developed various smart nano-drugs with outstanding advantages of low 
cytotoxicity, complete biodegradability, targeting and selective delivery and high anticancer 
performance to MDR cells. Our approach suppresses traditional gene and drug delivery 
concepts, and advances knowledge for successive design of delivery systems in clinical 
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Chapter 1. Introduction                                                                  
 
1.1 Background 
To date, cancer is one of the highest causes of human death, but cancer treatment remains an 
unsolved task because of the unusual growth patterns of cancer cells. Opposed to healthy cells, 
cancer cells lose apoptotic functions and grow rapidly [1]. The abnormally growing cells 
undergo epithelial to mesenchymal transition (EMT) that induces the loss of cell adhesion and 
polarity [2], and the mesenchymal stem cells then accumulate to form an abnormal cell mass 
being referred to as tumor. Tumor cells secrete vascular endothelial growth factor (VEGF), 
which stimulates tumor vasculature formation [3]. The tumor cells metabolize and transport 
blood and nutrients to newly generated tumor cells through the tumor vasculature. The tumor 
cells utilize the vasculature for invasive migration into other tissues, becoming a malignant 
tumor being termed as cancer [4].  
Anticancer chemotherapy targets the abnormalities of cancer cells such as apoptotic function 
loss, EMT and tumor angiogenesis [5-7]. However, long-term administration is accompanied 
with serious multidrug resistance (MDR) and dose-dependent side-effects. MDR mechanisms 
are the source of multiple self-defense systems of cancer cells, including target alteration, 
detoxification, activation of pro-survival pathways, and overexpression of ATP-binding 
cassette (ABC) transporters [8-11]. The MDR-induced reduction of therapeutic effect prompts 
the increased dosage of anticancer drugs, causing severe side-effects such as cardiotoxicity, 
hepatotoxicity and nephrotoxicity [12-14]. 
Co-drug therapy with chemotherapeutic and gene drugs exerts synergistic effects on anticancer 
treatment by reversing MDR and reducing dosage. Recent genetic drug developments include 
microRNAs (miRNAs), which are small non-coding RNAs of approximately 22 nucleotides 
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[15]. The miRNAs can target multiple messenger RNAs (mRNAs) to regulate gene expression 
associated with apoptosis, EMT, angiogenesis, and MDR in malignant tumor cells [16-19]. 
miRNA-21 (miR-21), a cancer-promoting oncogenic miRNA, downregulates tumor suppressor 
genes that inhibit the pro-survival pathways in cancer cells [20]. miR-21 inhibitor (miR-21i) 
hinders the activity of miR-21 and upregulates the tumor suppressor genes. Aptamers are short 
single-stranded oligonucleotides that strongly bind specific molecules such as adenosine 
triphosphate (ATP) [21]. The ATP aptamer (Apt) may act as a gene drug to isolate ATP, which 
is a driving force of the ABC transporters involved in MDR. 
On the other hand, non-selective cellular uptake of co-drugs in the absence of suitable delivery 
systems leads to side-effects as well [22]. The demands to enhance therapeutic efficiency and 
minimize side effects have prompted the development of co-delivery systems. Delivery 
systems have been developed with improved functional conditions to satisfy some of the 
essentially required factors in the course of systemic administration such as non-toxic materials, 
effective loading of co-drugs, degradation avoidance, prolonged blood circulation, passive and 
active targeting, effective cellular uptake, endosomal escape, control of spatiotemporal release, 
complete urinary excretion of the drug-released carriers from patients’ body, and traceability 
of their biodistribution [23, 24]. However, the functional conditions of the delivery systems 
that are required to achieve all the factors can be in conflict with each other, such as charges, 
sizes, and mechanisms of co-drug loading and release, resulting in inefficient therapeutic 
effects or less biocompatibility. Moreover, both anticancer synergy and biocompatibility 
require the effective control of the spatiotemporal release of co-drugs. In this thesis, we propose 
advanced multifunctional polymer microgels to selectively and efficiently deliver doxorubicin 
(DOX) and gene drugs to multidrug-resistant cancer cells by satisfying all the above factors. A 
series of intracellular stimuli-cleavable linkages for DOX conjugation was designed to enhance 
controllability of the spatiotemporal release for both exceptionally high anticancer effects and 
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negligible side effects and is presented in this thesis to confirm its potential for the further 
therapeutic applications. 
1.2 Aim and Objectives 
This thesis aims to develop novel multifunctional microgels as the co-drug delivery carriers of 
a model drug DOX and a model microRNA (miR-21i) to maximize their anticancer 
performance and minimize relevant side-effects. The detailed objectives are 
1. To produce low-toxic and biodegradable microgel-based delivery carriers through the 
reaction of diselenide crosslinkers and low molecular weight branched 
polyethyleneimine (PEI800). 
2. To load the model anticancer drug of DOX to the microgel carriers through conjugation 
via different intracellular stimuli-responsive linkers and load miR-21i and/or Apt via 
electrostatic interaction. 
3. To handle surface modification via hyaluronic acid (HA) coating to eliminate serum 
protein adsorption and promote receptor-meditated endocytosis. 
4. To evaluate the performance of resulting nano-drugs such as controlled release of DOX 
and miR-21i ex vivo and in vitro, biocompatibility with normal cell line HEK293T, and 
anticancer effects on metastatic breast cancer cell line MDA-MB-231 and multidrug 
resistant cancer cell line MDA-MB-231-R. 
5. To further improve synergetic anticancer efficacy by introducing Apt for the inhibition 
of ABC transporters, or developing sequential release systems of miR-21i and DOX.  
1.3 Thesis outline 
This thesis has seven chapters. Chapter 1 introduces the background of cancer treatment 
strategic approaches. After highlighting research gaps, aim and objectives of the thesis is 
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defined. Chapter 2 reviews the rationale for co-delivery system design on cancer treatment after 
understanding DOX-induced apoptotic pathway, MDR, side-effects and co-drug synergies of 
miR-21i and Apt. Current difficulties in designing co-delivery systems before administration, 
in blood circulation, in extracellular/intracellular microenvironment, and over the delivery 
course are critically analyzed. Chapter 3 proposes smart multifunctional microgels with HA 
surface coating for selective co-delivery of DOX and miR-21i to enhance anticancer effects. 
Synthesis of microgels utilizing low cytotoxic PEI800 and diselenide crosslinkers allows to 
load miR-21i electrostatically and release in GSH-rich cancer cytosol, and DOX conjugation 
via a hydrazone bond enables the release of DOX in endosome/lysosome of cancer cells. 
Chapter 4 proposes advanced microgels with dual-lock conjugated DOX and electrostatically 
interacted miR-21i to further improve their biocompatibility with normal cells and achieve 
anticancer synergy in multidrug-resistant cancer cells. Conjugation of DOX to microgels via 
hydrazone and diselenide dual-lock suppresses premature leakage under mimicked 
physiological conditions and promotes intensive release in a mimicked sequential route of 
lysosome and cytosol. Chapter 5 develops traceable nanomedicines of DOX, miR-21i, and Apt 
for further enhancement of the therapeutic effects on cancer cells with MDR by inhibiting miR-
21 and ABC transporters. DOX conjugation to the microgels via diselenide bond enables DOX 
release in cancer cell cytosol with GSH, and BHQ2 conjugation to the microgels allow to 
monitor DOX release in vitro. Chapter 6 proposes smart microgels containing DEVDC 
peptides for the sequential release of miR-21i followed by DOX to maximize therapeutic 
effects on multidrug-resistant cancer cells and minimize side effects. DOX conjugation to the 
microgels via peptide linkers containing DEVDC allows to release DOX in the presence of 
activated caspase-3 enzyme after reversing MDR by formerly released miR-21i in MDA-MB-
231-R cells. Chapter 7 concludes key scientific contribution from the thesis and future research 
directions are recommended. 
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1.4 Key contributions of this thesis 
This thesis demonstrates the strategic development of anticancer drug/gene co-delivery carriers 
based on a deep understanding of pro-apoptotic and pro-survival pathways for a high feasibility 
of complete therapeutic effects and negligible side effects. The research outcomes directly 
contribute to the development of low toxic intracellular stimuli-responsive drug and gene co-
delivery systems. An outline of key contributions is presented below: 
1. For the first time, we designed a series of nano-drugs from our developed biocompatible 
and biodegradable low-toxic smart microgels to achieve high drug co-loading ability, 
no premature leakage and protein adsorption with blood circulation,  selective cellular 
uptake to target cancer cells, low toxic to heathy cells and high anticancer effects to 
MDR cells.  
2. For the first time, we developed nanomedicines by introducing Apt as a supplementary 
gene drug to inhibit ABC transporters in multidrug resistant cancer cells. 
3. For the first time, we developed the sequential release approach of miR-21i and DOX 
from the co-delivery systems.  
4. For the first time, we chemically conjugated BHQ2 to the microgels to provide real-
time tracing of DOX release profiles and crucial information concerning the synergetic 
interaction between DOX and supplementary gene drugs of miR-21i or Apt.  
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Infallible cancer treatment has yet to be achieved. Doxorubicin (DOX) as an active anticancer 
drug causes apoptosis as well as serious multidrug resistance and adverse side effects. The 
merits and defects of DOX are reviewed in the scope of its interaction with physiological 
mechanisms and signaling pathways. Co-therapy using supplementary drugs such as miRNA-
21 inhibitor or adenosine triphosphate aptamer is reviewed to devise a strategy to enhance 
therapeutic efficacy by mitigating the side effects caused by long-term DOX administration. 
We also review detailed mechanisms for adverse side effects caused by non-selective delivery 
of co-drugs to normal cells. The development of modern delivery systems with multifunctional 
conditions to satisfy all essential factors during the delivery course of before administration, in 
blood circulation, in extracellular/intracellular microenvironment and overall the delivery 
course is analyzed to provide guidance on rationale design of potential co-drug delivery 
systems with enhancing therapeutic efficiency and minimizing side effects.  
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Because of the abnormal growth of cancer cells, complete treatment of cancers has not been 
achieved. Cancer growth is rapid and widespread, and anticancer chemotherapy is a relatively 
less invasive treatment method than therapeutic radiation and local surgery. The initial 
anticancer effects from chemotherapy decline with the increased rounds of chemotherapy that 
accompany the recurrence and resistance of cancer cells. Thus, patients suffer from the recurred 
cancer as well as dose-dependent side effects. Delivery carrier-mediated co-drug therapy with 
combined anticancer chemotherapeutic and nucleic acid drug has great potential for enhancing 
the anticancer effects and minimizing side effects.  
This review aims to provide a crucial rationale to encourage the successive design of the above-
mentioned co-drug delivery systems.  In detail, the advantages and disadvantages of DOX 
(doxorubicin) -based chemotherapy are reviewed against the scope of intracellular signaling 
pathways to support therapeutic strategies. To enhance its anticancer efficacy, co-therapy of 
DOX and different gene drugs, including microRNA 21 inhibitor (miR-21i) and adenosine 
triphosphate (ATP)-aptamer (Apt), is further analyzed with an explanation of their synergistic 
effects on signaling pathways to mitigate DOX-induced multidrug resistance (MDR). 
Strategies for increasing therapeutic efficiency with new delivery carriers by overcoming the 
causes of side effects will be reviewed for each delivery course. The mismatches between the 
essential factors in an ideal delivery course and functional conditions of the delivery systems 
will be discussed to outline current research gaps and significant information for the feasibility 
of the systems in potential clinical application. 
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2.2 DOX as an anticancer drug 
2.2.1 Merits of DOX in anticancer therapy 
DOX is one of the most effective anticancer drugs against many types of cancers, such as breast 
cancer [1], gastric cancer [2], non-small-cell lung cancer [3], ovarian cancer [4], and bladder 
cancer [5]. DOX was the first anthracycline [6], consisting of a hydrophobic tetracyclic ring 
and a glycoside-linked daunosamine sugar (Figure 2.1).  
 
Figure 2.1 Chemical structure of doxorubicin (DOX) consisting of a tetracyclic ring, a 
glycoside-linked daunosamine sugar and functional groups.  
 
In DOX, the tetracyclic ring is an aligned structure of a methoxybenzene, benzoquinone, 
hydroquinone, and cyclohexane ring. A short side chain of the cyclohexane ring contains a 
carbonyl group and a primary alcohol. A primary amine group is located at the sugar moiety. 
The DOX morphology causes an active anticancer effect initiated by intercalation with 
topoisomerase II (Topo II) and the production of reactive oxygen species (ROS) (Figure 2.2). 
On the one hand, DOX acts as an initiator in the Topo II intercalation-induced anticancer 
pathways. Topo II is a key enzyme for the transcriptional activity of DNA via unwinding of 
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the twisted DNA double helix without altering its sequence [7]. The hydrophobic tetracyclic 
ring of DOX allows intermediate intercalation with both a Topo II active site and DNA bases 
in nucleus, forming a stable Topo II-DOX-DNA ternary complex that inhibits Topo II activity 
in DNA replication [7]. The Topo II intercalation-induced DNA damage promotes p53 
activation, which stimulates tumor-suppressing pathways [8]. The nuclear transcription factor 
p53 is involved in tumor cell cycle arrest. p53 negatively affects the activity of proto-oncogene 
c-Jun as a subunit of activator protein 1 transcription [9]. The inhibition of c-Jun activity assists 
in hindering the cell cycle progression from G1- to S-phase and tumor cell proliferation, 
resulting in cancer cell cycle arrest [10]. Furthermore, p53 activation caused by DNA damage 
drives the mitochondrial apoptotic pathway in tumor cells via upregulation of B-cell 
lymphoma-2 (Bcl-2)-associated X protein (Bax), a pro-apoptotic regulator in the Bcl-2 protein 
family [11]. The relative expression of Bax to the anti-apoptotic protein Bcl-2 contributes to 
the apoptotic pathway. Both Bax-Bcl-2 heterodimers and Bax homodimers allow mitochondria 
to release the pro-apoptotic factor cytochrome c (cyt c) while Bcl-2 homodimers inhibit its 
release [12]. Cytoplasmic cyt c interacts with both apoptotic peptidase activating factor-1 and 
procaspase-9 to form an apoptosome and activate caspase-9 [13]. The active caspase-9 
subsequently activates caspase-3, and the caspase cascade culminates with apoptosis in tumor 
cells via a number of protein cleavage and DNA fragmentation mechanisms [11]. 
On the other hand, DOX acts as a free radical intermediate to stimulate ROS production-
induced anticancer pathways. Reduced nicotinamide adenine dinucleotide phosphate (NADPH) 
in the cytosol acts as a cellular anti-oxidative defense system [14]. The NADPH transfers one 
electron to DOX in a metabolic process by reducing quinone in the tetracyclic ring of DOX to 
a semiquinone moiety [15]. The semiquinone is promptly oxidized back to quinone by reducing 
oxygen as an electron acceptor, thereby generating ROS such as superoxide anion and 
hydrogen peroxide [6]. The semiquinone is also oxidized to its parent quinone by reducing the 
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glycosidic linkage of DOX between a daunosamine sugar and a cyclohexane ring in an 
anaerobic state and generating 7-deoxyaglycone [16]. The removal of the sugar moiety from 
DOX increases the lipid solubility of the 7-deoxyaglycone metabolite, which intercalates with 
the inner mitochondrial membrane and results in ROS production [16]. During the redox 
cycling, DOX can form a complex with intracellular iron, and the complex transforms 
superoxide anion and hydrogen peroxide to more reactive hydroxyl radicals as more toxic ROS 
[15].  
The higher production of ROS than the cellular anti-oxidative defense systems brings about 
oxidative stress that can induce cell death via two routes. The oxidative stress can directly 
damage DNA or mitochondria to stimulate apoptotic signaling pathways initiating from p53 or 
Bax to cause caspase-9/caspase-3 activation, resulting in cell death [17]. The other is the death 
receptor-induced apoptotic pathway. ROS over-production can activate the transmembrane 
death receptors of the tumor necrosis factor (TNF) receptor superfamily, including Fas, TNF 
receptor 1 (TNF-R1), and TNF-related apoptosis-inducing ligand receptor 1/2 [18]. This 
activation can recruit Fas-associated protein with death domain, which is an adaptor protein, 
and procaspase-8 to form death-inducing signaling complex, which activates caspase-8 and its 
downstream caspase-3, thereby resulting in cell death. Caspase-8 can interconnect the two 
death pathways. Caspase-8 stimulates the production of truncated BH3 interacting death 
domain (tBid) that inhibits the activity of Bcl-2 in mitochondria [18]. Inhibition of Bcl-2 
facilitates the mitochondria-mediated caspase-9 activation required for apoptosis. 
Work carried out by Pilco-Ferreto and Calaf well supports the DOX-induced apoptotic 
pathways in different types of breast cancer cell lines, MCF-10F, MCF-7, and MDA-MB-231 
[19]. DOX administration leads to upregulation of caspase-9 and caspase-3 in all of the cell 
lines, indicating activation of the mitochondrial apoptotic pathway. Hydrogen peroxide 
production and upregulation of caspase-8 protein are also observed in MCF-10F and MDA-
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MB-231 as evidence of the death receptor-mediated pathway. Bcl-2 downregulation and Bax 
upregulation by DOX in the cancer cells proves the crosstalk between the two pathways. Thus, 
these results indicate that DOX effectively activates apoptosis via two signaling pathways 
starting from nucleus and cytosol of the cell lines. 
 
 
Figure 2.2 DOX-induced apoptotic pathways. The intrinsic pathway indicates the 
mitochondrial pathway initiated by Topo II intercalation or ROS-induced DNA damage in the 
nucleus. The extrinsic pathway indicates the death receptor-mediated pathway that is initiated 
by ROS production by DOX in cytosol. Casp represents caspase. 
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2.2.2 Defects of DOX in anticancer therapy 
Despite the wide clinical utilization of DOX for its merits, long-term administration brings 
about clinical defects. The culture of cancer cell lines in a DOX-incorporated culture medium 
for > 3 months has demonstrated that the cell lines gain gradual tolerance to the 
chemotherapeutic agent with a decreasing cell death rate following identical doses of the agent 
[20, 21]. The surviving cancer cells enhance their self-defense systems, known as multidrug 
resistance (MDR), which resultantly increases drug dosage and dose-dependent side effects. 
2.2.2.1 MDR 
Long-term administration-induced MDR to DOX causes target alteration, detoxification, 
activation of pro-survival pathways, and overexpression of ATP-binding cassette (ABC) 
transporters. 
2.2.2.1.1 Target alteration and detoxification 
Tumor cells can avoid the effects of DOX treatment by alteration of the DOX target, Topo II, 
via mutations or reducing its expression [12, 22]. To counterbalance the role of Topo II, 
topoisomerase I is overexpressed in cells lacking Topo II [23]. 
Increasing levels of glutathione (GSH) and glutathione S-transferase have been observed in 
tumor cells following the administration of low-dose DOX [24, 25]. The thiol molecules are 
involved in detoxifying free radicals and ROS as anti-oxidative defense systems. 
2.2.2.1.2 Pro-survival pathways 
Importantly, the exposure of DOX to tumor cells can activate a number of pro-survival 
pathways to inhibit apoptosis and rather promote survival, cell growth, angiogenesis, invasion, 
and metastasis (Figure 2.3). Following chemotherapy, Bcl-2 expression in a DOX-resistant 
myeloid leukemia cell line, HL-60-DOX, decreases far less than that in DOX-sensitive HL-60 
[26]. An abundant amount of the anti-apoptotic Bcl-2 proteins can interrupt the activity of pro-
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apoptotic Bax proteins in the formation of pores on the outer membrane of mitochondria [13]. 
Since cyt c can be released through these pores, Bcl-2 upregulation can inhibit the 
mitochondria-mediated apoptotic pathway. 
DOX-based chemotherapy is accompanied by overexpression of the epidermal growth factor 
receptor (EGFR) family, which enhances chemotherapeutic resistance [27]. The EGFR 
family is a transmembrane tyrosine kinase receptor family, and their cytoplasmic domains 
can activate downstream signaling pathways such as the phosphatidylinositol-3-kinase 
(PI3K)/Akt pathway, rat sarcoma (RAS)/rapidly accelerated fibrosarcoma (RAF)/mitogen-
activated protein kinase (MAPK) pathway, and Janus kinase (JAK)/signal transducers and 
activators of transcription (STAT) pathway [28].  
PI3K/Akt pathway 
The PI3K/Akt pathway is associated with cancer cell survival via apoptosis inhibition and 
supporting the cancer cell cycle and angiogenesis. The PI3K/Akt pathway inactivates the pro-
apoptotic protein of Bcl-2-associated agonist of cell death and procaspase-9 [29]. Blocking the 
apoptotic pathway for caspase-9 activation encourages cancer cell survival. Akt in the pathway 
downregulates p53 in the nucleus by phosphorylating a proto-oncogene of mouse double 
minute 2 homolog [29]. Loss of p53 inhibits apoptosis. The PI3K/Akt pathway hinders the role 
of p21 and p27 in inhibiting the cell cycle the G1 phase. Phosphorylation of p21 and p27 by 
the PI3K/Akt pathway impairs their nuclear localization from cytoplasm, resulting in 
progression of the cancer cell cycle and cancer growth [30]. Activation of mammalian target 
of rapamycin (mTOR), a downstream pathway of PI3K/Akt, transmits a signal to increase the 
secretion of vascular endothelial growth factor (VEGF) and accelerates tumor angiogenesis 
and therapeutic resistance [31]. 




Figure 2.3 Pro-survival pathways: PI3K/Akt/mTOR, RAS/RAF/MAPK and JAK/STAT, and 
roles of miRNA-21 (miR-21) in downregulating multiple inhibitors of the survival pathways. 
 
RAS/RAF/MAPK pathway 
The RAS/RAF/MAPK pathway is another downstream signaling pathway of the cytoplasmic 
tyrosine kinase domain [32]. The MAPK pathway includes extracellular signal-regulated 
kinase (ERK), which promotes cell cycle progression from G1- to S-phase by inhibiting the 
activity of retinoblastoma tumor suppressor protein (Rb) [33]. The ERK in the MAPK pathway 
is also involved in the secretion of transforming growth factor β (TGF-β) that induces epithelial 
to mesenchymal transition (EMT), a process whereby cancer cells lose adhesion to their 
surroundings and subsequently migrate as a metastasis [34]. Notably, ERK2 activates EMT 
  Chapter 2 
21 
 
transcription factors as well as CD44 overexpression as a biomarker of cancer stem cells (CSCs) 
in breast cancer cell line MCF-10A [35]. Cancer cells include a small percentage of CSCs, 
which are capable of recurrence, invasive metastasis, heterogeneous tumorigenesis, and 
resultant resistance to chemotherapy [36]. 
Environmental stress induces a MAPK pathway downstream of the c-Jun N-terminal kinases 
(JNK) pathway that plays roles in cancer as both a tumor suppressor and a stimulator of 
oncogenesis [37]. While JNK activation assists apoptosis by phosphorylating Bcl-2 protein and 
activating Bax [38], the JNK pathway rather encourages drug resistance by downregulation of 
p53 expression through its downstream effector c-Jun [9]. In addition to p53 regulation, c-Jun 
activation directly influences VEGF expression and angiogenesis in invasive breast cancer [10]. 
Importantly, the JNK signaling pathway maintains the mesenchymal properties of human 
epidermoid carcinoma cells via the downstream transcriptional factors of snail and twist 1 [39]. 
Such angiogenesis and sustainable mesenchymal properties allow cancer cells to avoid the 
effects of chemotherapy. 
JAK/STAT pathway 
In the JAK/STAT pathway downstream of the EGFR family, JAK stimulates the formation of 
STAT dimers by phosphorylating tyrosine residues, and the dimers translocated in the nucleus 
activate matrix metalloproteinase-1 (MMP-1) [40]. MMP-1 is a collagen-digesting enzyme that 
is essentially required to break down the extracellular matrix for the migration of human bone 
marrow-derived mesenchymal stem cells and myoblasts [41, 42]. This suggests that activation 
of the JAK/STAT pathway in cancer cells may promote their migration and chemotherapeutic 
resistance. 
  Chapter 2 
22 
 
2.2.2.1.3 ABC transporter  
DOX administration significantly increases ABC transporters in invasive cancer cell lines 
MDA-MB-231 and MDA-MB-435 via upregulation of EMT markers [43]. Activation of a 
JNK/c-Jun signaling pathway is has also been correlated with ABC transporter overexpression 
in human colon cancer cell line SW1116/HCPT [44]. The ABC transporters are a superfamily 
of bifunctional transmembrane proteins that import hydrophilic nutrients into the cytoplasm 
and export hydrophobic substrates (including cancer drugs, lipids, and antigenic peptides) out 
of the cytoplasm [45]. ATP hydrolysis via a pair of cytoplasmic nucleotide-binding domains 
converts the structure from a pair of transmembrane domains in the transporters facing inward 
to an outward-facing direction when transporting hydrophobic anticancer drugs [45]. The 
overexpression of ABC transporters in cancer cells plays a key role in MDR as DOX exporters, 
thereby reducing the intracellular accumulation of DOX and the demand for an increased 
dosage.  
2.2.2.2 Side effects 
MDR allows cancer cells to tolerate constant chemotherapy and confers a high probability of 
survival, which correspondingly requires higher dosages of anticancer drugs to compensate for 
the loss of treatment effectiveness. Long-term DOX administration induces dose-dependent 
side effects such as heart failure, liver injury, chronic kidney dysfunction, and skeletal muscle 
function loss [46-49].  
As presented in Figure 2.4, in addition to the side effects, administration of free DOX without 
any carrier demonstrates a far lower cellular uptake by tumors compared with that of other 
normal organs such as the spleen, kidneys, liver, lung, heart, and intestine [50]. The 
hydrophobicity of protonated free DOX in the slightly acidic extracellular cancer environment 
can limit its interaction with the lipid cellular membrane, whereas the hydrophobicity of 
unprotonated free DOX at the neutral pH of normal extracellular conditions can promote higher 
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transmembrane permeation [51]. Eksborg’s partition experiments demonstrate that dimer and 
tetramer formation with protonated DOX in the acidic extracellular aqueous phase could be the 
cause of poor diffusion to intracellular organic phase and the reduced cellular uptake by tumors 
[52]. 
Such side effects that negatively compensate the anticancer effects of DOX promote the 
development of diverse strategies to enhance therapeutic efficacy via mitigation of MDR and 
increase efficiency using delivery carriers. 
 
 
Figure 2.4 Cellular uptake of free DOX without any carrier to normal organs and tumors via 
systemic administration, reproduced from [50] with copyright. 
 
2.3 Supplementary gene drugs 
There have been some strategies to achieve higher therapeutic efficacy via MDR suppression, 
such as co-therapy with supplementary gene drugs like miR-21i or Apt in DOX-based 
chemotherapy.  
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2.3.1 microRNA-21 inhibitor as a sub-drug 
A microRNA (miRNA) is a small, non-coding RNA of approximately 22 nucleotides that 
negatively regulates messenger RNAs (mRNAs) of target genes at the posttranscriptional level 
[53]. A diverse range of miRNAs are directly or indirectly involved in the creation or 
maintenance of MDR in cancer cells [54]. miRNA-21 (miR-21) critically modulates the 
resistance of cancer cells to DOX-based chemotherapy [55] by targeting multiple inhibitors of 
pro-survival signaling pathways to support MDR (Figure 2.3). 
DOX-induced DNA damage promotes Akt activation that upregulates IκB kinase as a regulator 
of nuclear factor kappa B (NF-κB), which expresses miR-21 [29, 56]. The upregulated miR-21 
facilitates cancer cell growth, invasion, and resultant survival by inhibiting phosphatase and 
tensin homolog (PTEN) that restricts the PI3K/Akt/mTOR signal transduction pathway [57, 
58]. miR-21 can also be regulated by oxidative stress-induced NF-κB and VEGF-related 
STAT3 activation [19, 59]. The overexpression of miR-21 maintains cancer cell survival, 
metastasis, and resistance to apoptosis by inhibiting programmed cell death 4 to block the 
JNK/c-Jun signaling pathway [60]. Additionally, miR-21 also downregulates tumor suppressor 
genes, such as Sprouty homolog 1/2, as an inhibitor of the MAPK pathway and tissue inhibitor 
of metalloproteinase 3 and reversion-induced cystine-rich protein with Kazal motifs (RECK) 
as inhibitors of MMPs [61]. 
Therefore, disturbance of miR-21 activity in the protection of such diverse pro-survival 
signaling pathways from their inhibitors becomes a strategy to enhance therapeutic efficacy. 
The introduction of a miR-21i with DOX in human glioblastoma cell lines demonstrates 
synergistic increase of anticancer effects via upregulation of E-cadherin, RECK, PTEN, and 
p21 for the successful reversal of MDR [62]. Importantly, miR-21i administration in multidrug-
resistant breast cancer cell line MCF-7/ADR causes a 45% reduction in the expression P-
glycoprotein (P-gp), an ABC transporter family [63]. Such recovery of chemosensitivity via 
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inhibition of miR-21 activity by its inhibitors has been observed in many tumors such as renal 
carcinoma, bladder cancer, non-small cell lung carcinoma, and human breast cancer [64-67]. 
2.3.2 ATP aptamer as a sub-drug 
Aptamers are short single-stranded oligonucleotides that selectively bind their target molecules 
with strong affinity [68]. Apt, an aptamer to selectively detect ATP, has been developed as a 
biosensor to recognize intracellular ATPs [69, 70]. ATP is a driving force of ABC transporters 
that export intracellular hydrophobic drugs such as DOX [45]. A study on mice carrying the 
colon carcinoma cell line HCT-8/T has shown that depletion of ATP is directly correlated to 
the downregulation of P-gp [71]. Mo et al. have employed Apt in ATP-responsive DNA 
scaffolds or DNA-graphene hybrid nanoaggregates for DOX delivery systems [72, 73]. 
However, the utilization of Apt as a supplementary drug requires further elucidation and could 
be another strategy to enhance therapeutic efficacy by inhibiting ABC transporters via isolation 
of their driving force. 
2.4 Enhance therapeutic efficiency using delivery carriers 
Although co-therapy with DOX and supplementary gene drugs and their sequential therapy 
have great potential to improve therapeutic efficacy against multidrug-resistant cancers, the 
systemic administration of DOX and gene drugs without any delivery carrier can unselectively 
deliver them to both cancer and normal cells [50]. In addition, gene drugs might be de-
functioned associated with blood circulation. The off-target delivery of anticancer drugs causes 
direct damages and metabolic alterations to normal cells as well as dose-dependent side effects 
by reducing therapeutic efficiency [47, 74]. Therefore, suitable delivery carriers are crucial to 
selectively deliver co-drugs to target cells for enhancing therapeutic efficiency and minimizing 
side effects. 




Figure 2.5 Schematic description of the delivery course of MSNs loaded with DOX and gene 
via IV injection: loading, blood circulation, extravasation, active target-mediated endocytosis, 
endosomal escape, and controlled release of the drugs, reused from [128] with copyright. 
 
The successive design of co-delivery carriers to increase therapeutic efficiency should satisfy 
all essentially required factors in the delivery course, summarized in Table 2.1 and Figure 2.5. 
Before administration, there are basic factors of delivery carriers, such as choosing low-toxic 
materials with effective loading ability of DOX and genes [75, 76]. The delivery vectors should 
effectively load the diverse properties of anionic genes and either hydrophobic DOX or cationic 
DOX hydrochloride (DOX·HCl) without premature leakage [77, 78]. After systemic 
administration, the delivery carriers in the blood vessels should avoid serum nuclease 
degradation, reticuloendothelial system (RES) clearance, and renal clearance to achieve 
prolonged circulation and effectively extravasate to the tumor site via the pores of tumor 
vasculature [79]. Importantly, the carrier should be able to selectively deliver the co-drugs to 
cancer cells via active targeting and effective endocytosis from the extracellular 
microenvironment [80]. In the intracellular microenvironment setting, the carriers loaded with 
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the drugs should enable endosomal escape and drug release in a spatiotemporal manner as well 
as their complete urinary excretion [81-83]. Over the delivery course, traceability of the carriers 
is also fundamental to monitor the invisible and non-harmful delivery process [84, 85]. 
Therefore, ideal delivery vehicles should be designed to fulfill these essential required factors 
in the order of delivery course. 
 










Natural polymers [89] 
Degradable polymers [90], [94] 
Negative charge [92] 
Lipids [95] 
Biocompatible inorganics [98-105] 
Effective DOX 
loading 
Physical adsorption [78], [110-119] 
Chemical conjugation [120-123] 
Effective gene 
loading 
Positive charged carriers 
[129], [78] 
[125-128] 






Negative charges [138] 
Avoiding RES 
clearance 
Size < 200 nm in diameter [144-145] 
Avoiding renal 
clearance 
Size > 20 nm in diameter [150] 
Effective 
extravasation 





Size < 50 nm in diameter for 
penetration 
[156-157] 
CPPs or pHLIPs for penetration [158-159], [162] 
Size 50–200 nm in diameter for 
endocytosis 
[163-166] 
Positive charge for endocytosis [169-170] 





















Thermal responsive moiety [186-187] 
Magnetic field responsive moiety [188] 
Ultrasound responsive moiety [189] 
NIR responsive moiety [129], [191] 
pH responsive moiety 
[115], [118], 
[122], [194-196] 
Enzyme responsive moiety [197-198] 





Size < 6 nm in radius 
[121], [146], 
[204-207] 





Optical inorganics [209-211] 
Label-free polymer nanogel [212] 





FRET between fluorophores [216] 
Aggregation-caused quenching [217] 
BHQ2-mediated quenching [219] 




2.4.1 Before administration 
Consideration of the basic factors to produce a successful co-delivery vector begins before 
systemic administration. This includes how to enhance DOX and gene loading to their low-
toxic co-delivery vectors. 
2.4.1.1 Low-toxic materials 
The use of low-toxic and biocompatible co-delivery vector materials is an obvious choice due 
to the requirement of clinical purpose and prevention of activating host immune systems. As 
viral vectors are unsuitable for DOX loading [86], the scope of co-delivery carriers is limited 
to non-viral vectors consisting of polymer-, lipid-, or inorganic-based materials (Figure 2.6). 




Figure 2.6 Illustration of types of non-viral vectors and a rough mechanism of loading and 
release of anticancer drugs via liposome, reused from [75] with copyright.  
 
Polymer-based materials are widely employed in medical applications, such as regenerative 
medicine and drug delivery carriers due to their excellent functional modifications and 
biocompatibility [87, 88]. Naturally produced polymers, such as collagen, chitosan, and 
hyaluronic acid (HA), exhibit inherent biocompatibility via enzymatic biodegradation but 
perform at a relatively low transfection efficiency [89]. The weakness of the natural polymers 
promotes the development of synthetic polymers for both biocompatibility and delivery 
efficiency. A representative biocompatible synthetic polymer is poly(lactide-co-glycolide) 
(PLGA) due to its hydrolysis into easily eliminated monomers of lactic acid and glycolic acid 
and its hydrophobicity for effective loading of hydrophobic DOX [90]. However, the limitation 
of hydrophobic PLGA in binding with negatively charged genes contributes to the use of 
positively charged synthetic polymers. High molecular weight polyethyleneimine (PEI) and 
polyamidoamine (PAMAM) dendrimer not only exhibit effective gene binding but also disrupt 
plasma membrane integrity to cause mitochondria and lysosome damages in normal cells [91-
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93]. Surface modification with anionic succinamic acid or neutral aminoethanol on Generation 
6 (G6) PAMAM did not cause severe cell mortality compared with non-modified G6 PAMAM 
[92]. Moreover, the use of biodegradable dendrimers, such as polyester, polyacetal, or other 
types of dendrimers, can avoid accumulation-induced cytotoxicity [94]. The amphiphilic 
property of lipid molecules, which consist of fatty acid hydrophobic tails and hydrophilic 
phosphate heads, in cell membranes is incorporated in liposome, micelle, nanoemulsion, and 
solid lipid nanoparticle delivery vectors [95]. The lipid-based vectors are beneficial for the 
sufficient loading of different types of multiple drugs, the control of carrier size, the simple 
modification of functions, and their minimal carrier-induced cytotoxicity [95]. However, lipid-
based delivery vectors still face some drawbacks, such as instability of the loaded drugs, 
positive charge surface-induced toxicity, and uncontrolled drug precipitation [96]. 
Non-toxic or less toxic inorganic materials are key components for biocompatible delivery 
systems, such as mesoporous silica nanoparticles (MSNs), gold nanoparticles (AuNPs), carbon 
nanotubes (CNTs), quantum dots (QDs), and iron oxide nanoparticles (IONPs). Although 
silicone dioxide or silica is approved as biocompatible by the Food and Drug Administration 
(FDA) of the United States, MSNs are in conflict due to in vivo toxicity depending on the 
diversity of size, shape and surface charge, and ROS production from their surface [97]. Renal-
clearable and optical nanoparticles, such as AuNPs, CNTs, and QDs, have not been observed 
in vivo or assessed for in vitro cytotoxicity and immunological toxicity, but deposition has been 
monitored in the liver, spleen, and lungs with possible long-term toxicity [98-105]. Although 
the biocompatibility of IONPs is approved for wide clinical use as a magnetic resonance (MR) 
imaging contrast agent and they are biodegraded into iron and iron ions, immune response by 
ROS production and the accumulation of large amounts in the spleen and liver have been 
observed [106-109]. 
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The current trend of non-toxic materials for delivery vectors is a modified mixture of materials 
depending on the enhancement of specific functional conditions and biocompatibility. 
2.4.1.2 Effective DOX loading 
Drug delivery carriers have been developed to enhance the loading efficiency of a tunable 
solubility of DOX, such as cationic DOX·HCl and hydrophobic DOX (Figure 2.7).The 
conventional method of DOX loading is the physical adsorption of cationic DOX·HCl to the 
delivery carriers. For example, cationic DOX·HCl and another cationic chitosan can assemble 
nanoparticles with anionic HA, tripolyphosphate, and miR-34a via electrostatic interaction in 
aqueous media, expressing >40% encapsulation efficiency [78]. The hydrophilic DOX·HCl 
has been encapsulated in the internal aqueous cavity of a liposome, a phospholipid bilayer, 
producing the clinical product Doxil® [110]. The cationic DOX·HCl can also be loaded in the 
internal pores of anionic MSNs via electrostatic interaction, with possible leakage via the open 
pores [111]. 
Curry et al. produced citrate-capped AuNPs to effectively load DOX [112]. AuNPs incorporate 
four different mechanisms in DOX loading, namely, cation-π interaction between the cationic 
AuNP surface and tetracyclic ring of DOX, coordination chemistry between the AuNP surface 
and carbonyl moieties of DOX, electrostatic interaction between a protonated amine group in 
DOX and anionic citrate, and hydrogen bonding between DOX molecules. Rungnim et al. 
loaded DOX·HCl to CNTs via π-π stacking interaction and encapsulation in the inner cavity 
with subsequent wrapping by deprotonated chitosan at pH 7.4 to protect leakage [113]. Hollow 
magnetic colloidal nanocrystal, a type of IONP, can effectively load DOX via 
nanoprecipitation to its inner large pore volume [114]. A zeolitic imidazolate framework (ZIF-
8), a class of metal organic frameworks (MOFs), can encapsulate DOX·HCl in its large volume 
of pores via nanoprecipitation in a one-pot process with >40% loading capability [115]. 




Figure 2.7 Schematic DOX loading mechanisms. Upper left: electrostatic interaction with 
DOX and HA as well as miRNA and chitosan, reused from [78] with copyright. Lower left: 
hydrophobic interaction of DOX with the hydrophobic core of polymer micelles, reused from 
[116] with copyright. Right: physical adsorptions of DOX to AuNPs, reused from [112] with 
copyright. 
 
Another loading approach of hydrophobic DOX is the mainly hydrophobic interaction with the 
core space of micelles, solid lipid nanoparticles (SLNs), and nanoemulsions. Feng et al. 
prepared an amphiphilic triblock polymer of polyethylene glycol (PEG)-poly(β-benzyl L-
aspartate) (PBLAsp)-PEI, where a hydrophobic block of PBLAsp interacts with the poorly 
water soluble DOX via self-assembling to micelles [116]. The hydrophobic DOX can be 
dispersed in a solid core of SLNs with a monolayer phospholipid coating [117]. Chen et al. 
produced cholesterol-PEG incorporated in pH-responsive SLNs that entrap DOX in the 
trilaurin-based hydrophobic core of the SLNs at pH 7.4 [118]. A nanoemulsion is an aqueous 
droplet consisting of two immiscible liquids to dissolve the hydrophobic DOX in an oil phase 
core, but its anionic surface charge is unsuitable to co-load anionic genes unless the surface is 
modified [119]. 
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The avoidable pre-leakage of the physically loaded DOX from the delivery vectors encourages 
the covalent conjugation of DOX using chemical bonds to carriers on a polymer base or other 
material bases with a surface modification. Leong et al. prepared a PEG-protected Generation 
4 polylysine dendrimer to conjugate DOX via cathepsin B-cleavable peptide linkers to enhance 
prolonged lung retention and good systemic circulation [120]. Ranjbar-Navazi et al. conjugated 
DOX to D-glucosamine and folate bifunctionalized InP/ZnS QDs via stable amide bond 
formation between the primary amine of DOX and the carboxylic surface of the QDs in the 
absence of amidase [121]. The functional groups of DOX used in covalent conjugation are the 
ketone group on a short side chain of the cyclohexane ring and the primary amine group at a 
daunosamine sugar linked to the cyclohexane ring (Figure 2.1). Ou et al. conjugated DOX to 
an enzyme-degradable diblock-N-(2-hydroxypropyl) methacrylamide (HPMA) polymer via a 
hydrazone bond between the ketone group of DOX and the acid-sensitive hydrazine moiety of 
the polymer with an excellent in vivo biocompatibility at a high loading capacity [122]. Zhu et 
al. produced PAMAM dendrimer-entrapped AuNPs with the covalent conjugation of DOX via 
acidic-sensitive cis-aconityl linkage using the primary amine group of DOX [123]. 
2.4.1.3 Effective gene loading 
Therapeutic synergy with DOX and sub-gene drugs, such as miRNAs, siRNAs, plasmid DNAs 
(pDNAs) and aptamers, can be diverse, depending on the delivery efficiency of the carriers. 
Due to their anionic property, effective gene loading is directly associated with the intensity of 
positively charged moieties in the carriers, cationic polymers, cationic lipids, and surface-
modified inorganics [79, 80]. 
Chitosan is a natural polymer-based gene delivery vector. Deng et al. formed natural polymer 
nanoparticles as a co-delivery vector via simultaneous interaction of miR-34a with chitosan 
and protonated DOX with anionic HA, but the chitosan-based nanoparticles demonstrated less-
controlled release profiles [78]. The strongly positively charged synthetic polymers, PEI with 
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molecular weight of 25 kDa and PAMAM G6, demonstrate a high gene loading capacity and 
severe cytotoxicity, while the weakly charged polymers, low molecular weight of PEI (PEI800) 
and PAMAM G0, reduce both gene loading and cytotoxicity [91, 92, 124]. Our team 
synthesized degradable microgels from PEI800 with redox-cleavable disulfide crosslinkers to 
amplify the positive charge to be sufficiently strong for effective pDNA loading [88]. The 
degradable microgels return the charge to one weak enough for losing interaction with the 
genes and releasing them in a reductant cytosol condition as well as maintaining an acceptable 
cytotoxicity level to normal kidney cell line HEK293T. Yue et al. produced PEI nanoparticles 
using diselenide bonds as crosslinkers, thereby demonstrating better durability under 
physiological conditions and faster degradation in a cytosol environment than those using 
disulfide bonds [125]. 
The cationic surface of lipid vesicles is also suitable for gene interaction. Xu et al. produced 
cationic liposome, consisting of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP), 
cholesterol, and core-entrapped hydrophilic DOX, to co-deliver miR-101 to hepatocellular 
carcinoma with synergetic in vivo and in vitro antitumor effects [126]. Liu et al. prepared 
cationic DOTAP-based SLNs for the electrostatic interaction with miR-200c and the 
encapsulation of a hydrophobic drug in their core to treat CSCs in breast cancer [127]. 
Cationic modification on the surface of inorganic-based vectors allows the loading of anionic 
genes. Liu et al. modified the surface of MSNs with disulfide bond-linked PEI (1.8 kDa) to 
interact with miR-145 and entrap DOX in MSN pores, resulting in synergistic antitumor effects 
on orthotopic colorectal cancer [128]. Ren et al. synthesized PAMAM-modified hollow AuNPs 
for the interaction of miR-21i with the strong polycations and the adsorption of DOX in the 
hollow surface to enhance anticancer efficacy [129]. 
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Therefore, the large molecular weight of cationic moieties can effectively load the genes via 
electrostatic interaction, but the remaining positive charges can result in a low delivery 
efficiency by RES clearance and severe cytotoxicity by non-selective charge interaction-
mediated endocytosis. Furthermore, over-binding of the carriers to both DOX and genes can 
impede the drug release at the tumor site, creating a dilemma. 
2.4.2 Blood circulation 
Non-toxic material-based co-delivery carriers loaded with DOX and genes are systemically 
administrated via intravenous (IV) injection. The carriers are expected to prolong the 
circulation in the bloodstream without degradation of the loaded genes by serum nucleases and 
clearance of the vectors by RES or the kidney until their successive extravasation via the pores 
of tumor vasculature. 
2.4.2.1 Avoiding nuclease degradation 
The supporting nucleic acid drugs, miRNAs, siRNAs, pDNAs, and Apts, are easily degraded 
during blood circulation by serum nucleases that hydrolyze the phosphodiester bonds of the 
polynucleotides. Zagorovsky et al. discovered the superior avoidance of the shorter 
oligonucleotide, such as miRNAs, from nuclease degradation compared with other nucleic 
acids [130]. 
Non-viral gene delivery vectors have been used to protect the loaded genes from degradation 
using protective layers. A conventional material used in the protective layer on the surface of 
the vectors is PEG, a polyether, consisting of long hydrophilic polymer chains that create a 
steric hindrance to the approach of nucleases [131]. Chemical modification with PEG, termed 
PEGylation, has been widely applied to the surface of diverse carrier types, e.g., polymers, 
micelles, SLNs, and MOFs. [71, 118, 132, 133]. However, the long polymer chain of PEG for 
the steric hindrance of serum adsorption also hinders the cellular uptake of the PEGylated 
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carriers [134]. Hama et al. suggested a charge-convertible liposome to overcome the PEG 
dilemma via surface coating with a peptide consisting of the negatively charged glutamic acid 
under physiological conditions and the positively protonatable histidine in the slightly acidic 
extracellular tumor environment [135]. The negatively charged vectors in blood circulation 
could avoid serum adsorption via electrostatic repulsion, while the positively converted charge 
at the tumor site could enhance cellular uptake of the vector via electrostatic interaction with 
the anionic cell membrane. 
Serum protein binding to the positively charged surface of the vectors is also associated with 
their non-selective biodistribution due to the presence of targeting ligands in the serum proteins, 
such as transferrin, that can transport the bound carriers to the erythron and peripheral tissues 
[136]. Another newly emerging material for the protective layer on delivery vectors to avoid 
serum protein adsorption is HA, a glycosaminoglycan of the soft tissue extracellular matrix. 
An anionic surface modification using HA can permanently protect the co-delivery carriers 
from anionic serum protein adsorption via charge repulsion and support the selective cellular 
uptake via HA receptor-mediated endocytosis [137, 138]. 
2.4.2.2 Avoiding RES clearance 
To prolong systemic circulation of co-delivery vectors, it is significantly important to evade 
detection and removal by the immune system, termed RES or mononuclear phagocyte system 
(MPS) clearance. The presence of a foreign substance in the bloodstream can stimulate 
antibody generation by B lymphocytes for marking as an antigen to enhance phagocytosis in 
the immune response [139]. Activation of the immune response is dependent on the 
characteristics of the vectors, such as surface charge, size, and geometric structure. 
Such an antibody is a type of opsonin, anionic serum molecules in blood that bind to the 
cationic surface of delivery vectors via a process termed opsonization [140]. Opsonization 
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promotes opsonin receptor-mediated phagocytosis and the entrapment of the vectors in the RES 
organs, such as the spleen, liver, lung, and lymph nodes, resulting in clearance from the delivery 
course [141]. Therefore, surface modification using PEG or HA can confer a stealth function 
to the carriers for the protection from opsonization via steric hindrance or charge repulsion, 
thereby prolonging their systemic circulation [142, 143].  
In addition to the surface charge, opsonization enlarges the carrier size, which facilitates 
detection by the RES and removal from delivery pathway [80]. By measuring in vivo blood 
circulation half-life, maximal limitations of particle size diameter to minimize RES clearance 
have been identified as 200 nm for micelles and 150 nm for spherical nanoparticles [144]. A 
particle size >200 nm limits the passage through spleen pores, resulting in accumulation in the 
spleen [145]. However, inorganic nanoparticles, such as AuNPs, silver nanoparticles, and 
titanium dioxide nanoparticles (TiO2NPs), sized <100 nm have reported a high level of liver 
accumulation [76]. The flow of blood to the liver sinusoids occurs via fenestrated capillaries 
with a pore size up to 150 nm [146]. Nanoparticles smaller than the pores can extravasate and 
become accumulated in the liver. Kulkarni et al. produced anionic polystyrene nanoparticles 
(PSNPs) sized 20, 50, 100, 200, and 500 nm to investigate the size effect on in vivo distribution, 
resulting in an exceptionally high accumulation of the 50-nm PSNPs in the liver and spleen 
and 500-nm PSNPs in the spleen [147]. On the basis of RES clearance, a suitable size of 
delivery carriers can be narrowed to 100–200 nm. 
RES clearance is also associated with the carrier geometric structures, such as spheres, 
hexagons, and rods, and their aspect ratio (AR) and axial length. Increasing the AR of CdTe 
QD-cystine composites in sphere, rod, and needle structures decreases macrophage uptake 
[148]. Hexagonal block copolymer nanoparticles exhibit less accumulation in the MPS organs 
than spherical nanoparticles at sizes >120 nm, while no difference in their behaviors are 
observed at sizes <70 nm [149]. In a comparison of the accumulation of rod structures in the 
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liver and spleen depending on axial length, shorter rods are mostly found in the liver, whereas 
longer ones are trapped in the spleen [146]. Therefore, a long and high AR of non-spherically 
shaped delivery carriers is better suited to prolonged blood circulation than spherical 
nanoparticles. 
2.4.2.3 Avoiding renal clearance 
Another factor to consider for prolonging systemic circulation of delivery vectors is the 
avoidance of renal clearance. Active kidney glomerular filtration strongly relies on a carrier 
size <6 nm in radius due to the diffusion through capillary endothelial pores, regardless of 
geometric features [146]. From an in vivo inhalation study, TiO2NPs with a diameter < 20 nm 
were found in the kidney as well as the spleen, liver, and lungs [150]. Hence, delivery carrier 
size >20 nm can effectively avoid the renal clearance. 
2.4.2.4 Effective extravasation 
Tumorigenesis is accompanied by rapid angiogenesis via an exceptionally high expression of 
VEGF to deliver blood and nutrients to newly created neighboring tumor cells [151]. The new 
blood vessels are rapidly generated and contain large permeable endothelial layers [151]. 
Extravasation of delivery carriers into the tumor interstitium is possible via the leaky 
vasculature, termed by Maeda et al. as the enhanced permeability and retention (EPR) effect 
[152]. In general, carriers <500 nm can extravasate, although the pore size of the tumor 
vasculature varies according to tumor type [80]. However, a delivery carrier with a diameter 
smaller than the endothelial pore of fenestrated capillaries located in other organs can lead to 
non-selective distribution and reduction of delivery efficiency. 
Passive targeting of delivery carriers to the tumor interstitium via the EPR effect occurs when 
the leaky blood vessel-induced high interstitial fluid pressure (IFP) inside tumors is 
compromised [144]. Larger pores generate higher IFPs that drive fluid flow away from the 
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tumor center and negatively influence the approach delivery vectors to tumors [153]. Chauhan 
et al. demonstrated that tumor interstitial normalization decreases the pore size of tumor 
vasculature and increases tumor penetration rates of particles [154]. 
To summarize, surface-modified delivery carriers with an appropriate size and shape enhance 
blood circulation via evasion of nuclease degradation, opsonization, RES, and renal clearance. 
However, it appears inefficient to allow the flow of delivery carriers to target cancer cells by 
matching the size of the carrier and the pore that is passively targeted via EPR and IFP, unless 
the passive targeting is supplemented by a more active targeting method. 
2.4.3 Extracellular microenvironment 
Following successful extravasation, delivery carriers loaded with DOX and genes and present 
in the extracellular tumor microenvironment are confronted with effective and selective cell 
internalization. 
2.4.3.1 Effective cell internalization 
The delivery carriers can enter cells via direct penetration or endocytosis. The cellular uptake 
of the carriers highly relies on their physicochemical properties, such as size, charge, solubility, 
and components. 
2.4.3.1.1 Penetration 
A direct route to the cytosol involves cellular uptake of the carriers via penetration without 
passage though endosomes and lysosomes, which eliminates the possible risk of lysosomal 
degradation by multiple enzymes in the acidic environment. Direct translocation of the carriers 
involves some hypothetical mechanisms, such as micelle formation, pore formation, and 
adaptive translocation, which is an energy and temperature-independent destabilization of the 
plasma membrane [155]. Conditions enabling the carriers to penetrate and cross over the 
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plasma membrane include a small diameter size and association with cell-penetrating peptides 
(CPPs) or pH-low insertion peptides (pHLIPs). 
Delivery carriers with a small size can directly enter cells via an energy independent non-
endocytic pathway. Mu et al. synthesized amorphous silica nanoparticles with a diameter of 14 
nm, which enter the cytoplasm of A549 cells via direct penetration [156]. Bao et al. prepared 
positively charged-layered double hydroxide lactate nanosheets with a diameter of 30–60 nm 
and thickness of 0.5–2 nm, which freely penetrated into BY-2 cells [157]. 
The delivery carriers associated with CPPs, including human immunodeficiency virus (HIV) 
transactivator of transcription (Tat), arginine, and penetratin peptides, facilitate cellular uptake 
via energy independent membrane destabilization. Zaro and Shen discovered that Tat 
(YGRKKRRQRRR) and arginine YG(I-R)9 primarily translocate into the cytosol of ovarian 
cells [158]. Watson et al. found longer penetratin (P16) more efficient for cytosol translocation 
than shorter penetratin (P7), due to better interaction of P16 with the fluid phase of bilayered 
lipid membranes than P7 [159]. However, the strong positive charge of carriers obtained by 
increasing the length of arginine or concentration of Tat and R9 prefers the endocytic pathway 
instead of penetration [158, 160]. The large size also allows nanoparticles to preferentially 
enter cells via endocytosis. Arginine-conjugated MSNs with a size of 300 nm show 80% 
cellular uptake via endocytosis and only 20% uptake via penetration [161]. 
pHLIP-mediated penetration is another non-endocytic uptake pathway. pHLIPs are water 
soluble and remain in the extracellular environment at neutral pH, and they insert and remain 
in the cellular membrane by forming a stable transmembrane α-helix [155]. Cheng et al. 
delivered miR-155 inhibitor (antimiR-155) with pHLIP conjugation via disulfide bond to a 
mouse model of lymphoma, demonstrating direct translocation of antimiR-155 to the cytosol 
and inhibition of miR-155 in solid tumors (pH 6) [162]. 




The most common route for cellular uptake of the carriers is endocytosis. In the endocytic 
pathway, the plasma membrane engulfs the carriers and subsequently pinches off to form 
endocytic vesicles that develop into or fuse with endosomes and transport the carriers to 
lysosomes [163]. Endosomal rupture releases the delivery carriers into the cytosolic 
environment. 
Phagocytosis in the process of RES clearance is a class of endocytosis via specific ligand 
receptor mediation for particles with opsonization or sized 200–2000 nm [164, 165]. The major 
endocytic route is clathrin-mediated endocytosis, which includes receptor mediation to form 
membrane vesicles sized 60–120 nm for particle entry into cells [163]. Another route is 
caveolae-dependent endocytosis using caveolae, flask-shaped membrane invaginations with a 
cavity size of 50–80 nm, for transporting signals of cell growth, apoptosis, and angiogenesis as 
well as transcytosis of diseases, such as viruses and other pathogens [166]. As caveolae-
dependent endocytosis sometimes bypasses lysosomes, it is better to avoid this route for 
delivery carriers that utilize lysosomal acid-responsive bonds in drug conjugation and release 
by controlling carrier size. 
The surface charge of the delivery carrier is a critical factor for effective endocytosis. Positively 
charged carriers can strictly enter cells via clathrin-mediated endocytosis, whereas negatively 
charged carriers enter via both clathrin- and caveolae-mediated endocytosis [167]. Engineering 
of the surface charge of the carriers to a positive charge can enhance the electrostatic interaction 
with the phospholipid membrane in terms of the thermodynamic aspect and accelerate 
membrane engulfment [168]. Liu et al. demonstrated that PEI-PEG nanoparticles deliver DOX 
and pDNA to breast cancer cells with better transfection efficiency over a counter-carrier of 
liposomes [169]. Lin et al. prepared AuNPs with negative, neutral, and positive surface charges 
to compare cellular uptake and cytotoxicity [170]. As the surface charge increases from 
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negative to positive, cellular uptake of AuNPs is enhanced. However, strengthening the 
positive charge density results in direct penetration due to membrane disruption and severe 
cytotoxicity. Furthermore, it is highly probable that positively charged carriers will undergo 
opsonization followed by phagocytosis. 
The hydrophobicity of delivery carriers affects their binding to the hydrophobic core of 
bilayered lipid membranes. The hydrophobic nanoparticles are stable in the middle of the 
membrane and become stuck without stimulating membrane wrapping for endocytosis, 
whereas semi-hydrophilic nanoparticles induce membrane engulfment [166]. However, 
hydrophobic nanoparticles sized 10–40 Å can become embedded in the hydrophobic core of 
the membrane and directly penetrate into the cytosol instead undergoing endocytosis [171]. 
Taken together, an effective cellular uptake of delivery carriers can be obtained by the 
determination of their size, surface charge, water solubility, and components, which lead to 
strategic delivery via penetration or endocytosis. However, cellular uptake via both routes still 
induces non-selective tumor delivery, potentially causing side effects. 
2.4.3.2 Selective cell internalization 
The cellular uptake of delivery vectors to only target cancer cells highly supports carrier-aided 
anticancer chemotherapy with enhanced delivery efficiency and minimized off-target-induced 
side effects. Targeting ligands on the surface of nanocarriers can allow interaction with specific 
receptors of the target cells via ligand–receptor binding. The specific receptors should be 
widely spread on the surface of the target cancer cells compared with normal cells. Targeting 
ligands can be classified as antibodies, peptides, aptamers, and HA. 
Monoclonal antibodies (mAB) originating from cloned immune cells have been clinically 
utilized following US FDA approvals over the past three decades [172, 173]. Native forms of 
mABs possess their two binding sites as a merit, but their fragment crystalline (Fc) domain 
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interaction with Fc receptors on normal cells induces immunogenicity as a defect [174]. 
Fragment forms of mAB, such as antigen-binding fragment and single-chain variable fragment, 
can reduce the binding to normal cells and enhance specific binding to EGFR and VEGF 
receptors on cancer cells [173]. 
In the class of peptides, transferrin, a serum protein, allows carriers to arrive at the transferrin 
receptor-overexpressed cancer cells [80, 136]. Other targeting peptides include linear Arg-Gly-
Asp (RGD) and cyclic RGD (cRGD), which interact with overexpressed αvβ3 integrin in tumor 
cells as well as neovascular endothelial cells and macrophages [175, 176]. The cationic 
peptides from lysine or arginine can induce cytotoxicity by disrupting mammalian membranes 
[177]. 
Targeting ligands with anionic properties are synthetic aptamers that bind to specific receptors, 
such as AS1411 to nucleolin and A10 to prostate-specific membrane antigen (PSMA). 
However, in practice, low satisfaction with their targeting ability requires their improvement 
[68]. Another negatively charged targeting agent is HA, a polysaccharide, which binds to its 
receptors overexpressed in invasive cancer cells. The interaction between HA and its receptors, 
such as CSC biomarker CD44 and receptor for HA-mediated motility, plays roles in 
inflammation, tumorigenesis, and metastasis [178]. Zhao et al. synthesized lipid nanoparticles 
with surface modification using HA for active cancer targeting and CPPs for direct 
translocation to the cytosol [179]. Additionally, HA-modified delivery carriers effectively enter 
the invasive cancer cells via HA receptor-mediated endocytosis [180]. Therefore, surface 
modification with HA holds great potential for anionic protection in blood circulation, active 
targeting, and receptor-mediated endocytosis into invasive cancer cells. 
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2.4.4 Intracellular microenvironment 
Cellular internalized delivery vectors via active targeting and endocytosis should satisfy 
intracellular factors such as endosomal escape, spatiotemporal release, and excretion. 
2.4.4.1 Effective endosomal escape 
Following endocytosis, delivery carriers loaded with co-drugs are trapped in endosomes and 
further lysosomes with the danger of degradation by lysosomal enzymes and acidic conditions 
[181]. Cationic polymer-based carriers can avoid lysosomal degradation via the proton sponge 
effect [81]. Cationic or pH-responsive polymers in endosomes and lysosomes act as a proton 
sponge by adsorbing protons influxed from exterior endosomes to decrease the pH up to 4.0. 
Accumulation of the counter-ions supplied with the protons leads to osmotic swelling and 
triggers endosomal membrane rupture. The nanocarriers can escape from the endosome, termed 
endosomal escape. 
Patil et al. synthesized triblock polymer nanocarriers of PAMAM-PEG-poly-L-lysine with 
effective endosomal escape via a tertiary amine-induced proton sponge effect [182]. Bonner et 
al. compared the endosomal escape with different types of PEIs, such as linear PEI, branched 
PEI (bPEI), and crosslinked linear PEI [183]. The effective performance of most of the PEIs, 
with the exception of low molecular weight bPEI, indicates secondary amine-dominated pH 
buffering. Panyam et al. measured the time for endosomal escape of the PLGA-based 
biodegradable nanoparticles as <10 min [184]. 
Although endocytotic pathways possess a risk of lysosomal degradation, cationic amine group-
incorporated carriers can actively escape the endosome to the cytosol within a very short time. 
2.4.4.2 Spatiotemporal release 
Delivery carriers loaded with DOX and genes in the intracellular microenvironment are 
confronted with a controlled release of their cargoes by overcoming premature leakage and 
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incomplete release. In the case of physical loading of DOX to inside pores of MSNs, DOX can 
be prematurely released in the delivery course via open pores and become stuck in the deep 
inside of the pores. The electrostatic interaction between a slightly protonated amine group of 
DOX (pKa = 7.6) and deprotonated silanol groups of MSN (pKa = 3.5) is relatively stable at a 
physiological pH of 7.4, with possible leakage [51, 185]. However, the interaction in an acidic 
lysosomal pH of 4.5–5.0 is insufficiently stable to protonate the silanol group for the 
electrostatic repulsion-mediated release of the stuck DOX. 
Delivery vectors should release their cargo drugs in targeted locations at an appropriate time 
to maximize therapeutic effects. The spatiotemporal release of DOX and gene can be triggered 
by extracellular or intracellular stimuli. 
2.4.4.2.1 Extracellular stimuli-driven release 
The use of extracellular stimuli has a key merit in the predetermination of location and timing 
for the release of co-drugs. Extracellular stimuli for co-drug release include high temperature, 
magnetic fields, ultrasound, and near infrared (NIR) light. 
Thermoresponsive linkages or materials are involved in delivery systems for drug release under 
an external heating. Riedinger et al. conjugated DOX via local temperature-cleavable linkage 
of 2,2' azobis[N-(2-carboxyethyl)-2-methylpropionamidine] to IONPs [186]. The DOX release 
profile is directly proportional to increasing local heat. However, the effective release of DOX 
requires local heating up to 45 °C, higher than body temperature, which may damage normal 
cells and gene drugs. Rehman et al. produced thermoresponsive SLNs using lauric acid with 
oleic acid or linoleic acid, resulting in a burst release of co-entrapped drugs following heating 
to 39 °C due to solid-liquid phase transition [187]. However, a sustained leaking of drugs at 
37 °C due to the narrow temperature range decreases delivery efficiency. 
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An alternating magnetic field (AMF) can generate thermal fluctuations, which drive the 
rotational movements of DOX. Santos et al. applied AMF at H × f = 4.9 × 109 A m−1s−1 for 30 
min to release the physically adsorbed DOX in β-cyclodextrin-decorated superparamagnetic 
nanoparticles [188]. The release of 92% of the loaded DOX with effective anticancer results 
on human lung cancer cell line A549 was observed. The AMF can increase heat up to 45 °C, 
with possible damages. 
Therapeutic ultrasound is another external stimulus that triggers drug release. Rapoport et al. 
directly applied ultrasound to tumor tissue for the conversion of nanoemulsion droplets to 
microbubbles, which increases the volume containing the drugs and effects their release [189]. 
However, the instant high temperature shock from the ultrasound may damage normal cells. 
NIR laser or light can be applied to release drugs from AuNPs via surface plasmon resonance. 
A continuous exposure to NIR light decays plasmons on the surface of AuNPs with electron 
relaxation, which reduces the attraction between AuNPs and drugs and releases the drugs [190]. 
Ren el al. applied NIR laser (964 nm wavelength) to PAMAM-modified hollow AuNPs to 
release DOX from the surface of AuNPs [129]. NIR light can also destabilize a micelle. Cao et 
al. employed NIR light (765 nm wavelength) to cleave 2-nitrobenzyl alcohol on the 
hydrophobic moiety in chitosan-based micelles, achieving fast, controlled release of drugs in 
deep tissue [191]. 
Although extracellular stimuli can remotely control the drug release as predetermined by the 
operator, the extra operation required for generating stimuli can induce possible side effects 
and a burden of cost and time to patients. 
2.4.4.2.2 Intracellular stimuli-driven release 
Intracellular environments, including acidic conditions, reductants, and enzymes, can stimulate 
delivery carriers to release their cargoes via hydrolyzing covalent linkers, decomposing carrier 
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morphologies, or reducing crosslinkers in the carrier structure (Figure 2.8). The methods of 
biostimuli-mediated drug release do not require any extra operation after IV injection. 
 
Figure 2.8 Intracellular stimuli-cleavable linkers. Upper left: acid-cleavable hydrazone bond 
and lysosomal enzyme cathepsin B-cleavable GFLG peptide linker, reused from [122] with 
copyright. Upper right: acid-cleavable acetal crosslinker, reused from [194] 
(https://pubs.acs.org/doi/10.1021/mz5004097) with copyright, further permission directed to 
ACS. Lower left: weak acid-cleavable benzoic imine bond used in self-gatekeeping, reused 
from [196] with copyright. Lower right: disulfide bond crosslinkers, reused from [200] with 
copyright. 
 
The acidity of the extracellular tumor space endosome-lysosome pathway is gradually 
strengthened from pH 6.8 in the tumor extracellular microenvironment to pH 6.0–6.6 in early 
endosomes and pH 5.0 in late endosomes to pH of 4.5 in lysosomes [192, 193]. The acidic 
environment can hydrolyze pH-sensitive linkers, such as hydrazone bonds, acetal linkers, cis-
aconityl linkers, and benzoic imine bonds. Ou et al. used a hydrazone bond to conjugate DOX 
to an HPMA polymer, resulting in effective leakage control at pH 7.4 and the intensive release 
of DOX at pH 5.4 [122]. Gao et al. utilized low pH-cleavable acetal crosslinkers in both brush-
arm star polymer nanoparticle formation and DOX conjugation, thereby simultaneously 
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degrading the carriers and releasing DOX in an acidic environment [194]. Srinophakun and 
Boonmee conjugated DOX to glycol chitosan using cis-aconityl linkage that releases DOX via 
effective hydrolysis in the acidic environment of the lysosome [195]. The cis-aconityl linkage 
is a thermodynamically more stable conjugation in a normal environment, which can suppress 
the leakage of loaded DOX in the bloodstream. Zeng et al. also minimized the leakage problem 
of MSNs using a pH-sensitive benzoic imine covalent bond between DOX and benzaldehyde-
functionalized MSNs as a gatekeeper [196]. In an acidic tumor extracellular microenvironment, 
the MSNs can open the gate via hydrolysis of the benzoic imine bond to allow the release of 
DOX from conjugation and encapsulation deep inside the pores. 
Acidic cellular conditions can also reduce the encapsulation capability of drug carriers by 
decomposing the structure or altering the properties to cause drug release. Zhang et al. prepared 
ZIF-8 for the delivery of DOX using its high pore volume and a pH-stimulated release behavior 
[115]. The DOX release under acidic conditions of pH 5.0 is attributed to ZIF-8 decomposition 
via metal-oxygen bond-accelerated hydrolysis, thereby releasing approximately 40% of loaded 
DOX over 132 h. However, premature leakage through the pores in aqueous buffer at pH 7.4 
remains less controlled, with the release of approximately 30% of loaded DOX over an equal 
time. Chen et al. produced SLNs to deliver DOX via acidic condition-facilitative release of 
DOX in the breast cancer cell line MCF-7/MDR, resulting in the release of 55% of the loaded 
DOX at pH 4.7 and 25% at pH 7.4 [118]. The protonated DOX in the acidic condition can lose 
interaction with hydrophobic core components of SLNs, such as hydrophobic trilaurin and 
protonated laurate (pKa = 5.34 for the carboxyl moiety), thereby being releasing them from the 
core. Therefore, delivery carriers with pH-sensitive moieties can effectively control DOX 
release in an acidic pathway. However, lysosomal environment-based releasing strategies 
require an extremely active reaction to intensively release DOX over a short time because of 
lysosomal nuclease degradation of the co-delivered genes. 
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Other intracellular stimuli include enzymes that cleave amide bonds in peptide linkages. The 
amide bonds are normally stable under physiological conditions, whereas specific enzymes 
selectively hydrolyze them. Zhang et al. synthesized methoxy-PEGylated dendrimer with DOX 
conjugation via a Gly-Phe-Leu-Gly (GFLG) tetrapeptide linker that can be hydrolyzed by 
cathepsin B, a cysteine protease overexpressed in lysosomes of tumor endothelial cells [197]. 
These allow the release of drugs in a specific location: the lysosomes of tumor cells. A more 
specific tumor-related enzyme is prostate-specific antigen (PSA), which is secreted by prostate 
tumor cells. DeFeo-Jones et al. used N-glutaryl-(4-hydroxyprolyl)-Ala-Ser-cyclohexaglycyl-
Gln-Ser-Leu-COOH to covalently bond to the amine moiety of DOX for selective DOX 
delivery in prostate cancer [198]. The PSA cleaves the peptide linkers, including Gln-Ser-Leu 
sequences, releasing Leu-DOX in PSA-secreting prostate cancer cells but not in non-PSA 
secreting cells. Hence, site-specific enzymes can tightly control the target location and cells for 
drug release. 
Endogenous thiol molecules, such as GSH, cysteine, and other cysteine-containing peptides, 
are highly concentrated in the tumor cytosol (14–20 mM) for the detoxification of free radicals 
and ROS [24, 199]. The thiol molecules play a role in disulfide exchange with redox-sensitive 
crosslinkers used in the formation of carrier structures, resulting in degradation of the carriers 
and drug release into the cytosol. Yin et al. synthesized a redox-sensitive micelle, (HA-SS-
(octandioic acid (OA)-g-bPEI), to deliver aurora kinase A gene-specific siRNA and 
hydrophobic drugs to MDA-MB-231 cells [200]. In an aqueous buffer at pH 7.4 with 20 mM 
GSH, the micelles can cleave disulfide linkage between HA and OA, resulting in micelle 
disassembly and rapid release of the loaded co-drugs. Lu et al. synthesized disulfide-
crosslinked Arg-Asp polypeptide to deliver pDNA in a bone-metastatic tumor by 
electrostatically forming a polypeptide-pDNA complex between the Arg moieties with the 
enhanced positively charged and negatively charged pDNA [201]. The complex loses the 
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electrostatic interactions with pDNA in the cytosol via reduction of the disulfide crosslinkers, 
becoming oligopeptides that release the pDNA. Therefore, the location of drug release from 
delivery carriers crosslinked with a disulfide bond can be controlled in the cytosol of cancer 
cells. 
The location of DOX release influences its therapeutic effects via different apoptotic signaling 
pathways. Nuclear DOX directly induces DNA damage-induced apoptosis, while cytosolic 
DOX is highly involved in ROS-induced apoptosis. This broadens the stereotyped site of DOX 
release and DOX activity from only the nucleus to the cytosol. Besides, DOX released in the 
tumor extracellular microenvironment can reduce delivery efficiency. Therefore, it is critical 
to choose appropriate biostimuli-sensitive moieties for highly controlled drug release at the 
target location without premature leakage. 
2.4.4.2.3 Sequential release 
An advanced strategy to maximize therapeutic efficacy in multidrug-resistant cancers is the 
sequentially temporal treatment of anti-MDR gene drugs in advance of DOX treatment. The 
anti-MDR gene drugs, such as small interfering RNA (siRNA) and miR-21i, play a key role in 
reversing MDR prior to DOX administration as the major anticancer drug. The first 
administration of siRNA for P-gp inhibition leads to notable suppression of DOX exporters 
and requires a far less amount of DOX incorporation to achieve an identical therapeutic 
efficacy on multidrug-resistant cancer cell lines Caco-2/MDR1, MDA-MB-468/MDR1, and 
MCF-7/A than conventional chemotherapies [202, 203]. Ren et al. sequentially delivered miR-
21i and then DOX, separated by a 4-h interval, to MDA-MB-231 CSCs, resulting in a >3-fold 
increase in anticancer efficacy than could be achieved with simultaneous delivery of the co-
drugs [129]. They used an extracellular stimulus of NIR laser to control the timing of DOX 
release. However, we do not know the most appropriate timing of drug release in each target 
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cell. Such higher therapeutic efficacy with lesser DOX usage via sequential therapy of the co-
drugs requires further research to obtain complete anticancer therapy with minimal side effects. 
Taken together, a matching between intracellular stimuli and their sensitive moieties can equip 
co-drug delivery systems with the function of auto-control in their cargo release at the most 
suitable timing in each targeted cell, which may critically enhance delivery efficiency. 
2.4.4.3 Complete excretion 
The accumulation of delivery carriers after the release of loaded drugs in patient’s body can 
induce considerable cytotoxicity and hinder further administration. Carriers are completely 
removed from the patient’s body via urinary excretion and should be <6 nm in radius to filter 
through the kidneys [146]. Recent research has shown that a renal-clearable size of the delivery 
vectors and the use of biodegradable carriers should overcome the remaining accumulation 
obstacles. 
Renal-clearable nanoparticles have been synthesized in the form of QDs, silica nanoparticles 
(SiNPs), polymer nanodots, and ultrasmall AuNPs. Choi et al. firstly synthesized CdSe/ZnS 
QDs with a hydrodynamic diameter <5.5 nm for rapid and efficient renal clearance [204]. 
Benezra et al. produced SiNPs with cRGD and optical dye incorporation in a hydrodynamic 
size of 7.0 nm for the detection of metastatic melanoma [205]. Shen et al. prepared ultrasmall 
coordination polymer nanodots with a renal-clearable diameter 5 nm for imaging [206]. 
However, the small-sized nanoparticles have been utilized for the purpose of optical imaging 
but not drug delivery. Ranjbar-Navazi et al. synthesized DOX-conjugated InP/ZnS QDs with 
a diameter of 11 nm by transmission electron microscopy [121]. Huo et al. used ultrasmall 
AuNPs with a size of 2.0 nm for the purpose of interfering with target gene transcription in the 
nucleus of cancer cells and HIV-infected cells by delivering triplex-forming oligonucleotides 
on the surface of the AuNPs [207]. 
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Biodegradable nanoparticles have been developed to overcome the possible renal clearance of 
the ultrasmall nanoparticles in the delivery course before reaching their target cells. There are 
a number of biodegradable delivery vectors, e.g., biodegradable polymer nanogels and 
biodegradable dendrimers [94, 208]. Degradation of the biodegradable vectors into small 
molecular weight monomers or oligomers can be achieved via intracellular stimuli following 
the release of their cargo drugs. It is noteworthy that the degraded monomers and oligomers 
should be sufficiently small and non-toxic to the kidney for biocompatible urinary excretion. 
 
Figure 2.9 Methods to trace carriers and drug release. Left: label-free autofluorescent polymer 
nanogels and degradation-induced fluorescence-off, reused from [212] with copyright. Upper 
right: FRET-on between GQDs loaded with DOX and FRET-off when DOX is released, reused 
from [216] with copyright. Lower right: quenching of DOX via ACQ when conjugated to TPE 
and fluorescence-on of DOX after cleaving the hydrazone bond, reused from [217] with 
copyright. 
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2.4.5 Traceability over delivery course 
Invisible conditions inside the body require traceability of the carriers and drugs to assess their 
delivery process in real-time (Figure 2.9). The association of imaging materials in delivery 
carriers provides information concerning their biodistribution and delivery efficiency. The 
optical properties of inorganic material-based carriers facilitate tracking of the delivery course. 
The superparamagnetism of IONPs enables MR imaging. Li et al. designed PEI-modified 
Fe3O4@SiO2 nanoparticles for delivery of VEGF small hairpin RNA and MR imaging [209]. 
QDs are inorganic fluorophores with advanced properties of a wide wavelength range of 
excitation, a narrow emission bandwidth, and long-term imaging in vitro and in vivo. Wang et 
al. produced manganese-doped ZnSe QDs (d-dots) with PEI surface modification for the 
delivery of K-Ras siRNA and fluorescence imaging [210]. AuNPs with optical properties of 
light scattering and surface plasmon resonance allow computed tomography (CT) imaging and 
control spatiotemporal drug release. Kim et al. synthesized PSMA targeting aptamer-
conjugated AuNPs for CT imaging and DOX delivery to prostate cancer cells [211]. 
Non-optical polymer-based delivery carriers also enable tracking of their pharmacokinetics. 
Our group proposed label-free autofluorescent nanogels for fluorescence imaging and pDNA 
delivery [212]. Disulfide-crosslinked bPEI contains autofluorescent aldehyde-L-cystine that 
emits fluorescence at 488 nm with excitation at 462 nm and releases pDNA in the cytosol. An 
anticancer DOX drug possesses inherent fluorescence with maximum excitation at 480–490 
nm and emission at 580 nm. Delivery carriers with DOX conjugation allow monitoring of the 
cellular uptake of the carriers via fluorescence imaging of DOX [213]. Gene drugs obtain 
fluorescence via labeling with organic dyes, such as fluorescein amidite (FAM) and cyanine 
5.5 (Cy5.5). Lin et al. utilized FAM-labeled siRNA to trace delivery carriers via siRNA binding 
to cationic poly(lactic acid) nanoparticles for silencing mutant K-Ras genes [214]. Palanca-
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Wessels et al. synthesized polymeric micelles to deliver Cy5.5-labeled siRNA for traceable 
delivery and target gene suppression [215]. 
The detection of drug release from delivery systems provides spatiotemporal information to 
assess delivery quality and efficiency. To distinguish between loaded and released drug states, 
fluorescence from fluorophore-labeled co-drugs, such as DOX and FAM- or Cy5.5-labeled 
nucleic acids, should be transferred or quenched by carrier fluorophores, such as graphene 
quantum dots (GQDs), tetraphenylethylene (TPE), and black hole quencher. Chen et al. 
synthesized GQDs with Tat peptide and PEG surface modification for the delivery of DOX to 
the nuclei of HeLa cells and real-time monitoring of the DOX separation process [216]. The 
fluorescence emission wavelength of GQDs under excitation at 405 nm in the loaded DOX 
state is 565 nm due to Förster resonance energy transfer (FRET) between GQDs and DOX, 
while that of DOX in the released state is 515 nm due to off of the FRET. Xue et al. produced 
TPE molecules with hydrazone bond-linked DOX to monitor DOX release in MCF-7 cells 
[217]. In the DOX-conjugated state, TPE under excitation at 330 nm transfers the emitted 
energy to DOX under excitation at 477 nm, but both TPE and DOX are quenched due to energy 
transfer relay (ETR) from TPE to DOX as well as aggregation-caused quenching (ACQ) of 
DOX itself. In the DOX-released state, both TPE and DOX can emit the quenched fluorescence 
due to their far distance that hinders ETR and ACQ. For the effective quenching of the 
fluorescence emitted from a donor excitation, the emission wavelength of the donor should be 
the same as the excitation wavelength of an acceptor and the distance between them <100 Å 
[218]. Qiu et al. designed a photocontrolled aptamer-based molecular beacon with a Cy3 
fluorophore and a BHQ2 quencher modification to detect manganese superoxide dismutase 
(MnSOD) messenger RNA (mRNA) in blastoderm cells [219]. Detection of the MnSOD 
mRNA by the molecular beacon occurs via emission of the quenched fluorescence of Cy3 at 
563 nm by BHQ2. 
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2.5 Summary and Future perspectives 
The most active anticancer effects caused by DOX-based chemotherapy are due to the 
activation of two apoptotic pathways starting from the nucleus and cytosol of the target cells. 
Long-term DOX administration induces MDR, which encourages the incorporation of sub-
drugs for therapeutic synergy. Strategies for enhancing therapeutic efficacy include co-therapy 
with gene drugs miR-21i and Apt and their sequential release to mitigate MDR by inhibiting 
anti-apoptotic signaling pathways and DOX exporters. However, non-selective distribution of 
the cytotoxic drugs induces severe side effects and low therapeutic efficiency. The strategy for 
high therapeutic efficiency and minimal side effects is the use of smart co-delivery carriers to 
selectively deliver the co-drugs to the target cells. 
Successive design of smart co-delivery carriers should meet all the required factors in the 
delivery course via systemic administration. On the basis of the crucial factors, delivery carriers 
are expected to be biocompatible over the delivery course. Delivery systems for side-effect-
free administration should satisfy all the factors, such as non-toxic materials in the carriers, no 
premature drug release, no clearance via systemic circulation, no normal cellular uptake, and 
no accumulation in the patient’s body. Hence, the delivery systems should be non-toxic 
material-based biodegradable particles sized 100–200 nm with covalent conjugation to DOX, 
a negatively charged surface, and active targeting ligands. Furthermore, the delivery systems 
should yield degraded fragments with a radius < 6 nm that are biocompatible with kidney cells. 
Additionally, higher delivery efficiency requires the further functions of a high loading 
capacity of DOX and gene, rapid endosomal escape, spatiotemporally controlled release, and 
real-time monitoring. Therefore, the carriers should utilize stimuli-sensitive crosslinkers in 
their formation and DOX conjugation or gatekeepers on the DOX encapsulated in pores, 
contain strong positively charged moieties for electrostatic interaction with gene and 
endosomal escape, and include optical materials. 
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Some functional conditions, such as materials, charge, size, and loading mechanism, are still 
in conflict with each other for both side-effect-free and high delivery efficiency, but this must 
be overcome. Moreover, an exceptionally safe and effective anticancer therapy encourages 
designing the co-delivery systems to include a biocompatible evaluation in vitro and in vivo 
when delivery systems are loaded with co-drugs, which increases their feasibility in clinical 
applications. The use of Apt as a supplementary drug in isolating ATP to inhibit ABC 
transporters may be another strategy to enhance therapeutic efficacy. Advanced therapeutic 
strategies of multiple drug delivery and sequential delivery should involve an appropriately 
engineered design for the controlled release of multiple drugs by matching intracellular stimuli 
with the location and timing of drug release. More engineering approaches to the real-time 
assessment of spatiotemporal drug release should be motivated to provide crucial feedback on 
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Chemotherapy using most active anticancer drugs, such as doxorubicin (DOX), is devalued 
due to the dose-dependent side-effects by their unselective cell intakes and the therapeutic 
pathway interruption in the presence of miRNA-21. Herein, a co-delivery system of DOX and 
miRNA-21 inhibitor (miR-21i) based on multifunctional microgels is developed to maximize 
therapeutic synergies and minimize side effects. The microgels were prepared by cationic low 
molecular weight polyethyleneimine and glutathione-responsive diselenide crosslinkers, where 
DOX was loaded to microgels via acidic-cleavable hydrazone bonds and miR-21i was 
interacted with microgels electrostatically. Further negative charged hyaluronic acid (HA) 
surface coating inhibits protein adsorption during circulation and promotes active target on 
metastatic cancer cells through HA receptor-mediated endocytosis. The loaded DOX and miR-
21i can be rapidly released to endosome/lysosome and cytosol of target cancer cells, rather than 
health cells, due to the effective cleavage of hydrazone and diselenide bonds in cancer cell 
microenvironment. Its anticancer efficiency to breast cancer MDA-MB-231 cells is 4.4-fold 
higher than free DOX, but its cytotoxicity to health cells is impressively low. While the delivery 
system is stable before endocytosis, it can be fully biodegradable in the cytosol environment 
for safe excretion from body. Therefore, the reported multifunctional microgels enable 
effective co-delivery of DOX and miR-21i to target cells with high anticancer therapeutic 
performance but minimal side effects. 








Doxorubicin (DOX), a most active anticancer drug, is able to mitigate a wide range of cancers 
via regulating B-cell lymphoma-2 (Bcl-2) family proteins and activating an apoptotic pathway 
afterwards [1-6]. However, DOX also causes significant side effects, e.g. cardiotoxicity, 
hepatotoxicity and nephrotoxicity, which outweigh its anticancer therapy when increasing 
DOX dosage [7-11]. The severer side effects from DOX are due to higher uptake by normal 
cells than cancer cells when DOX is administrated systemically without a delivery agent [10, 
12, 13]. Additionally, the presence of miRNA-21 (miR-21) as the oncogenic RNA in cancer 
cells reduces chemo-sensitivity by down-regulating programmed cell death 4 (PDCD4) and 
thus suppressing the apoptotic pathway [14, 15]. The co-drug therapy with DOX and miR-21 
inhibitor (miR-21i) has exhibited synergistic effect on improving anticancer efficacy of DOX 
by inhibiting miR-21, resulting in recovery of chemo-sensitivity and activation of apoptosis 
[16-18]. However, miRNA therapy without a suitable delivery carrier is often associated with 
rapid blood clearance and metabolic alteration by the off-target effect [19, 20]. These transport 
issues have drawn scientific attentions to the development of a co-delivery system although a 
range of delivery vectors have been explored for delivering DOX or miRNA separately.  
DOX delivery systems have been developed with effective loading mechanisms, such as solid 
lipid nanoparticles with solvent diffusion, DNA duplex with intercalation, polysaccharide with 
charge interaction, carbon nanotube with physical adsorption and micelle with hydrophobic 
interaction [21-25]. However, these loading mechanisms cannot allow DOX release in a 
controlled manner. To better control release, limited study has been reported on the conjugation 
of DOX and carriers via cleavable moieties, disulfide bonds and hydrazone bonds [26-28]. 
Among them, DOX conjugation by a hydrazone bond can minimize premature release at 
physiological circumstance (pH 7.4), enhance DOX accumulation in tumor site and release 
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DOX in the cancerous extracellular matrix (pH 6.0-7.0) and endosomes-lysosomes (pH 4.0-
6.0) [29]. 
Vectors for miR-21i are confronted with dilemmatic issues in the delivery courses of gene 
loading, systemic circulation, extravasation, endocytosis, endosomal escape, gene release and 
excretion from patients’ body [30, 31]. Cationic lipid-based delivery vectors, liposomes and 
solid lipid nanoparticles have been used to form lipoplexes with anionic genes by electrostatic 
interaction [32-36]. Polymer-based carriers forming polyplexes with genes have been used for 
aiding endosomal escape to cytosol through the proton sponge effect [32-36]. 
Polyethyleneimine with a molecular weight of 25k Da (PEI25k) as a gold standard of gene 
vectors demonstrates its high gene transfection efficiency but high cytotoxicity, whereas PEI 
with a low molecular weight of 800 Da (PEI800) possesses a weak gene loading ability but 
more biocompatibility [37]. In order to achieve high transfection and low cytotoxicity of PEI, 
our team reported the synthesis of biodegradable PEI microgels by crosslinking low molecular 
weight PEI800 by a redox cleavable disulfide linker [38-40]. Similarly, diselenide has also 
been reported to be redox cleavable, but with better stability in extracellular environments and 
faster cleavage in intracellular GSH environment [41].  
Besides, high molecular weight cationic polymeric vectors can enhance gene loading, increase 
blood circulation time without renal clearance (> 20 nm), and improve electrostatic interaction-
mediated endocytosis [31, 42]. On the other hand, these cationic carriers may interact with  
anionic serum to yield complexes with a large size, resulting in reticuloendothelial clearance 
for a size greater than 200 nm, inhibition of their extravasation through tumor derived vascular 
pores for a size greater than 500 nm, and their cytotoxic accumulation in patient body [30, 43]. 
Although polyethylene glycol (PEG) modification has been developed to overcome protein 
adsorption, steric hindrance derived from long PEG chains suppresses cellular uptake [44]. 
Hyaluronic acid (HA), a natural glycosaminoglycan as an extracellular matrix component, is 
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an alternative to protect cationic carriers from elimination by the immune system because of 
its anionic property. HA not only can avoid serum opsonization and prolong blood circulation, 
but also facilitate active targeting and subsequent receptor-mediated endocytosis into 
metastatic breast cancer cells (MDA-MB-231) due to the overexpress of a cluster of 
differentiation 44 (CD44) on cell surface as the HA receptor [45, 46].  
 
Scheme 3.1 Schematic representation of the developed microenvironment-degradable 
multifunctional PSeHD/miR-21i/HA for selective delivery of DOX and miR-21i. 
 
In this study, we developed a co-delivery system of DOX and miR-21i aiming for enhancing 
their synergistic effect on the treatment of invasive breast cancer (Scheme 3.1). This multi-
functional microgel-based carrier system was prepared by crosslinking PEI800 using bio-
cleavable diselenide crosslinkers. DOX was chemically conjugated by hydrazone bonds and 
miR-21i was introduced via electrostatic interaction. Such a system revealed high loading 
capability for DOX and miR-21i, but low cytotoxicity to health cells. HA surface coating was 
applied electrostatically to minimize serum adsorption and enhance target cell delivery through 
the HA receptor-meditated endocytosis. The HA coated polyplexes maintained their 
morphologies with a size of 160 nm during stable circulation and passive targeting. Co-loaded 
DOX and miR-21i could be selectively released to target cells via acidic cancer environment-
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induced cleavage of hydrazone bonds and cytosol GSH-induced cleavage of diselenide bonds. 
The small-sized microgel fragments (< 10 nm) after the reduction of diselenide crosslinkers of 
microgels could be easily excreted. As a result, the reported multi-functionalized microgels 
have the great potential as effective carriers for anticancer drugs and miRNA co-delivery in 




Branched polyethyleneimine MW 800 Da (PEI800), branched polyethyleneimine MW 25k Da 
(PEI25K), selenium, 3-chloropropionic acid, 1-ethyl-3-(3-dimethyl-laminopropyl) 
carbodiimide (EDC), N-hydroxysulfosuccinimide (NHS), sodium borohydride (NaBH4), 
succinic anhydride, tert-butyl carbazate, trifluoroacetic acid (TFA), agarose, 1M DL-
dithiothreitol solution (DTT), L-Glutathione reduced (GSH) and cell counting Kit-8 (CCK-8) 
were purchased from Sigma-Aldrich. Doxorubicin hydrochloride (DOX·HCl) was purchased 
from Wuhan Wang Lianshang Biotechnology. MicroRNA-21 inhibitor (sequence 5’-
GUCCACUCUUGUCCUCAAUG-3’) (miR-21i) and FAM-labelled miRNA inhibitor single 
stranded negative control (sequence 5’-CAGUACUUUUGUGUAGUACAA-3’) (FAM-miR) 
were purchased from Shanghai Gene Pharma Co., Ltd. Sodium hyaluronate 60k Da (HA) was 
obtained from Lifecore Biomedical, LLC. Dulbecco modified eagle medium (DMEM), fetal 
bovine serum (FBS), penicillin-streptomycin (PS), phosphate buffered saline (PBS), Trypsin-
EDTA (0.25 %) and CellMaskTM Deep Red Plasma membrane Stain were purchased from Life 
Technologies Australia Pty Ltd. Deionised water was from a Milli-Q water system with 
resistance of 18.2 MΩ·cm. Spectra/Por® molecularporus membrane tubing 3.5 kDa MWCO 
was purchased from Spectrum Laboratories, Inc. HEK293T cell line was kindly gifted by 
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Professor Andrew Zannettino from South Australia Health and Medical Research Institute 
(SAHMRI). MDA-MB-231 cell lines were appreciably given by Dr. Qian Tang from School 
of Pharmacy at University of South Australia. All chemicals with analytical grade were used 
without further purification. 
3.2.2 Synthesis of PSeH microgels 
3.2.2.1 Synthesis of diselenide crosslinker (-SeSe-) 
3,3’-diselanediyldipropanoic acid (-SeSe-) was synthesized following previous research with 
slight modification [47]. 5 mL water was added to selenium powder (1.18 g, 15 mmol) in a 
three-necked flask under nitrogen protection. NaBH4 (1.13 g, 30 mmol) in 12.5 mL water was 
added dropwise to the flask in an ice bath over a period of 10 min under stirring. After the 
mixture turned colorless, another 1.18 g selenium powders were added under N2 protection. 
The mixture was heated up to 105 °C for about 20 min and a reddish brown color mixture was 
obtained. After cooling the mixture to room temperature, 3-chloropropionic acid (3.26 g, 30 
mmol) in 7.5 mL water and pH 8 (adjusting using sodium carbonate) was added. The mixture 
was stirred overnight at room temperature under N2 protection, and then exposed to atmosphere 
for 12 h to oxidize unreacted selenium, following by filtration using a 0.45 µm syringe filter. 
pH was adjusted to 3 with HCl, and the coagulant was extracted twice with ethyl acetate and 
washed twice with water. The organic part in ethyl acetate was dried with magnesium sulphate. 
After ethyl acetate evaporation, crystallized pale yellow color diselenide crosslinker (-SeSe-) 
was produced and confirmed by Raman spectroscopy and Fourier-transform infrared 
spectroscopy (FTIR). 
3.2.2.2 Synthesis of diselenide crosslinked PEI800 (PSeSe) 
-SeSe- (304 mg, 1 mmol), NHS (460.4 mg, 4 mmol) and EDC (1150.2 mg, 6 mmol) were 
dissolved in 2.1 mL DMSO under N2 protection with magnetic stirring for 45 min. PEI800 
(800 mg, 1 mmol), pH 7.4 being adjusted using 3M HCl and lyophilized, was dissolved in 1.6 
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mL of DMSO and injected into the EDC activated solution. The mixture was magnetically 
stirred at room temperature for 2 days under nitrogen, and then dialyzed against water using 
dialysis tubes (3.5 kDa MWCO) for 5 days with daily change of water. After lyophilisation, 
PSeSe was obtained and checked by FTIR. The quantity of amine groups in PSeSe was detected 
through conductivity and pH titration. 2.4 mg of PSeSe in 48 mL of deionized water was titrated 
dropwise by 0.1 M sodium hydroxide solution with continuous magnetic stirring. The pH and 
conductivity (µS) data from a pH-conductivity meter (AQUA conductivity/pH) were recorded 
to quantify amine groups of PSeSe. 
3.2.2.3 Synthesis of hydrazine bond conjugated PEI microgels (PSeH) 
PSeSe (100 mg, 496 µmol of amine group) was re-dissolved in 10 mL DMSO in a two-necked 
flask under nitrogen protection. Succinic anhydride (4.96 mg, 49.6 µmol, 10 % molar ratio to 
amine in PSeSe) in 2 mL DMSO was injected to the suspension of PSeSe. After overnight 
magnetic stirring at room temperature under N2, the mixture turned into transparent grey color. 
After dialysis against deionized water using a 3.5kDa MWCO tube and freeze drying, 
PSeCOOH10%, carboxylic group conjugated microgels, was obtained. Besides, the feed molar 
ratio of succinic anhydride to amine in PSeSe were also varied from 5 to 20 % to produce the 
PSeCOOH5% and PSeCOOH20%.  
PSeCOOH10% (61.1 mg, 28.6 µmol of COOH group) was re-dissolved in 10 mL of DMSO 
under nitrogen gas flow. NHS (13.17 mg, 114.4 µmol) and EDC (32.9 mg, 171.6 µmol) 
dissolved in 2 mL DMSO were added into the suspension with magnetic stirring for 45 min. 
Tert-butyl carbazate (5.67 mg, 42.9 µmol) dissolved in 1 mL of DMSO was then injected into 
the mixture and stirred at room temperature for 16 h. Dialysis against deionized water was 
carried out to purify the microgels for 5 days. After being lyophilized, microgels with BOC-
protected hydrazine bond conjugates (PSeBOC10%) was produced. Similarly, PSeBOC5% 
and PSeBOC20% were also synthesized from PSeCOOH5% and PSeCOOH20%. 
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Finally, TFA (2 ml, 26 mmol) was injected into the suspension of PSeBOC10% (55.3 mg, 23.7 
µmol of BOC group) in 10 mL DMSO under nitrogen environment. The mixture was 
magnetically stirred at room temperature for 24 h. After dialysis and freeze dry, hydrazine bond 
conjugated microgels of PSeH10% (PSeH) was obtained. Similar approach was used to prepare 
the microgels of PSeH5% and PSeH20% as well. 
The hydrodynamic size distributions of PSeH microgels in 25 mM DTT aqueous solution was 
detected at 37 °C for 5 days via dynamic light scattering (DLS) measurement in a Malvern 
Zetasizer Nano ZS (ZEN 3600).   
 3.2.3 Co-drug loading and release 
3.2.3.1 DOX loading (PSeHD) and release 
PSeH (30 mg, 13.4 µmol of hydrazine group) was dissolved in 5 mL pH 7.4 PBS buffer solution, 
and DOX·HCl (7.8 mg, 13.4 µmol) dissolved in 5 mL pH 7.4 PBS with 2 µL of acetic acid. 
The mixture was magnetically stirred at room temperature under dark and nitrogen atmosphere 
for overnight. Dark dialysis of the mixture against deionized water was carried out in a cold 
room at 4 °C with vigorous stirring, and 31.2 mg of DOX loaded microgels (PSeHD) was 
obtained after lyophilisation.  
Since the quantity of unloaded DOX was measured from the UV-vis absorbance of DOX at 
479.5 nm (DOX calibration curve in Figure 3.S5), DOX loading could be calculated using the 
equation:  
DOX Loading (%) =  
(feed DOX−unloaded DOX)
DOX loaded microgels
 × 100                              (1) 
PSeH5% and PSeH20% were also utilized to load DOX and quantify DOX loadings. 
For the ex vivo DOX release assay, each 5 ml of PSeHD (1mg mL-1) placed in a dialysis bag 
(MWCO 3.5kDa) was immersed in 95 mL of PBS pH7.4, PBS pH6.5 and acetate buffered 
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saline (ABS, 0.2 M) pH5.0, and then incubated in a horizontal shaker at 37 °C with 100 rpm.  
1 mL of buffer saline was taken to measure the absorbance of the released DOX from the 
dialysis bags using a UV-vis spectrophotometer at pre-determined time intervals.   
3.2.3.2 MicroRNA-21 inhibitor (miR-21i) loading (PSeHD/miR-21i) and release  
1 µL miRNA-21 inhibitor (miR-21i, 0.42 nmol µL-1) in RNase-free water (DEPC water) was 
mixed with pre-determined N/P ratios of PSeHD dissolved in DEPC water, and incubated at 
room temperature for 20 min. For the N/P ratios, amine contents in PSeHD were determined 
by conductivity and pH titration (Figure 3.S7). Agarose gel (0.8%) electrophoresis was run at 
100 V for 60 min, and then the fluorescent images of RNA migration patterns under UV 
irradiation were photographed using a G-BOX (SYNGENE, A Division of Synoptics Ltd). For 
comparison, PSeH20%D complex was also employed to determine the fully retarded N/P ratio 
in electrophoresis. 
For ex vivo releasing of loaded miR-21i, PSeHD/miR-21i polyplexes with a 4.0 N/P ratio were 
incubated in 20 mM GSH at 37 °C for 24 h. Gel electrophoresis was carried out in 0.8 % 
agarose gel at 100 V for 60 min. The RNA migration image of PSeHD/miR-21i treated with 
20 mM GSH for 24 h was captured by a G-BOX and compared with the one without GSH 
treatment. 
3.2.4 Ex vivo multi-function assays 
3.2.4.1 Hyaluronic acid surface coating (PSeHD/miR-21i/HA) 
PSeHD/miR-21i (at a 10.0 N/P ratio) suspended in DEPC water was mixed with hyaluronic 
acid (HA) at 5.0 w/w ratio of HA to miR-21i at room temperature for 20 min to obtain the 
designated PSeHD/miR-21i/HA.  
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3.2.4.2 Surface charge conversion and ex vivo serum protein adsorption 
Zeta-potentials of PSeHD, PSeHD/miR-21i and PSeHD/miR-21i/HA in 10 mM NaCl solution 
were measured via a Malvern Zetasizer Nano ZS (ZEN 3600) at 25 °C to confirm the 
electrostatic interaction. 
100 µL of PSeHD/miR-21i/HA polyplex (1 mg mL-1) and 100 µL of bovine serum albumin 
(BSA) solution (2 mg mL-1) were incubated with gentle shaking at 37 °C for 30 min and 
centrifuged. 100 µL of supernatant was diluted in 1 mL serum-free deionized water to 
determine the concentration of BSA in the supernatant via a UV-vis measurement at 280 nm. 
The BSA adsorption rate (%) was calculated using following equation: 
BSA adsorption rate (w/w %) =
feed BSA−supenatant BSA
feed BSA
× 100                   (2) 
PEI800 and Lipofectamine2000 were utilized as controls with a UV-vis calibration curve 
shown in Figure 3.S9.   
3.2.4.3 Degradation of PSeHD/miR-21i/HA polyplexes  
The hydrodynamic particle sizes of PSeHD/miR-21i/HA was detected at 37 °C via dynamic 
light scattering using a Malvern Zetasizer Nano ZS (ZEN 3600). PSeHD/miR-21i/HA, 
consisting 20 µL of miR-21i (0.42 nmol µL-1) at a 10 N/P ratio of PSeHD and five times HA 
to miR-21i (w/w), were diluted in deionized water for particle size measurements. 
Degradation of PSeHD/miR-21i/HA polyplexes was evaluated by measuring their particle 
sizes under three mimicking environments at PBS buffer pH7.4: 0 M GSH for physiological 
condition, 10 µM GSH for extracellular microenvironment, and 20 mM GSH for cytosols. An 
aliquot from the microgel solutions was collected at the pre-designed time during continuous 
shaking at 100 rpm under 37 °C with their size being detected using dynamic light scattering 
at 37 °C. 
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3.2.5 Cell culture 
Breast cancer cell line (MDA-MB-231) and kidney cell line (HEK 293T) were incubated with 
Dulbecco Modified Eagle Medium (DMEM) supplemented with 10% (vol/vol) fetal bovine 
serum (FBS) and 1% (vol/vol) penicillin-streptomycin (PS) in an incubator (Contherm 
Scientific Ltd.) under a humidified atmosphere at 37 °C with 5 % CO2. Trypsin-EDTA (0.25 %) 
was used to recover cells after culture.  
3.2.6 Cellular uptake assays 
Cellular uptake into cells was monitored qualitatively by an Olympus FV3000 confocal laser 
scanning microscope (CLSM). MDA-MB 231 cells with a seeding density of 0.1×106 cells per 
well were cultured on a glass cover slip at the bottom of a 12 well plate with their culture 
medium for 24 h in an incubator. 50 µL sample was prepared with 12.5 µg PSeHD/FAM-
miR/HA at 4.0 % DOX, 10.0 N/P of FAM-labelled miRNA inhibitor single stranded negative 
control (FAM-miR) and 5.0 folds weight of HA to FAM-miR. The sample was applied to the 
cells after replacing the old medium with 950 µL of fresh one, and further incubated at 37 °C 
for 4 h. After being washed by PBS, cells were stained by the CellMaskTM Deep Red Plasma 
Membrane Stain for 10 min, and then fixed in 4 % formaldehyde for 10 min. After 3 washes 
with PBS, the cellular uptake of carriers was observed by fluorescent images of DOX (blue), 
FAM-miR (green) and cells (red) via the CLSM. The uptake images of carriers were compared 
to those of cells without carriers and those of cells after HA pre-treatment (10 mg HA/mL culture 
medium for 24 h). 
Quantitative cellular uptake was determined by a flow cytometer (BD FACSCaliburTM). MDA-
MB 231 cells with a density of 0.05×106 cells per well were grown in a 24 well plate with 500 
µL culture medium for 24 h. The culture medium was replaced with 450 µL of fresh medium 
and 50 µL of solution containing 5 µg PSeHD/FAM-miR/HA at 10.0 N/P and 5.0 wt HA/wt 
FAM-miR. Control cells without PSeHD/FAM-miR/HA and HA pre-treated cells with 
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PSeHD/FAM-miR/HA were prepared. The 24 well plate were incubated for another 4 h. After 
rinsing 3 times by PBS, cells were collected by trypsin-EDTA treatment to quantify the 
fluorescent intensities of DOX and FAM-miR for cellular uptake. The intensity of FL-1 (ex. 
488, em. 530 nm) and FL-2 (ex. 488, em. 585 nm) represents FAM-miR and DOX. 
3.2.7 In vitro biocompatibility assays of microgels without co-drugs 
Biocompatibility of PSeH microgels was evaluated via in vitro HEK293T viability assays using 
the Cell Counting Kit-8 (CCK-8). Cell survival rates were compared to these from PEI25k as 
a negative control and from PEI800 and lipofectamine2000 as positive controls. HEK293T 
cells (5000 cells per well) were cultured in a 96 well plate with 100 µL of culture medium in 
an incubator for 24 h. 10 µL of three different concentrations (1.0, 10.0, 50.0 µg mL-1) of 
microgels were added to the well plate, followed by another 48 h incubation. After another 4 h 
incubation with CCK-8 solution, the well plate were inserted in a microplate reader (ELx808 
BioTek) to measure the absorbance at 450 nm with cell survival rates being determined from 
the following equation: 
𝐶𝑒𝑙𝑙 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑟𝑎𝑡𝑒 (%) =  
𝐴−𝐵
𝐶−𝐵
 × 100                                         (3) 
where A is the absorbance of microgel samples; B is the absorbance of blank (no cells); and C 
is the absorbance of control (only cells without samples). 
Biocompatibility of biodegraded microgels was evaluated against HEK 293T cells. Various 
concentrations (1.0, 10.0, 50.0 µg mL-1) of PSeH solutions with 20 mM GSH were incubated 
at the same condition for cell culture for 24 h. These biodegraded microgels were applied to 
pre-cultured HEK 293T cells in a 96 well plate for another 48 h incubation. After CCK-8 
treatment, the survival rates of kidney cells in each well were determined via the microplate 
reader and Equation 3.  
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3.2.8 In vitro cell viability assays for the efficacy of PSeHD/miR-21i/HA 
The therapeutic efficacy of PSeHD/miR-21i/HA was evaluated via the cell viability assays 
using both MDA-MB-231 and HEK 293T cells. Each type of cells was incubated in a 96 well 
plate for 24 h, and then incubated for another 48 h in the presence of PSeHD/miR-21i/HA 
(DOX loaded concentration varies from 0.1, 0.25, 0.5, 1.0 to 2.5 µg mL-1). After subsequent 4 
h CCK-8 treatment, cell survival rates were obtained from microplate reader. Cell viabilities 
against PSeHD/miR-21i/HA were compared with those against PSeHD/miR-21i, PSeHD and 
DOX·HCl for both cell lines. 
 
3.3 Results and Discussion 
3.3.1 Synthesis of PSeH microgels 
Positively charged polymers are oftentimes chosen as the non-virus vectors to load and deliver 
nucleic acids. PEI with its molecular weight of 25 KDa is a gold standard for gene delivery but 
has significant cytotoxicity. Our previous studies have shown that chemical-crosslinked 
PEI800 microgels had minor cytotoxicity and excellent gene delivery capability [39]. In this 
study, low toxic and multifunctional PSeH microgels were synthesized by crosslinking low 
molecular weight branched-PEI800 with diselenide bonds (Scheme 3.2A) and then conjugating 
anticancer drug of DOX by hydrazine bonds as new co-delivery carriers of DOX and 
microRNA-21 inhibitor (miR-21i) (Scheme 3.2B).  
The smart crosslinker of 3,3’-diselanediyldipropanoic acid (-SeSe-) containing a redox-
cleavable diselenide bond was synthesized with a yield of 57 %. The Raman peaks of the 
selenium-selenium bond (-Se-Se-) and selenium-carbon bond (-Se-C-) are evident at the 
Raman shifts of 291 and 517 cm-1 (Figure 3.S1) [48, 49]. In addition, the new peak at 520 cm-
1 can be observed from the FTIR spectrum (Figure 3.S2) of (-SeSe-), which is related to the 
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new selenium-carbon bond. 1690 cm-1 is the vibration band of –COOH, which is consistent 
with the 3-chloroproionic acid precursor. 
PEI800 was crosslinked by 3,3’-diselanediyldipropanoic acid (-SeSe-) to form PEI microgel 
(PSeSe) with a yield of 73 %. FTIR spectra (Figure 3.S2) confirm successful synthesis of 
microgels. Distinct PEI800 peaks at 3351, 1547, and 1042 cm-1 correspond to the N-H 
stretching, N-H bending and C-N stretching, and the peak at 520 cm-1 is related to for Se-C 
stretching. The shift of C=O stretching from 1690 to 1630 cm-1 indicates the formation of amide 
bonds between PEI800 and the crosslinker (-SeSe-). The amount of amine groups of PSeSe 
was measured by pH and conductometric titrations (Figure 3.S3B), where 4.96 µmol amine mg
-
1 
PSeSe is obtained and this crosslinking reaction consumes 35 % of amine of PEI800 (Figure 
3.S3A). 
pH-responsive hydrazine bond was then introduced to PSeSe to produce smart co-delivery 
carrier PSeH10% (PSeH) microgels with a yield of 48 %. Besides, PSeH5% and PSeH20% 
microgels with 5% and 20% feed molar ratios of hydrazine to amine in PSeSe microgels were 
also synthesized. Successful synthesis of these redox-sensitive PSeH microgels is confirmed 
via measuring the hydrodynamic sizes and relevant particle size distributions in 25 mM DL-
dithiothreitol solution (DTT) over time in Figure 3.S4. There is only one narrow single peak of 
the microgel at 217 nm before exposure to DTT, and the size distribution after 0.5 h DTT 
interaction centered at 198 nm. After 2 h, two peaks are observed in the distribution with the 
small size at 10 nm and the large one at 190 nm. Increasing time from 8 to 24 h, the amount of 
10 nm particles increases and the peak of large particles keep on dropping. Associated with the 
cleavage of diselenide crosslinkers of microgels, more and more PEI fractures are detached. 
After 5 days, only 10 nm small particles can be observed, indicating the fully degradation of 
the PSeH microgels in the presence of DTT. 




Scheme 3.2 (A) Synthesis of PSeH microgels as co-delivery carriers, (B) loading of DOX 
(PSeHD), miR-21i (PSeHD/miR-21i) and HA (PSeHD/miR-21i/HA) to PSeH microgels. 
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3.3.2 Controlled loading and releasing of DOX and miR-21i 
3.3.2.1 DOX loading (PSeHD) and releasing 
To effective eliminate leakage and uncontrolled release during the delivery course, DOX as a 
model anticancer drug was loaded to PSeH microgels through a hydrazone bond. The ketone 
group of DOX in the presence of acetic acid was covalently conjugated to the hydrazine amine 
group in PSeH [50]. DOX loading to the microgels via various molar hydrazine groups 
produced PSeH5%D, PSeH10%D, and PSeH20%D. DOX loading was determined by the 
difference between DOX feed and residual using the Equation 1. The amount of feed and 
unloaded DOX was obtained via spectroscopic measurements (Figure 3.S6) with a UV-vis 
calibration curve at a wavelength of 479.5 nm (Figure 3.S5). DOX loading for PSeH5%D, 
PSeH10%D, and PSeH20%D are 1.0, 4.0 and 18.7 wt %, indicating DOX loading increases 
with the substituted hydrazine in microgels.    
The selective ex vivo DOX release profiles of PSeH10%D (PSeHD) complexes were 
conducted using a dialysis method against different pH buffer solutions mimicking intracellular 
environments: pH 5.0 for endo-lysosomes, pH 6.5 for extracellular environment of cancer cells, 
and pH 7.4 for the extracellular environment of normal cells. In Figure 3.1A, 92 ± 4.6 % of 
loaded DOX is released from PSeHD at pH 5.0 over 48 h, while 52 ± 4.2 % and 28 ± 2.2 % of 
DOX at pH 6.5 and pH 7.4 during the same duration. These controlled releasing patterns of 
DOX outweigh those from non-conjugative DOX loading methods [21-25]. The formed 
hydrazone bonds can be cleaved at the pH of intracellular late endosomes or lysosomes and the 
extracellular environment of cancer cells, but are rather stable at the physiological pH of the 
extracellular environment of normal cells. The pH responsive release of chemically loaded 
DOX in PSeHD microgels confirms its potential for controlled release of anticancer drugs to 
target cells. 
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Figure 3.1 (A) Hydrazone bond cleavage to determine DOX release from PSeHD microgels at 
pH 5.0, 6.5 and 7.4 buffer solutions after 48 h. (P <0.05, n = 3), (B) Loading of miR-21i to 
PSeHD at different N/P ratios (1, 2, 4 and 6), PEI25K as the reference, (C) Comparison of miR-
21i release after incubation in 20 mM GSH for 24 h. 
 
3.3.2.2 MicroRNA-21 inhibitor loading (PSeHD/miR-21i) and releasing  
The anticancer efficiency of DOX in metastatic cancer cells is undermined due to the presence 
of miRNA-21 (miR-21), which requires a co-delivery carrier for miR-21 inhibitor (miR-21i) 
and DOX to enhance the therapeutic effect of DOX by inhibiting miR-21 and activating 
apoptosis [14, 18]. PSeHD complexes loaded miR-21i by electrostatic interaction, forming 
PSeHD/miR-21i polyplexes. Anionic phosphate (P) in miR-21i binds to cationic nitrogen (N) 
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in PSeHD complex in aqueous solution. The miR-21i loading capacity was evaluated via a 0.8 % 
agarose gel retardation assay. In Figure 3.1B, full retardation of PSeHD is achieved at an N/P 
ratio (PSeHD to miR-21i) of 4. Comparing with the PEI25K as a positive control, miR-21i 
migration from the polyplexes with PEI25K is slightly less than PSeHD at an equivalent N/P 
ratio of 1, but far more than PSeHD at the N/P ratio of 2. Therefore, PSeHD shows miR-21i 
loading capability as good as PEI25K. miR-21i loading to PSeH20%D was also evaluated 
(Figure 3.S8), and full retardation occurred at 10 N/P. PSeH20%D complexes have a high DOX 
loading but a low miR-21i loading capacity since DOX conjugation consumes some amine 
groups of microgels and thus sacrifices positive charge density for miR-21i loading. In addition, 
the amine groups in hydrazine and DOX are inefficient to load miR-21i since their pKa values 
(7.20 and 7.55) are closed to physiological pH 7.4 [51, 52]. Moreover, the presence of large 
and hydrophobic DOX in microgels further contributes to a decrease in electrostatic interaction 
between nucleic acid and PEI. That can be further confirmed with a high miR-21i loading 
affinity and a low DOX loading by PSeH5%D. Taken together, miR-21i loading capacity of 
the complexes is inversely proportional to their DOX loading ability, and PSeH10%D (PSeHD) 
shows a balanced DOX and miR-21i loading (Table 3.S1).  
The ex vivo miR-21i releasing profiles were evaluated via agarose gel electrophoresis after 
incubating PSeHD/miR-21i (4 N/P) microgels for 24 h at 37 °C with and without the presence 
of 20 mM GSH (Figure 3.1C).  miR-21i is migrated out of the PSeHD/miR-21i polyplexes with 
GSH, while miR-21i is full-retarded by PSeHD/miR-21i polyplexes without GSH. The 
diselenide bonds in complexes can be reduced in the presence of 20 mM GSH similar to the 
reductive microenvironment in cytosol [53]. PSeHD is degraded into small fragments after 
cleavage of crosslinkers. Low molecular PEI has weak interaction with miR-21i, and thereby 
the previously loaded miR-21is are released. This result strongly supports the polyplexes 
release miR-21i in the cytosol of cancer cells due to the presence of reducing enzymes. 
















Figure 3.2. (A) Zeta potentials of PSeHD, PSeHD/miR-21i at 10 N/P and PSeHD/miR-21i/HA 
at 5 w/w ratio of HA to miR-21i (P < 0.05, n = 3). (B) Protein adsorption by PSeHD/miR-
21i/HA (5 w/w ratio of HA to miR-21i) against BSA with PEI800 and Lipofectamine2000 as 
controls (n = 3), (C) ex vivo biodegradability of PSeHD/miR-21i/HA by measuring 
hydrodynamic sizes in PBS 7.4 with 0 M, 10 µM and 20 mM GSH over 168 h. (n = 3) 
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3.3.3 Ex vivo multi-function assays 
3.3.3.1 Hyaluronic acid surface coating (PSeHD/miR-21i/HA) 
Cationic polymer gene delivery carriers may interact with anionic serum during blood 
circulation, leading to capture by reticuloendothelial system (RES), such as liver and spleen, 
before reaching their destination [30, 54]. The carriers may be endocytosed by electrostatic 
interaction with any cell membrane unselectively, resulting in a low delivery selectivity and 
strong side effects [55, 56] . To protect the delivery systems from serum adsorption and enable 
selective endocytosis, hyaluronic acid (HA) was coated to PSeHD/miR-21i polyplexes (at a 10 
N/P) by electrostatic interaction with a HA to miR-21i feed weight ratio of 5, producing the 
PSeHD/miR-21i/HA.  
3.3.3.2 Surface charge conversion and ex vivo serum protein adsorption 
Positive charged PSeHD complexes facilitates miR-21i and HA loading through electrostatic 
interaction, and endosome/lysosome escaping via the proton sponge effect [57]. After loading 
miR-21i to PSeHD, HA is introduced to generate a surface negative charged PSeHD/miR-
21i/HA. Zeta-potentials of PSeHD, PSeHD/miR-21i and PSeHD/miR-21i/HA were measured 
at 25 °C (Figure 3.2A). A positive zeta-potential of PSeHD at +30.0 ± 1.4 mV slightly decreases 
to +28.0 ± 1.1 mV after loading miR-21i at the 10 N/P, and further reduces to -26.1 ± 0.9 mV 
after HA surface coating. The results indicate successful HA coating to the PSeHD/miR-21i 
polyplexes via electrostatic interaction.   
Negative-charged co-delivery system of PSeHD/miR-21i/HA is able to minimize protein 
adsorption and maintain its structural integrity during the blood circulation. The stability of 
delivery carriers during blood circulation was evaluated by ex vivo BSA adsorption assays. In 
Figure 3.2B, BSA adsorption onto the PSeHD/miR-21i/HA is almost negligible, as low as 0.15 
± 0.01 % of total BSA, in comparison with 25.2 ± 1.3 % and 51.2 ± 2.6 % for PEI800 and 
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Lipofectamine2000. Negatively charged surfaces of PSeHD/miR-21i/HA induce electrostatic 
repulsion against negatively-charged serum proteins. As a result, PSeHD/miR-21i/HA is able 
to escape from rapid RES removal and prolong blood circulation time, and thus maintain its 
high stability during systemic circulation.  
3.3.3.3 Controlled degradation of PSeHD/miR-21i/HA delivery systems 
PSeHD/miR-21i/HA polyplexes are designed to ensure their sizes between 20 and 200 nm, 
which promotes passive targeting of the polyplexes to cancer cells by the EPR effects [58]. The 
polyplexes maintain their morphology during systemic circulation to minimize miR-21i loss 
before cellular uptake. On the other hand, the PSeHD/miR-21i/HA delivery system is 
biodegradable under the intracellular cytoplasm microenvironment to release miR-21i and the 
degraded fragments are excreted from the patient body [31]. Diselenide crosslinkers are stable 
under a physiological condition to maintain the polyplex structures of PSeHD/miR-21i/HA, 
but can be cleaved in the presence of reductive enzymes at a high concentration. The 
responsiveness of PSeHD/miR-21i/HA polyplexes to the reductive environment was evaluated 
in pH 7.4 PBS buffer with different ex vivo mimicking environments: 0 M GSH for a normal 
physiological condition, 10 µM GSH for an extracellular tumor environment, and 20 mM GSH 
for a cytosol condition [53]. Degradation experiments were monitored with the hydrodynamic 
size change of PSeHD/miR-21i/HA polyplexes at these conditions and 37 °C. 
In pH 7.4 PBS with 0 M of GSH, PSeHD/miR-21i/HA polyplexes have good stability by 
retaining their initial size of 161 ± 8.1 nm over 7 days (Figure 3.2C). At the GSH level of 10 
µM and pH 7.4, the polyplex size slightly drops to 121 ± 5.5 nm over 7days. These results 
confirm PSeHD/miR-21i/HA possesses a stable size under the mimicking environments of 
blood circulation and the extracellular environment of heathy cells so that its accumulation in 
cancer tissue can be enhanced by passive cancer targeting due to the enhanced permeability 
and retention (EPR) effect and minimal premature leakage of miR-21i [59]. 
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On the other hand, a high concentration of GSH in cancer cytosol condition induces a reduction 
in particle size associated with the degradation of polyplexes by cleavage of the diselenide 
bonds of crosslinkers. 20 mM GSH was chosen to mimic the cytosol condition. From Figure 
3.2C, the initial size of PSeHD/miR-21i/HA rapidly reduces to 46 ± 1.7 nm within 24 h, and 
further decreases to 10 ± 1.1 nm after 5 days. This result strongly supports PSeHD/miR-21i/HA 
polyplexes are fully biodegradable in the mimicking cytosol condition. After releasing cargoes 
into cytosol, the microgel carrier will be fully degraded into small-sized particles and excreted 
from body [31, 42, 60].   
3.3.4 Cellular uptake assays 
Delivery systems with surface HA coating can be endocytosed via HA receptors, such as CD44 
and RHAMM, which are widely spread on the surface of invasive MDA-MB-231 cells, but are 
rarely distributed on the surface of normal cells or non-invasive breast cancer cells (e.g., MCF7)  
[61]. To monitor cellular uptake of PSeHD/miR-21i/HA to MDA-MB-231 cells via HA 
receptors meditated endocytosis, PSeHD/FAM-miR/HA was prepared using fluorescent dye 
labelled miRNA (FAM-miR) replacing miR-21i with evaluation being qualitatively and 
quantitatively measured by CLSM and flow cytometer. 
Cellular uptake of PSeHD/FAM-miR/HA were imaged under a CLSM.  FAM-miR and DOX 
were excited at 488 nm and emitted at 530 and 580 nm, and cells were stained by the 
CellMaskTM Deep Red plasma membrane stain (ex: 640 nm, em: 666 nm). Figure 3.3A shows 
cells without any loading as a control with red color for the stained membranes. For the system 
in the presence of PSeHD/FAM-miR/HA, the red color (cells) overlaps with green (FAM-miR) 
and blue (DOX) colors to emit a purple color (Figure 3.3B), indicating uptake of the 
PSeHD/FAM-miR/HA to cells. While incubating PSeHD/FAM-miR/HA with the HA pre-
treated cells, Figure 3.3C shows a limited amount of green and blue colors, indicating cell 
uptake of PSeHD/FAM-miR/HA is impaired due to block of the HA receptors by pretreated 
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HA. The CLSM results suggest that the PSeHD/miR-21i/HA is endocytosed to metastatic 
cancer cells via surface HA receptors, while it has a limited capacity of entering cells without 
HA receptors.  
(A)                                 (B)                                 (C)                     
 
Figure 3.3 Qualitative cellular uptake under a confocal laser scanning microscope (CLSM): 
(A) MDA-MB-231 cells without delivery carriers, (B) MDA-MB-231 cells with delivery 
carriers loaded with FAM-miR and DOX (PSeHD/FAM-miR/HA), (C) HA pre-treated MDA-
MB-231 cells with the delivery carriers loaded with FAM-miR and DOX (PSeHD/FAM-
miR/HA), scale bar 15 µm. 
 
Cellular uptake of PSeHD/FAM-miR/HA into MDA-MB 231 was further quantitatively 
evaluated via flow cytometry. For the control of cells without PSeHD/FAM-miR/HA (Figure 
3.S10A), 97 % cells in left-down section exhibit no fluorescence at the wavelengths of FAM 
and DOX. In the presence of PSeHD/FAM-miR/HA, 98 % cells are positioned at the right-
upper side in Figure 3.S10B with strong fluorescent signals of FAM and DOX, indicating a 
high efficiency of cellular uptake of PSeHD/FAM-miR/HA. For the HA pre-treated cells, less 
than 4 % FAM and DOX signals are depicted in Figure 3.S10C. Quantitative analysis results 
agree well with those from CLSM that PSeHD/FAM-miR/HA selectively enters MDA-MB-
231 cells via HA receptor-meditated endocytosis. Since HA pre-treated MDA-MB 231 cells 
have no free surface receptors for PSeHD/FAM-miR/HA, these cells behave as normal cells or 
non-invasive breast cancer cells. It may conclude that the PSeHD/miR-21i/HA polyplexes 
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actively target invasive breast cancer cells of MDA-MB-231, while they may not be uptaken 
by normal cells or non-invasive breast cancer cells. 
3.3.5 Biocompatibility evaluation 
If anticancer chemotherapy is conducted with a delivery carrier, it is mandatory to demonstrate 
its minimal side effects to healthy cells throughout delivery process. Healthy cell viability 
assays were operated to evaluate biocompatibility of the delivery system under conditions of 
before co-drug loading, after co-drug loading and after co-drug release.  
3.3.5.1 Microgels before DOX and miR-21i loading 
The biocompatibility of PSeH microgels before DOX and miR-21i loading were in vitro 
evaluated via cell viability assays on the kidney cell line (HEK293T) after 48 h incubation. In 
Figure 3.4A, the PSeH microgels exhibit 85 ± 7.1 % cell survival at a concentration of 50 µg 
mL-1, which is comparable to the 86 ± 5.0 % for PEI800 and 82 ± 3.9 % for Lipofectamine2000 
as positive controls. In contrast, PEI25k shows high cytotoxicity with 49 ± 4.1 % HEK293T 
cell survival rate at 50 µg mL-1. The PSeH microgels as delivery carriers prepared by 
crosslinking low molecular weight PEI800 retain competent biocompatibility of PEI800, which 
is similar to our previously reported disulfide crosslinked PEI800 [39]. 
3.3.5.2 Microgels after DOX and miR-21i loading  
Biocompatibility of delivery carriers with therapeutic loading was examined via HEK293T cell 
viability assays after 48 h incubation against free DOX, DOX loaded microgels (PSeHD), and 
miR-21i inhibitor (10 N/P) loaded PSeHD with HA coating (PSeHD/miR-21i/HA). Diverse 
DOX loading concentrations of PSeH microgels from 0.1 to 2.5 µg mL-1 were employed to 
evaluate their side effect to normal cells. PSeHD and PSeHD/miR-21i/HA show remarkably 
high cell survival (96.2 ± 2.0 % and 93.6 ± 4.5 %) as a DOX concentration below 1 µg mL-1 
(Figure 3.4B), and the cell survival rate decreases to 75 % at the highest DOX concentration 
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of 2.5 µg mL-1. As a negative control, free DOX displays significant cytotoxicity to healthy 
cells with a sharp drop of the cell survival rate to 45.9 ± 10.7 % at a DOX concentration of 0.5 
µg mL-1, and further down to 35.4 ± 4.7 % at a DOX concentration of 2.5 µg mL-1. The most 
cytotoxic sample to HEK293T cells is free DOX due to its highest cellular uptake via diffusion 
and hydrophobic interaction with the lipid cellular membrane [52]. However, for the developed 
smart delivery systems, DOX being conjugated to microgels to form hydrazone bonds are 
stable in physiological condition (pH 7.4), and thus effectively minimizing DOX release. The 
stability of the hydrazone bond in PSeHD may be maintained after endocytosis, even in the 
acidic endosomes-lysosomes. Time for highly positive charged polymer nanoparticles to 
escape from endosomes-lysosomes is less than 10 minutes, too short to effectively cleave the 
hydrazone bond and intensively release DOX, supported in Figure 3.1A and Panyam et al. [62, 
63]. On the other hand, PSeHD/miR-21i/HA maintains good biocompatibility as that of PSeHD, 
whereas PSeHD/miR-21i without HA is less biocompatible (Figure 3.4E). DOX release 
profiles from PSeHD and PSeHD/miR-21i in pH 7.4 PBS are compared in Figure 3.S11. An 
increase in DOX release might be attributed to a decrease in the buffering capability of PSeHD 
after miR-21i loading. Additionally, cell apoptosis may be provoked by PDCD4 due to loss of 
suppression by miR-21 after miR-21i is released from PSeHD/miR-21i, while the miR-21 
activity of 3 relative inhibiting folds (RIFs) and the miR-21 expression level of near 0.005 (2ΔCt) 
in HEK293T cells are lower than those in many tumor-derived cell lines [64, 65]. The better 
biocompatibility of PSeHD/miR-21i/HA than PSeHD/miR-21i to normal cells is associated 
with HA coating. Endocytosis of negatively-charged PSeHD/miR-21i/HA into HEK293T cells 
is limited as HA receptors of CD44 and RHAMM are rarely expressed [61]. Due to the specific 
cancer-targeting function of PSeHD/miR-21i/HA, toxicity of this cancer chemotherapy system 
to healthy cells can be significantly reduced. The cell survival rate against PSeHD/miR-21i/HA 
at a DOX concentration of 2.5 µg mL-1 is 75 %, but this DOX concentration is far above the 
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recommended treatment dosage of around 0.1 µg mL-1 [66]. Therefore, the PSeHD/miR-
21i/HA system may be safely considered for cancer chemotherapy with minimal side effects. 
3.3.5.3 Microgel fragments after DOX and miR-21i release 
The HEK293T cell viabilities against biodegraded PSeH microgel fragments were evaluated. 
From previous ex vivo study, PSeH microgels is biodegraded into 10 nm fragments in the 
mimicking intracellular environment of 20 mM GSH. Although these small sized fragments 
can be readily excreted from a patient body via kidney, their in vitro cytotoxicity remains 
unknown [31, 67]. The fragments of biodegraded PSeH microgels under the mimicking cytosol 
environment (20 mM GSH 24 h) show 97.2 ± 3.7 % survival rate of HEK293T cells at a DOX 
concentration of 50 µg mL-1 (Figure 3.4C). The result is better than 86 % of cell survival against 
PSeH microgels and PEI800 respectively, which may be due to its smaller size than PSeH 
microgels and a lower charge density than PEI800. Therefore, it is expected that the 
biodegraded microgels can be excreted without damage to the patient’s kidney.  
As a result, the smart PSeH microgel delivery carriers before cargo loading, after cargo (DOX 
and miR-21i) loading and after cargo release have shown great biocompatibility, rendering a 
great potential for chemotherapy with minimal side-effects. 
3.3.6 Synergistic therapeutic effect on metastatic breast cancer cells 
The therapeutic efficacy of doxorubicin (DOX) and miRNA-21 inhibitor (miR-21i) delivered 
by PSeH microgels on metastatic breast cancer cells (MDA-MB-231) was evaluated via in vitro 
viability assays. The survival rates of the invasive breast cancer cell were studied after 48 h 
incubation with DOX·HCl (free DOX), PSeHD, PSeHD/miR-21i and PSeHD/miR-21i/HA 
over an equivalent DOX concentration range from 0.1 to 2.5 µg mL-1. The anticancer 
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therapeutic effect of DOX has been significantly enhanced for PSeHD, and further improved 
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Figure 3.4 Cell viability, (A) HEK293T survival rate against various carriers (PEI800, PSeH, 
lipofectamine2000 and PEI25k) before loading DOX (n = 4), (B) HEK293T survival rates 
against free DOX and DOX loaded PSeHD and PSeHD/miR-21i (10 N/P) (n = 4), (C) 
HEK293T survival rates against PEI800, PSeH and degraded fragments of PSeH after 
incubation in 20 mM GSH for 24 h (P < 0.05, n = 4), (D) MDA-MB-231 survival rate against 
free DOX, PSeHD and PSeHD/miR-21i (10 N/P) (n = 4), (E) Comparison of cell survival rates 
of HEK293T cells and MDA-MB-231 cells against PSeHD/miR-21i and PSeHD/miR-21i/HA 
(n = 3) (10 N/P and 5 w/w ratio of HA to miR-21i), and (F) IC50 values (µg mL
-1) of free DOX, 
PSeHD and PSeHD/miR-21i/HA. (P < 0.0001, n = 4)  
 
With increasing DOX concentration, cancer cell survival rates decrease for all samples. 
Treatment with free DOX leads to one half of cells survived at a DOX concentration of 2.5 µg 
mL-1. In the PSeHD group, a lower survival rate (37 ± 2.2 %) than free DOX at 2.5 µg DOX 
mL-1 is shown. The improved therapeutic efficacy of PSeHD is due to its higher cellular uptake, 
which aligns well with a similar result with a breast cancer cell line MCF-7 by Misra et al. [68]. 
Cancer cellular uptake of free DOX is lower than that of normal cells [10]. At a slightly acidic 
extracellular environment of cancer cells (~ pH 6.5), free DOX is protonated (pKa 7.55 of 
amine in DOX), which inhibits its interaction with hydrophobic tails of phospholipid cellular 
membrane and leads to a lower permeability than un-protonated DOX [52, 69]. Additionally, 
the Eksborg’s partition experiment also supports reduced diffusion of free DOX from a slightly 
acidic aqueous environment to an intracellular organic phase due to the formation of DOX 
dimer and tetramer with protonated DOX [70]. Therefore, less cytotoxicity of free DOX is 
found for cancer cells than normal cells, as shown in Figures 3.4B and 3.4D and previous 
reports [11, 12].  
In contrast to free DOX, PSeHD enters cancer cells via endocytosis by electrostatic interaction 
with cell membrane [71]. Conjugation of DOX with PSeHD via a pH responsive hydrazone 
bond is partially cleaved or weakened in a slightly acidic cancer extracellular environment 
(Figure 3.1A). The released DOX in the extracellular fluid or loosely bound DOX to the carriers 
might be engulfed into cells by micropinocytosis and transported to acidic endosomes-
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lysosomes for intensive release of DOX [72]. Therefore, delivery of DOX by PSeHD results 
in a higher therapeutic efficacy than free DOX to cancer cells. 
After loading miR-21i onto PSeHD microgels (PSeHD/miR-21i), the cell survival rate of 
MDA-MB-231 cells against PSeHD/miR-21i is down to 33.1 ± 2.6 % at a DOX concentration 
of 2.5 µg mL-1. PSeHD/miR-21i delivery systems can release miR-21i into cytosol of the cells 
in the presence of 10 to 20 mM glutathione (GSH), which induces cleavage of diselenide bonds 
of the polyplex carriers [53]. The biodegraded fragments have weak electrostatic interaction 
with miR-21i and release them to cytosol. Comparing with the therapeutic performance of free 
DOX and PSeHD, PSeHD/miR-21i demonstrates a synergistic effect from both DOX and miR-
21i on invasive breast cancer treatment. The miR-21i inhibits the activity of miR-21 in the 
cancer cells, thus inducing cell apoptosis by increasing PDCD4 and re-sensitizing to DOX by 
expression of phosphatase and tensin homolog (PTEN) [14, 17]. 
In order to understand the contribution of HA, MDA-MB-231 cell viabilities for the 
PSeHD/miR-21i with or without HA were evaluated (Figure 3.4E). The MDA-MB-231 cell 
survival rate (%) of PSeHD/miR-21i/HA is 33.5 ± 2.5 at a DOX concentrations of 2.5 µg mL-
1 with a difference of 0.45% in comparison with that of PSeHD/miR-21i. Endocytosis of 
PSeHD/miR-21i/HA is mainly through the receptor-mediated endocytosis pathway via CD44, 
while PSeHD/miR-21i endocytosis via electrostatic interaction with negatively charged 
phospholipids of cell membrane [73, 74]. These demonstrate HA-receptor and electrostatic 
interaction mediated endocytosis of the delivery system lead to identical therapeutic results to 
MDA-MB-231 cells with overexpressed HA receptors. However, significant difference is 
observed for HEK 293T cells (Figure 3.4E). The HEK293T survival rate against the HA coated 
delivery system, PSeHD/miR-21i/HA, is far higher than that against PSeHD/miR-21i without 
HA by 20 % at a DOX concentration of 2.5 µg mL-1. Due to lack of HA receptors on the surface 
of HEK293T cells and negatively charged HA coating, PSeHD/miR-21i/HA cannot enter 
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HEK293T cells through HA-receptors or electrostatic interactions, whereas positively charged 
PSeHD/miR-21i without HA can enter the healthy cells via electrostatic interaction [61, 71]. It 
is clear that the HA coated delivery system, PSeHD/miR-21i/HA, can selectively target cancer 
cells with an improved therapeutic efficiency and reduced off-target induced side effects.  
The DOX concentration for 50 % cell death is classified as the IC50 as shown in Figure 3.4F. 
The IC50 values of PSeHD/miR-21i/HA, PSeHD and free DOX are 0.610, 0.942 and 2.706 µg 
mL-1, respectively. The IC50 value difference for three samples is attributed to the synergistic 
effect of co-drug therapy using DOX and miR-21i. The quantitative therapeutic efficacy of 
PSeHD/miR-21i/HA to MDA-MB-231 cells is 4.4 times higher than free DOX, indicating the 
PSeHD/miR-21i/HA co-delivery system has outstanding advantages over traditional 
therapeutic systems, summarized in Table 3.S2.  
 
3.4 Conclusion 
Multifunctional microgels of PSeH with HA surface coating were synthesized for controlled 
delivery of DOX and miR-21i to target cancer cells for outstanding synergistic anticancer 
effects and minimal side effects. The delivery polyplexes, PSeHD/miR-21i/HA, consist of 
diselenide bond-crosslinked PEI800 to load miR-21i, functional hydrazine bonds for DOX 
conjugation loading and HA for protection and cell targeting. DOX conjugation to PSeH 
minimizes its pre-mature release and promotes controlled release at acidic cancer 
microenvironments. Diselenide-crosslinked PEI800 allows effective electrostatic interaction 
with miR-21i and its stability during blood circulation enables enhanced accumulation at the 
cancer sites before endocytosis. GSH in cytosol facilitates microgel degradation to renal 
clearable sized fragments and controlled release of miR-21i. HA surface coating inhibits 
protein adsorption and promotes active cancer targeting by the HA receptor-mediated 
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endocytosis. In vitro cell viability assays of metastatic breast cancer cell line (MDA-MB-231) 
demonstrate a great antitumor efficacy of PSeHD/miR-21i/HA over free DOX. On the other 
hand, PSeH microgels (before co-drug loading, after co-drug loading and after co-drug release) 
exhibit minimal toxicity to healthy cells. Therefore, this fully microenvironment-degradable 
smart microgels possess a great promise as a co-delivery carrier of DOX and miR-21i for high 
efficient antitumor chemotherapy with notable biocompatibility. 
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Table 3.S1 Comparison on the DOX and miR-21i loading capability of various complexes, 
PSeH5%D, PSeH10%D (PSeHD), PSeH20%D (P < 0.05) 
Type of 
complexes 
Hydrazine contents mol%                                                      
(hydrazine/amine) 




PSeH5%D 5 1.1 N/A 
PSeHD 10 4.0 4 















Table 3.S2 Comparison on the anticancer therapeutic performance of various DOX systems 
from their relative IC50 values on MDA-MB-231 cells. 
Therapeutic systems Relative IC50  
(free DOX / therapeutic systems) 
Citation 
Free DOX 1.0 
 
PSeHD/miR-21i/HA 4.4 Here 
PGA-PTX-DOX 1.6 [1] 
19F-DOX 1.5 [2] 
DOX loaded vesicles 1.0 [3] 
DOX/NG 1.3 [4] 
DOX@MSNs-PPPFA/Bcl-2 1.3 [5] 
 
  









Figure 3.S2 FTIR spectra of 3-chloropropionic acid, diselenide crosslinker of (-SeSe-), 
branched PEI800 and diselenide crosslinked PEI800 microgels (PSeSe). 
  













Figure 3.S4 Time dependent size distributions of PSeH microgels in 25 mM DTT aqueous 
solution at room temperature (n = 3) 
  
(A) (B) 





Figure 3.S5 UV-vis calibration curve of DOX aqueous solutions at the wavelength of 479.5 









Figure 3.S6 UV-vis absorbance at 479.5 nm of feed DOX and unloaded DOX after conjugation 
to PSeH microgels.  
  

















Figure 3.S8 Loading assays of miR-21i to PSeH20%D at different N/P ratios from 1 to 10, 
PEI25K at the N/P of 1 as the reference, images from agarose gel electrophoresis. 
  




Figure 3.S9 UV-vis calibration curve for bovine serum albumin (BSA) absorbance at 280 nm 




Figure 3.S10 Flow cytometry for quantitative cellular uptake of PSeHD/FAM-miR/HA, (A) 
MDA-MB-231 cells without PSeHD/FAM-miR/HA as a control, (B) MDA-MB-231 cells with 
PSeHD/FAM-miR/HA, and (C) HA pre-treated MDA-MB-231 cells with PSeHD/FAM-
miR/HA, FL1 and FL2 indicate FAM and DOX respectively.  




Figure 3.S11 Ex vivo DOX release in pH 7.4 PBS from PSeHD and PSeHD/miR-21i. (n = 3) 
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Multidrug resistance (MDR) of cancers with chronic administration of chemotherapy increases 
dosage and side effects. In this study, we develop novel functional microgels to deliver 
doxorubicin (DOX) and miRNA-21 inhibitor (miR-21i) to MDR cancer cells aiming of 
synergistic anticancer treatment and minimal side effects. To achieve this, our fully 
biodegradable microgels are prepared via crosslinking biocompatible low molecular weight of 
PEI800 with a redox-cleavable diselenide crosslinker. Double-locks of hydrazone and 
diselenide bonds are used for DOX conjugation, and cationic amines of PEI800 for loading 
miR-21i through electrostatic interaction. After drug and microRNA inhibitor loading, the 
complexes are coated by hyaluronic acid (HA) for charge convert and cancer cell targeting via 
HA receptor-mediated endocytosis. Stable systemic circulation of the designed co-delivery 
systems at physiological condition is evident associated with the structural advantages of 
anionic surface charges and dual-lock design to eliminate protein adsorption and drug pre-
mature leakage. On the other hand, selective cancer targeting of the system is strongly 
supported via cellular uptake assays owing to HA mediated endocytosis. Moreover, minimal 
side effect is proved from HEK293T cell survival rate of 95.1 % at a DOX concentration of 2.5 
µg mL-1. In targeting cancer cells, cancer intracellular environment are able to cleave 
hydrazone and diselenide bond to release loaded DOX and miR-21i in cytosol. Consequently, 
3.2 times higher anticancer effect than naked DOX on MDR cancer cell lines of MDA-MB-
231-R12w can appeal a great potential for its further high-efficient therapeutic applications. 
 Keywords: multidrug resistance, hydrazone bond, diselenide bond, DOX, miR-21 inhibitor, 
dual conjugation, PEI800, biocompatible, biodegradable 
 




Doxorubicin (DOX) is considered to a representative anthracycline drug for broad ranges of 
cancers, including triple-negative breast cancers with ineffective endocrine therapy via 
hormone receptors [1, 2]. DOX can effectively damage DNA by inhibition of topoisomerase 
IIα and support apoptosis activation by inhibition of B-cell lymphoma-2 protein [3, 4]. 
However, DOX also induces serious side effects to the organs of liver, spleen, lung, heart and 
kidney, caused by remarkable drug accumulation in organs during systemic administration [5-
7]. With chronic administration of DOX, the anticancer efficiency drops down with emerging 
multidrug resistance (MDR), such as DOX efflux-pump of ATP-binding cassette (ABC) 
transporter with overexpressing P-glycoprotein and chemo-resistance by targeting phosphatase 
and tensin homolog (PTEN) and programmed cell death 4 (PDCD4) with overexpressing 
miRNA-21 [8, 9]. With the aid of miRNA-21 inhibitor (miR-21i) to block the miRNA-21 
activity, DOX shows improving prognosis on cancer cells with MDR [10, 11]. For safe and 
systemic administration, co-delivery carriers of DOX and miR-21i should be developed to 
target MDR cancer cells and avoid side effects from off-target cells as well as eliminating drug 
pre-leakage. 
Practically, various delivery systems have been developed to load DOX by physical 
interactions, such as solvent diffusion, physical encapsulation and electrostatic interaction, but 
always expressing unmanageable premature release of loaded DOX at mimicking 
physiological condition [12-14]. The other method of DOX loading is to conjugate drug to 
carriers via a cleavable linker, such as esters, amides, hydrazones, acetal-core crosslinkers or 
disulfides, to controllably release under a certain internal/external stimuli such as pH and/or 
redox. Although this method reduced premature release, their averaged anticancer efficiency 
was lower than that of free DOX [15-17].  
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For miR-21i delivery, cationic polymer-based non-viral vectors have been widely developed 
recently to electrostatically load anionic gene drugs, such as plasmid DNA, siRNA and miRNA, 
to facilitate their endosomal escape through the proton sponge effects [18-22]. However, high 
positive charge densities of polymer vectors of polyethyleneimine (PEI) with a molecular 
weight of 25 kDa (PEI25k) or poly(L-lysine) (PLL) always induce cell membrane damage via 
the hydrolysis of lipid phosphoester bonds [23]. From our recent studies, high cytotoxicity of 
these polycations could be avoided by the introduction of biodegradable microgels via 
crosslinking biocompatible and weak-charged polymers using various cleavable crosslinkers 
to achieve effective gene loading but minimal cell toxicity [24, 25].  
On the other hand, stable systemic circulation is another essential factor in co-delivery system 
design. Although carriers with their sizes less than 10 nm or over 200 nm can be cleared by 
renal or reticuloendothelial system (RES), cationic carriers interact with anionic serum in blood 
circulation to increase size and easier clearance [26, 27]. Surface protection with polyethylene 
glycol (PEG) has been an option to avoid drug-protein adsorption/interaction, but block 
endocytosis by steric hindrance from long chains of PEG [28]. However, carrier surface with 
hyaluronic acid (HA), as an anionic polysaccharide of extracellular component, can overcome 
PEG dilemma with surface charge convert and HA receptor mediated endocytosis via cluster 
of differentiation 44 (CD44) or receptor for hyaluronan-mediated motility (RHAMM), which 
are overexpressed on the surface of metastatic cancer cells [29]. 
We here present an advanced design for the co-delivery of DOX and miR-21i to achieve 
outstanding anti-MDR cancer performance but minimal side effects. In detail, biodegradable 
cationic microgel carriers are synthesized by conjugating biocompatible PEI800 with 
diselenide crosslinkers for miR-21i loading. Besides, DOX are conjugated to the microgels via 
double-locks of pH sensitive hydrazone bonds and redox cleavable diselenide bonds to 
effectively suppress DOX premature leakage in systemic circulation. Finally, HA surface 
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coating to the DOX and miR-21i co-loaded polyplexes allows charge convert and selective 
endocytosis to metastatic cancer via HA receptor mediation. The delivery system with a 
hydrodynamic size of 150 nm at physiological condition can be full degraded after exposing to 
intracellular microenvironment of MDR cancer cells, allowing release of DOX and miR-21i in 
cancer cytosol (Scheme 4.1) together with easier excretion of carrier fractures from patient 
body. Resultantly, the co-delivery system with remarkable anti-MDR cancer synergies and 
minimal side effects can contribute to further therapeutic applications and provide optimistic 
future to patients who are suffering from MDR cancers. 
 
4.2 Material and methods 
4.2.1 Materials 
Selenium, 3-chloropropionic acid, sodium borohydride (NaBH4), branched-polyethyleneimine 
MW. 800Da (PEI800), 1-ethyl-3-(3-dimethyl-laminopropyl) carbodiimide (EDC), N-
hydroxysulfosuccinimide (NHS), succinic anhydride, tert-butyl carbazate, trifluoroacetic acid 
(TFA), and L-Glutathione reduced (GSH) were purchased from Sigma-Aldrich. Doxorubicin 
hydrochloride (DOX·HCl) was obtained from Wuhan Wang Lianshang Biotechnology Co., 
Ltd. FAM-labelled miRNA inhibitor single stranded negative control with a random sequence 
(sequence 5’-CAGUACUUUUGUGUAGUACAA) and miRNA-21 inhibitor (sequence 5’-
GUCCACUCUUGUCCUCAAUG-3’) were manufactured by Shanghai GenePharma Co.,Ltd. 
Sodium Hyaluronate MW. 66kDa-99kDa (HA) was purchased from Lifecore Biomedical, LLC. 
Dulbecco Modified Eagle Medium (DMEM), fetal bovine serum (FBS), penicillin-
streptomycin (PS), and phosphate buffered saline (PBS) from Life Technologies Australia Pty 
Ltd., and Leibovitz’s Medium (L-15) and Cell Counting Kit-8 (CCK-8) from Sigma-Aldrich 
were utilized in in vitro evaluation. MDA-MB-231 and HEK293T cell lines were kindly gifted 
from Dr Qian Tang from School of Pharmacy at University of South Australia and Professor 
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Andrew Zannettino from South Australia Health and Medical Research Institute (SAHMRI), 
respectively. Deionised water was supplied from Milli-Q water purification system (Spectrum 
Laboratories, Inc.). 
 
Scheme 4.1 Scheme description for the DOX and miR-21i co-loading and co-delivery to cancer 
cells: (A) DOX-conjugated PEI microgel via diselenide and hydrazone bonds (PSeHD-SeSeP) 
and miR-21i loading and HA surface coating to the PSeHD-SeSeP, (B) co-delivery system of 
PSeHD-SeSeP/miR-21i/HA, (C) HA receptor-mediated endocytosis, (D) PSeHD-SeSeP/miR-
21i/HA in endosome/lysosome, (E) hydrazone bond cleaved in acidic lysosome and endosomal 
escape, and (F) diselenide bond cleaved in glutathione-concentrated cancer cytosol and release 
of DOX and miR-21i.  
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4.2.2 Synthesis of DOX loaded microgels (PSeHD-SeSeP) 
4.2.2.1 Diselenide-bond crosslinker (-SeSe-) 
Diselenide crosslinker (-SeSe-) of 3,3’-diselanediyldipropanoic acid was synthesized with a 
slightly modified method from previous study [30]. Selenium powder (1.18 g, 15 mmol) 
suspension in water (5 mL) in a flask under nitrogen protection was stirred with dropwise 
adding sodium borohydride (1.13 g, 30 mmol) aqueous solution (12.5 mL, 4 °C) in an ice bath 
for 10 min. The same amount of selenium powder (1.18 g, 15 mmol) was subsequently added 
into the colorless solution under N2 protection. The mixed solution was heated and stirred at 
105 °C for about 20 min to become reddish-brown color. 3-chloropropionic acid (3.26 g, 30 
mmol) aqueous solution of 7.5 mL with pH adjusting to 8.0 by sodium carbonate was added to 
the reactor flask after cooling down to room temperature. The mixture was stirred under 
nitrogen protection for overnight and then open to atmosphere for another 12 h for unreacted 
selenium oxidization. The mixture pH after being filtered (0.45 µm syringe filter) was adjusted 
to 3.0 with 3 M HCl, and resultant coagulant was extracted with ethyl acetate. After water wash, 
magnesium sulphate dry and filtering, diselenide bond crosslinker (-SeSe-) was crystalized 
from ethyl acetate. To confirm successful synthesis of –SeSe-, Rama spectroscopy and Fourier-
transform infrared spectroscopy (FTIR) were employed.  
4.2.2.2 Diselenide bond crosslinked PEI800 microgels (PSeSe) 
Diselenide bond crosslinked PEI800 microgels (PSeSe) were synthesized with same methods 
in our previous study (Chapter 3). Mixture of -SeSe- (304 mg, 1 mmol), EDC (1150.2 mg, 6 
mmol), and NHS (460.4 mg, 4 mmol) in DMSO (2.1 mL) under nitrogen protection were 
magnetically stirred at room temperature for 45 min. Freeze-dried PEI800 (800 mg, 1 mmol, 
pH 7.4) after pH 7.4 adjustment with 3 M HCl, was dissolved in DMSO (1.6 mL) and added 
to the mixture for another 2 days stirring under N2 protection. PSeSe was produced after 
dialysis against deionized water using a 3.5 kDa MWCO tube for 5 days with daily water 
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change and freeze-dry. PSeSe was characterized with FTIR, conductivity and pH titration 
(AQUA conductivity/pH), and the zeta potential of PSeSe was measured in phosphate buffered 
saline (PBS) at pH 7.4 and 25 °C (Malvern zetasizer ZEN3600).  
Redox cleavable PSeSe was tested to confirm the successful microgel synthesis with measuring 
the size decreasing patterns through dynamic light scattering (DLS) using a zetasizer. 
Hydrodynamic sizes of PSeSe microgels at pH 7.4 of PBS with 20 mM of glutathione (GSH), 
10 µM GSH, and without GSH were measured at predetermined time. 
4.2.2.3 Hydrazine bond introduction to PSeSe microgels (PSeH) 
PSeH microgels were synthesized with slight modification of feed hydrazine mole ratio to 
amine in PSeSe microgels from our previous study. PSeSe (500 mg, 2.48 mmol of amine group, 
Figure 4.S4A) was re-suspended in DMSO (40 mL) in a flask under nitrogen environment. 
After injection of succinic anhydride (120 mg, 1.2 mmol) dissolved in DMSO (5 mL) to the 
flask, the mixture was stirred at room temperature for overnight, and the transparent grey color 
mixture was dialyzed with a MWCO 3.5 kDa tube. After freeze-dry of the mixture, carboxylic 
group conjugated PEI microgel (PSeCOOH) was obtained.  
PSeCOOH (337.5 mg, 0.65 mmol of carboxylic group) in DMSO (20 mL) was mixed with 
EDC (751.54 mg, 3.92 mmol) and NHS (300.8 mg, 2.61 mmol) in DMSO (10 mL) under N2 
protection, and stirred at room temperature for 45 min. Tert-butyl carbazate (129.53 mg, 0.98 
mmol) in DMSO (2 mL) was added to the mixture with further 16 h stirring. After dialysis and 
freeze-dry of mixture, microgels with BOC protected hydrazine group (PSeBOC) was 
synthesized. 
PSeBOC (304 mg, 0.482 mmol of BOC group) in DMSO (30 mL) was mixed with TFA (10 
ml, 130 mmol) under nitrogen circumstance, and stirred at room temperature for 24 h. PEI 
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microgels with hydrazine bond conjugation (PSeH) were produced after dialysis and 
lyophilization.  
4.2.2.4 DOX conjugation to PSeH microgels via hydrazone bond (PSeHD) 
PSeH (30.4 mg, 0.056 mmol of hydrazine group) was dissolved in PBS buffer solution (10 mL) 
of increased pH to 8.5 with 1 M NaOH. DOX·HCl (32.5 mg, 0.056 mmol) was suspended in 
the mixture of PBS (7 mL, pH 7.4) and acetic acid (5 µL). PSeH and DOX·HCl solutions were 
mixed and stirred under dark and nitrogen protection at room temperature for overnight. The 
mixture was dialyzed against deionized water in the cold room at 4 °C and light protection for 
24 h with frequent water change. After lyophilization, DOX conjugated microgels via 
hydrazone bond (PSeHD) were obtained, and the hydrodynamic size of PSeHD was measured 
with DLS from a zetasizer. DOX loading (wt. %) to PSeHD complexes were calculated using 
following Equation:  
𝐷𝑂𝑋 𝑙𝑜𝑎𝑑𝑖𝑛𝑔 (%) =
(𝑡𝑜𝑡𝑎𝑙 𝐷𝑂𝑋−𝑢𝑛𝑙𝑜𝑎𝑑𝑒𝑑 𝐷𝑂𝑋)
𝐷𝑂𝑋 𝑙𝑜𝑎𝑑𝑒𝑑 𝑚𝑖𝑐𝑟𝑜𝑔𝑒𝑙𝑠
 × 100                             (1) 
Quantification of unloaded DOX was obtained from the absorbance measurement of free DOX 
residual at 479.5 nm using a UV-vis spectrophotometer through a pre-established DOX 
calibration curve (Figure 4.S5). .  
4.2.2.5 Diselenide crosslinking loaded DOX and PEI800 (PSeHD-SeSeP) 
-SeSe- (15.21 mg, 0.05 mmol), EDC (57.5 mg, 0.3 mmol) and NHS (23 mg, 0.2 mmol) were 
dissolved in DMSO (2 mL), and magnetically stirred at ambient temperature for 45 min under 
nitrogen protection. PSeHD (40mg, 0.021 mmol of amine group in DOX) in DMSO (5 mL) 
was injected into the mixture, followed by another 45 min stirring under light protection. After 
injecting PEI800 (40 mg, 0.05 mmol) in DMSO (1 mL) into the mixture, magnetic stirring was 
continued for further 2 days. Dialysis against deionized water was carried out using dialysis 
tube (MWCO 7 kDa) at 4 °C for 7 days with daily water change. After lyophilization, PEI 
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microgels with dual-locker conjugated DOX (PSeHD-SeSeP) was produced (Scheme 4.2). 
Zeta potential and hydrodynamic size of PSeHD-SeSeP were measured with zetasizer (ZEN 
3600), and the amine content in PSeHD-SeSeP was obtained from conductivity and pH titration. 
DOX loading (wt. %) to PSeHD-SeSeP was determined from same methods as PSeHD.  
 
Scheme 4.2 Scheme of diselenide crosslinked PEI800 microgels with DOX loading via dual-
locks of hydrazone and diselenide bonds. 
 
4.2.3 Ex vivo DOX releasing assays 
PSeHD-SeSeP complexes dissolved in deionized water (5 mL, 1 mg mL-1) were transferred to 
a dialysis tube (MWCO 3.5kDa) for dialysis against various conditions of buffer solutions (95 
mL) in a horizontal shaker at 37 °C with 100 rpm for 48 h. The various conditions of buffer 
solutions are: 0 M GSH at pH 7.4; 10 µM GSH at pH 7.4; 20 mM GSH at pH 7.4; 0 M GSH at 
pH 6.5; 0 M GSH at pH 5.0; and 0 M GSH at pH 5.0 for the first 6 h and 20 mM GSH at pH 
7.4 for further 42 h. Phosphate buffered saline (PBS) was used for pH 7.4 and pH 6.5 and 
acetate buffered saline (ABS, 0.2 M) was prepared for pH 5.0. The absorbance of an aliquot 
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from the buffer solution was measured at the wavelength of 479.5 nm by UV-Vis 
spectrophotometer at pre-determined time intervals. The amount of DOX released was 
determined according to the DOX calibration curve (Figure 4.S5). For comparison, the quantity 
of ex vivo DOX releasing from PSeHD was evaluated with the buffer conditions of 0 M GSH 
at pH 7.4, pH 6.5, and pH 5.0. 
4.2.4 miR-21i loading and ex vivo releasing assay 
miR-21i in DEPC water (1 µL, 0.42 nmol µL-1) was incubated with the PSeHD-SeSeP 
complexes at predetermined mole ratios of nitrogen (N) in the microgels (Figure 4.S4B) to 
phosphate (P) in miR21i (N/P ratio) from 1.0 to 6.0 at ambient temperature for 20 min. 1 N/P 
ratio complex of PEI25k and miR-21i and naked miR-21i were used as positive control and 
negative control separately. Agarose gel (0.8%) electrophoresis was executed at 100 volts for 
60 min. The miR-21i migration patterns in the gel were fluorescently imaged under UV 
irradiation and captured by a G-BOX (SYNGENE). 
Ex vivo releasing assay of loaded miR-21i from PSeHD-SeSeP (10 N/P ratio) was evaluated 
with agarose gel electrophoresis after incubation in 20 mM GSH at 37 °C for 48 h and 72 h. 
Agarose gel electrophoresis was run at 100 volts for 60 min, and the miR-21i migration images 
were photographed with a G-BOX. 
4.2.5 Characterization of PSeHD-SeSeP/miR-21i/HA delivery systems 
4.2.5.1 HA surface coating (PSeHD-SeSeP/miR-21i/HA)  
PSeHD-SeSeP after miR-21i (20 µL, 0.42 nmol µL-1) loading at a 10 N/P ratio in DEPC water 
was mixed with 5-folds weight of hyaluronic acid (HA) to miR-21i. The mixture was incubated 
at ambient temperature for 20 min, and the PSeHD-SeSeP/miR-21i/HA delivery systems were 
produced.   
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4.2.5.2 Surface charge measurements 
Zeta potential of PSeHD-SeSeP/miR-21i/HA in pH 7.4 PBS buffer was detected at 25 °C from 
a Malvern Zetasizer (ZEN 3600), and compared with that of PSeHD-SeSeP and PSeHD-
SeSeP/miR-21i.  
4.2.5.3 Ex vivo stability and degradability of co-delivery systems  
PSeHD-SeSeP/miR-21i/HA delivery systems were suspended in buffered solutions with four-
different conditions, 0 M of GSH at pH 7.4, 10 µM of GSH at pH 7.4, 20 mM of GSH at pH 
7.4, and 0 M of GSH at pH 5.0 for initial 4 h and subsequent 20 mM of GSH at pH 7.4 (PBS 
for pH 7.4 and ABS for pH 5.0). The solutions were continuously shaken at 37 °C with 100 
rpm. Hydrodynamic sizes of PSeHD-SeSeP/miR-21i/HA in various buffered salines were 
detected at 37 °C via DLS measurements at pre-determined time over 7 days. 
4.2.6 Culture of cell lines (HEK293T, MDA-MB-231-S, MDA-MB-231-R) 
Cell lines of human embryonic kidney cell line (HEK293T), DOX sensitive breast cancer cell 
lines (MDA-MB-231-S), and DOX resistant breast cancer cell lines (MDA-MB-231-R) were 
cultured in a humidified incubator (Contherm Scientific Limited) with 5 % CO2 at 37 °C. 
Culture medium for HEK293T was prepared with mixture of Dulbecco Modified Eagle 
Medium (DMEM), fetal bovine serum (FBS) (10 % (vol.)), and penicillin-streptomycin 10,000 
U/mL (PS) (1% (vol.)) Breast cancer cell lines with DOX sensitivity (MDA-MB-231-S) were 
cultured with the mixture of Leibovitz’s Medium (L-15), FBS (10 %), and PS (1 %). DOX 
resistant breast cancer cell lines (MDA-MB-231-R) were incubated with L-15, FBS (10 %), PS 
(1%) and DOX incorporation of 0.01 µg mL-1 until 8th weeks and then 0.02 µg mL-1 from 9th to 
12th weeks. Culture mediums were refreshed every 48 h and Trypsin-EDTA (0.25%) was used 
to recover all three types of cells.  
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Resistance of MDA-MB-231-R to DOX was determined with cell viability assay at pre-
determined time of cell culturing period with DOX, such as 0th, 4th, 8th and 12th week, indicating 
to MDA-MB-231-S, -R4w, -R8w, and –R12w. MDA-MB-231-R cells were incubated in a 96-
well plate for 24 h, and were further incubated with various DOX concentrations in fresh 
medium, 0.1, 0.5, 1, and 2.5 µg mL-1 for 48 h. After changing medium to DMEM based medium 
and Cell Counting Kit-8 (CCK-8) treatment for 4 h, absorbance of surviving cell is measured 
by wavelength 450 nm in a microplate reader (ELx808 BioTek) to determine the MDA-MB-
231-R cell survival rates using following Equation:  
𝐶𝑒𝑙𝑙 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑟𝑎𝑡𝑒 (%) =
(𝑆−𝐵)
(𝐶−𝐵)
 × 100                                        (2) 
where S is the absorbance of DOX samples, B is that of blank without cells, and C is that of 
control with only cells but not DOX.  
4.2.7 Cellular uptake assays 
Cellular uptake of PSeHD-SeSeP/miR-21i/HA delivery systems was qualitatively assayed with 
a confocal laser scanning microscope (CLSM) (Olympus FV3000). Breast cancer cells (MDA-
MB-231-S) (0.1×106 cells per well) were seeded onto a glass cover slip in a 12-well plate, and 
cultured with L-15 based mixture medium for 24 h. PSeHD-SeSeP/FAM-miR/HA, insisting of 
PSeHD-SeSeP complexes (12.5 µg with 8.2 wt % of loaded DOX), FAM-labeled miRNA 
negative control with a random sequence (FAM-miR) at 10 N/P, and 5-folds HA to FAM-miR 
of weight ratio, were prepared for CLSM imaging analysis. PSeHD-SeSeP/FAM-miR/HA (50 
µL) were applied on the cells with fresh medium (950 µL), and incubated for further 4 h. After 
staining cell membrane with CellMaskTM Deep Red Plasma membrane Stain and fixing with 
formaldehyde (4%), fluorescent images from DOX, FAM-miR, and cells were monitored by 
CLSM, giving the color of blue, green and red. To block HA receptors on the surface of cells, 
MDA-MB-231-S cells were incubated with HA (10 mg mL-1) in the medium for 24 h, 
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producing the HA pretreated cells. For comparison, the fluorescent images of control cells 
without PSeHD-SeSeP/FAM-miR/HA and HA-pretreated cells with PSeHD-SeSeP/FAM-
miR/HA were obtained via CLSM.  
Cellular uptake of the delivery carriers was quantified with flow cytometer (BD 
FACSCaliburTM). MDA-MB-231-S cells (0.05×106 cells per well) were seeded in a 24-well 
plate and cultured by the same method for the CLSM. PSeHD-SeSeP/FAM-miR/HA delivery 
carriers (5 µg, at 10.0 N/P, 5-folds HA to FAM-miR, 50 µL per well) were added to the cells 
with fresh culture medium (450 µL per well). After incubation for 4 h, cells were washed 3 
times with PBS and collected with trypsin-EDTA to measure the intensities of fluorescence 
from DOX and FAM-miR, displaying as FL-2 (585 nm) and FL-1 (530 nm) with excitation at 
488 nm wavelength. Control cells without PSeHD-SeSeP/FAM-miR/HA and HA-pretreated 
cells with PSeHD-SeSeP/FAM-miR/HA were also prepared to compare the quantity of cellular 
uptake of PSeHD-SeSeP/FAM-miR/HA.  
4.2.8 Biocompatibility evaluation 
In vitro viability assays of human embryonic kidney cells (HEK293T) against PSeSe, PSeH 
microgels and the biodegraded PSeHat 20 mM GSH for 48 h were evaluated to confirm 
biocompatiblility of synthesized microgels. HEK293T cells (10,000 cells per well) were seeded 
in a 96-well plate, and incubated with DMEM based culture medium (100 µL per well) in a 
moisturized incubator at 37 °C and 5 % CO2 for 24 h. The microgels (10 µL, 50 µg mL-1) were 
inculated to the cells with a fresh medium for further 48 h. After 4 h CCK-8 treatment, 
absorbance of surviving cells was measured, and cell survival rate (%) was caculated with 
Equation (2). For comparison purpose, PEI800 and Lipofectamine2000 as positive controls and 
PEI25k as a negative control were assayed with identical methods.  
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In vitro viability of the HEK293T cells against the co-delivery systems with DOX and miR-
21i, PSeHD-SeSeP/miR-21i/HA, was evaluated to check the side-effect of the co-drug delivery 
system. HEK293T cells (10,000 cells per well) were incubated in a 96-well plate with DMEM 
medium for 24 h. The delivery systems (10 µL) at increasing DOX loaded concentrations, 0.1, 
0.25, 0.5, 1, and 2.5 (µg mL-1), and 10 N/P miR-21i with 5-folds HA (wt/wt), were applied to 
the cells with fresh medium for another 48 h incubation. With CCK-8 treatment for further 4 
h, cell survival rates were determined. The cell viability assays against PSeHD-SeSeP, PSeHD-
SeSeP/miR-21i and free DOX were executed for comparison.  
4.2.9 Viability assays on DOX sensitive or resistant cancer cells 
Therapeutic efficacy of combined DOX and miR-21i delivery system, PSeHD-SeSeP/miR-
21i/HA, was evaluated through the cell viability assays to one DOX-sensitive breast cancer 
cell line of MDA-MB-231-S and two DOX-resistant breast cancer cell lines of MDA-MB-231-
R4w and MDA-MB-231-R12w. Each cancer cell line (10,000 per well) was seeded into every 
single 96-well plate with their culture media, and incubated for 24 h. PSeHD-SeSeP/miR-
21i/HA of 10 µL per well, consisting of various DOX loaded concentrations, 0.1, 0.5, 1, and 
2.5 (µg mL-1), and 10 N/P ratio of miR-21i and 5-fold weight ratio of HA to miR-21i, was 
added to the top of fresh L-15 based medium (100 µL per well), and was incubated for 48 h. 
After changing L-15 based medium to DMEM based medium and CCK-8 treatment for further 
4 h,  the survial rate (%) of each type of cells against the co-drug delivery systems was obtained. 
In vitro cell viability assays against PSeHD-SeSeP/HA and free DOX were also evaluated to 
these three types of cells as comparison of therapeutic efficacy.  
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4.3 Results and Discussion 
4.3.1 Synthesis of DOX loaded microgels (PSeHD-SeSeP) 
4.3.1.1 Synthesis of biodegradable microgels (PSeSe) 
Polymer based vectors for advanced gene-delivery have contradictory conditions, i.e.,  
effective anionic gene loading from strong positive charged (e.g., PEI25k) polymers and minor 
cytotoxicity from week positive charged (e.g., PEI800) polymers. In this study, biodegradable 
microgels are synthesized to achieve both high charge density and outstanding biocompatibility 
by crosslinking low molecular weight PEI800 using a redox-sensitive diselenide crosslinker (-
SeSe-). 
3.3’-diselanediyldipropanoic acid of diselenide crosslinker -SeSe- was produced with a yield 
of 56.5 %. Raman shifts at 291 and 517 cm-1 (Figure 4.S1) confirm the successful synthesis of 
-SeSe-, indicating selenium-selenium and selenium-carbon bonds, [31, 32]. PSeSe microgels 
were prepared by crosslinking PEI800 via the -SeSe- with a yield of 72.4 %.  FTIR spectra are 
evident for successful microgel synthesis (Figure 4.S2). Peaks for primary amine N-H 
stretching,  N-H bending, and  C-N stretching of PEI800 are observed at 3351, 3273, 1547, and 
1070 cm-1 from PSeSe, as well as Se-C stretching of -SeSe- at 520 cm-1. In microgel spectrum, 
the formation of amide bond between PEI800 and -SeSe- are observed at 1630 cm-1 as amide 
C=O stretching, which is shifted from ketone C=O stretching of -SeSe- at 1690 cm-1. The molar 
amount of amine in 1 mg of PSeSe microgels was measured with conductivity and pH titration 
(Figure 4.S4A), displaying 4.96 µmol mg-1.  
To satisfy high gene loading capacity and biocompatibility, PSeSe microgels should be highly 
positive on surface and be biodegradable into small fractures after entering cells to avoid 
cytotoxicity coming from high charge density and their accumulation in patient body. For the 
surface charge density, zeta potential of the PSeSe microgels (38.1 ± 2.1 mV) was measured, 
  Chapter 4 
140 
 
and compared with that of PEI25k (38.7 ± 2.9 mV) and PEI800 (8.2 ± 3.7 mV) as a positive 
and a negative control (Figure 4.S3A). Zeta-potential of the PSeSe microgels is similar to that 
of PEI25k for promising gene loading. To confirm biodegradability, hydrodynamic sizes of 
PSeSe were monitored over 72 h with DLS measurement at pH 7.4 of PBS buffer at various 
conditions, 0 M, 10 µM, and 20 mM of reductive enzyme glutathione (GSH) (Figure 4.S3B). 
Initial hydrodynamic size of PSeSe is 228.0 ± 9.3 nm, which slightly decreases to 186.2 ± 6.0 
nm at 4 h and maintains until 72 h in the condition of 0 M GSH. The slight size decrease for 
the first 4 h might be attributed to nucleophilic attack on diselenide bonds in the PBS buffer 
with full of phosphate ions [33]. In 10 µM GSH, a moderate size decreasing pattern is observed 
with 176.4 ± 2.1 nm at 4 h and 163.1 ± 10.8 nm at 72 h. Opposed to stable microgels in 0 or 10 
µM GSH, PSeSe in 20 mM GSH shows steep size-drop to 11.1 ± 9.7 nm at 48 h and further 
decrease to 3.7 ± 1.9 nm at 72 h. These confirm the bio-degradation of the microgels via 
cleavage of diselenide crosslinker is highly dependent on the concentration of GSH. Yue et al. 
support two distinct cleavage patterns of the diselenide bonds at gradient GSH levels as an 
evidence of the controlled biodegradation [25].  
4.3.1.2 DOX loading to microgels with hydrazone and diselenide bonds (PSeHD-SeSeP) 
Doxorubicin possesses outstanding anticancer efficiency and also severe side effects induced 
by its cytotoxicity, which promotes us to develop delivery systems with highly controlled 
releasing function to eliminate premature leakage before reaching target cancer cells. In this 
study, two intracellular stimuli-cleavable linkers of hydrazone and diselenide bonds are utilized 
in DOX conjugation to the PSeSe microgels. 
For DOX loading, hydrazine bond was first conjugated to PSeSe to consume 48.4% (mol) of 
amine in PSeSe, producing PSeH microgels with a yield of 45.5 %. Subsequently, DOX was 
conjugated to PSeSe through Schiff base formation between ketone group in DOX and primary 
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amine in PSeSe, achieving PSeHD complexes with DOX loading via a pH sensitive hydrazone 
bond. To prevent hydrazone bond cleavage during its formation process, PBS buffer at pH 8.5 
was used to dissolve PSeH before mixing with acidic mixture of DOX·HCl and acetic acid. 
DOX loading in PSeHD can be calculated using Equation (1), where the amount of unloaded 
DOX can be obtained from its absorbance at 479.5 nm from UV-vis spectroscopic 
measurement with DOX calibration curve of light absorbance to DOX concentration (Figure 
4.S5), resulting in 29 wt. % of DOX loading.  
Another PEI800 was supplemented to further conjugate the loaded DOX to PSeHD complexes 
via diselenide crosslinkers. Activated carboxylic groups in both side of -SeSe- are covalently 
bonded to primary amine groups in DOX and PEI800 (Scheme 4.2). In addition to the 
crosslinking between DOX and PEI800, the added PEI800 can be crosslinked to amine groups 
in the surface of the complexes by -SeSe-, which produces PSeHD-SeSeP complexes (Scheme 
4.1A). 
With successful addition of PEI800 to PSeHD, some properties of PSeHD-SeSeP are shifted 
from PSeHD. First, hydrodynamic size increases from PSeHD of 176.5 ± 26.5 nm to PSeHD-
SeSeP of 213.1 ± 45.8 nm. Moreover, the added weight of PEI800 to PSeHD decreases DOX 
loading ratio from PSeHD of 29 wt. % to PSeHD-SeSeP of 8.2 wt. %. Furthermore, the 
sacrificed amine groups in PSeHD for the hydrazine introduction to PSeSe is found to be 
supplemented in PSeHD-SeSeP. The recovery of amine groups results in the amine content 
ratio of 4 µmol in 1 mg of PSeHD-SeSeP (Figure 4.S4B) and the increase of zeta potential 
from PSeHD of 7.7 ± 3.1 mV to PSeHD-SeSeP of 37.2 ± 1.5 mV. 
4.3.2 Exceptional control of DOX release 
Advanced suppression of side effects and high therapeutic efficiency require an exceptionally 
controlled DOX release from delivery carriers to suppress pre-mature release in systemic 
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circulation and accelerate target release in cancer cells. PSeHD-SeSeP with dual linkers for 
DOX conjugation is designed for the purpose of the exceptional control of DOX release. DOX 
release from PSeHD-SeSeP by dual-linker was compared with that from PSeHD by single-
linker via ex vivo releasing assays. In Figure 4.1A, DOX being released from the PSeHD are 
93.5 ± 4.8 % and 53.1 ± 4.8 % at pH 5.0 and 6.5 over 48 h due to the rapid cleavage of pH 
sensitive hydrazone bond. However, 29.0 ± 2.6 % of DOX release is observed at pH 7.4 over 
the same time intervals. Although hydrolysis of hydrazone is rapid at acidic pH, the hydrazone 
bearing two electron-withdrawing groups is also found being labile even at neutral pH and 
undergoes hydrolysis [34]. This supports the hydrazone bond for only conjugation route of 
DOX in PSeHD is not enough to suppress DOX pre-leakage at neutral pH during systemic 
circulation. 
Comparing to the single-linker, PSeHD-SeSeP with dual-linker for DOX conjugation via pH 
responsive hydrazone and redox sensitive diselenide bond displays outstanding controllability 
of DOX releasing. PSeHD-SeSeP can effectively control the premature leakage of DOX in the 
mimicking physiological condition of 0 M GSH at pH 7.4. DOX releasing from PSeHD-SeSeP 
is 5.8 ± 1.6 %, which is far low to that from PSeHD over 48 h. Although the pH value of buffer 
is decreased to 6.5 and 5.0 to cleave the hydrazone bond, the dual-DOX conjugation system 
releases 8.1 ± 1.4 and 8.7 ± 1.6 % over 48 h (Figure 4.1B), indicating DOX is still conjugated 
to the carriers by diselenide bond. In addition, the increasing concentration of GSH from 10 
µM to 20 mM at pH 7.4 to reduce the diselenide bond limitedly affects DOX releasing from 
8.7 ± 1.7 to 19.0 ± 2.8 % over 48 h (Figure 4.1C), which approves hydrazone bond in the 
systems is still conjugated with DOX. On the other hand, PSeHD-SeSeP can release DOX with 
90.8 ± 3.7 % over 48 h in the sequential condition of buffer, pH 5.0 in the first 6 h and then 20 
mM GSH at pH 7.4 for further 42 h (Figure 4.1D). These indicate the delivery system can 
release DOX due to two different linkers, hydrazone and diselenide bonds, are cleaved after 
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passing through mimicking acidic endo/lysosome and then reaching to the mimicking target 
cellular cytosol with 20 mM of reductive GSH. Therefore, with this dual-Dox conjugation 
system, PSeHD-SeSeP is likely to selectively release cytotoxic drugs in cancer cytosol, but not 
in systemic circulation.  
 
(A)                                                      (B) 
(C)                                                     (D) 
 
Figure 4.1 ex vivo DOX releasing assays, DOX releasing from (A) PSeHD at pH 7.4, 6.5, and 
5.0 with 0 M GSH over 48 h, (B) PSeHD-SeSeP at pH 7.4, 6.5, and 5.0 with 0 M GSH, (C) 
PSeHD-SeSeP at pH 7.4 with 0 M GSH, 10 µM GSH, and 20 mM GSH over 48 h, and (D) 
PSeHD-SeSeP at pH 7.4 with 0 M GSH and at sequential condition of 0 M GSH at pH 5.0 for 
6 h then 20 mM GSH at pH 7.4, (P < 0.05, n = 3).  
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4.3.3 miR-21i loading and ex vivo releasing assay 
Presence of miRNA-21 reduces the anticancer efficacy of DOX in metastatic cancer cells, and 
increases expression of miR-21 in DOX-resistant cancer cells, thus inhibiting the overall 
therapeutic effect [9, 11]. In this study, miRNA-21 inhibitor (miR-21i) is delivered to 
metastatic cancer cells and drug resistant metastatic cancer cells via the co-delivery system of 
PSeHD-SeSeP/miR-21i polyplexes. miR-21i loading capacity to the PSeHD-SeSeP was 
evaluated using 0.8 % agarose gel electrophoresis at various N/P (PSeHD-SeSeP to miR-21i) 
molar ratios of 1, 2, 4, 5, and 6. Full retardation of miR-21i from PSeHD-SeSeP is observed at 
the N/P of 5 (Figure 4.2A). Compared with PSeHD, it is obvious that the surface amines 
promote miR-21i loading because PSeHD cannot fully load miR-21i at an N/P ratio of 30 
(Figure 4.S6).  
(A)                                                                    (B) 
Figure 4.2 Agarose gel retardation assays for (A) miR-21i loading to PSeHD-SeSeP at N/P 
ratios from 1 to 6, where naked miR-21i and its polyplexes with PEI25k at the N/P ratio 1 are 
used as negative control and positive control. (B) miR-21i releasing profiles from the PSeHD-
SeSeP/miR-21i at a N/P ratio 10 after incubation with 20 mM GSH for 48 h and 72 h. 
 
The ex vivo miR-21i releasing was evaluated by agarose gel retardation assay after incubating 
PSeHD-SeSeP/miR-21i at a N/P ratio of 10 with mimicking cytosol of presence 20 mM GSH 
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at 37 °C for 48 h and 72 h. miR-21i migrations from the polyplexes in the presence of reductive 
enzyme GSH are enhanced with increasing incubation time from 48 to 72 h (Figure 4.2B). The 
diselenide crosslinker in PSeHD-SeSeP can be cleaved by GSH, and the PSeHD-SeSeP can be 
degraded to small fractures (Figure 4.S3B). Similar as PEI800, these low molecular PEI 
fractures will lose interaction with miR-21i (Figure 4.S3A) and resultantly release the loaded 
miR-21i. Ex vivo evaluation supports the PSeHD-SeSeP can release miR-21i to the cytosol of 
target cells by response of reducing enzyme. 
4.3.4 Characterization of PSeHD-SeSeP/miR-21i/HA delivery system 
Positive charges of synthesized microgel carriers promote miR-21i loading, but become 
obstacles during the delivery course due to possible serum protein adsorption and off-target 
endocytosis via electrostatic interaction, resulting in reticuloendothelial system (RES) 
clearance and cytotoxic to normal cells [26]. Here, PSeHD-SeSeP/miR-21i polyplexes are 
subject to further surface coating with hyaluronic acid (HA) to convert positive to negative 
surfaces in order eliminate serum adsorption and facilitate cancer cell uptake through HA 
receptor mediated endocytosis for selective delivery. HA was electrostatically coated to 
PSeHD-SeSeP/miR-21i (at a 10 N/P) with 5-fold weight ratio to miR-21i, producing the 
PSeHD-SeSeP/miR-21i/HA complex. Successful HA coating was confirmed from zeta 
potential measurements, where zeta potentials are 37.2 ± 1.5, 28.7 ± 1.5 and – 33.2 ± 1.8 mV 
for PSeHD-SeSeP, PSeHD-SeSeP/miR-21i and PSeHD-SeSeP/miR-21i/HA (Figure 4.3A). 
Our previous study shows HA coated polyplexes rarely adsorb bovine serum albumin, 0.15 % 
feed compared with 25.2% for PEI800 and 51.2 % for Lipofectamine2000 (Chapter 3). 
Therefore, the PSeHD-SeSeP/miR-21i/HA system can be stable during systemic circulation by 
avoiding RES clearance. To confirm the stability in circulation, hydrodynamic sizes of PSeHD-
SeSeP/miR-21i/HA in mimicking physiological environment (pH 7.4; GSH 0 M) and 
extracellular microenvironment (pH 7.4; GSH 10 µM) were ex vivo evaluated over 1 week 
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(Figure 4.3B). Initial size of PSeHD-SeSeP/miR-21i/HA at 192.2 ± 24.6 nm, is well maintained 
and reaches to 173.7 ± 4.9 nm over 7 days in mimicking physiological environment. On the 
other hand, in the mimicker extracellular environment, the size of PSeHD-SeSeP/miR-21i/HA 
decreases to 162.4 ± 11.9 nm after 48 h and to 158.7 ± 20.1 nm over 1 week. This means 
diselenide bonds in PSeHD-SeSeP are inefficiently cleaved in the low concentration of GSH. 
As polarizability volume of selenium (3.8 Å) is larger than that of sulfur (2.9 Å), a rate constant 
for nucleophilic attack of thiol from GSH can be lower than that for stability of diselenide bond 
[33]. Those results support the stable circulation of PSeHD-SeSeP/miR-21i/HA in delivery 
course. 
(A)                                                      (B) 
 
 
Figure 4.3 (A) Comparison on the zeta potentials of PSeHD-SeSeP, PSeHD-SeSeP/miR-21i 
and PSeHD-SeSeP/miR-21i/HA, (n=4), (B) Hydrodynamic sizes of PSeHD-SeSeP/miR-
21i/HA at pH 7.4 with different GSH concentrations of 0, 10, and 20 mM, and the sequential 
condition of pH 5.0 and 0 M GSH for 4 h then pH 7.4, 20 mM GSH, (n=4). 
 
Biodegradability of PSeHD-SeSeP/miR-21i/HA is crucial for releasing loaded DOX and miR-
21i to target cancer cells by cleavage of hydrazone bonds and diselenide bonds. Hydrodynamic 
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sizes of PSeHD-SeSeP/miR-21i/HA were ex vivo evaluated in mimicking intracellular cytosol 
(20 mM GSH in pH 7.4 PBS buffer) and sequential intracellular delivery course from 
endo/lysosome to cytosol (0 M GSH in pH 5.0 ABS buffer for first 4 h then 20 mM GSH in 
pH 7.4 PBS buffer) over 7 days (Figure 4.3B). In the medium of 20 mM of GSH and pH 7.4, 
particle size drops to 68.2 ± 15.8 nm over 1 day and then maintains at 50.5 ± 12.3 nm for 1 
week. Such results are opposed to the full degradation of PSeSe in 20 mM of GSH over 3 days 
(Figure 4.S3B). These indicate diselenide bonds in PSeHD-SeSeP/miR-21i/HA are reduced by 
the high concentration of reductive enzyme of GSH, but hydrazone bonds are still stable at pH 
7.4. On the other hand, in the mimicking delivery course from endo/lysosome to cytosol, initial 
size of the PSeHD-SeSeP/miR-21i/HA increases to 347.1 ± 23.2 nm at pH 5.0 over 4 h due to 
microgel electro-repulsive stretching after hydrazone bond cleavage. However, after 
subsequently exposing to 20 mM GSH in pH 7.4 PBS, particle size significantly drops to 34.0 
± 12.4 nm over 24 h and further decreases to 1-2 nm over 7 days. Under this mimicking 
condition, both hydrazone and diselenide bonds of PSeHD-SeSeP/miR-21i/HA can be 
sequentially destroyed by acidic pH and GSH and release loaded drugs to target cell cytosol. 
In addition, debris of the microgel carriers can be easily excreted from patient body as degraded 
fractures is smaller than 10 nm [35].   
4.3.5 DOX resistance of MDA-MB-231-R 
To evaluate in vitro anticancer synergistic effect of DOX and miR-21i to DOX resistant 
metastatic breast cancer cells, MDA-MB-231-R, were cultured in L-15 based culture medium 
with replenishing DOX for 12 weeks. At every 4 weeks after culturing the cells, the resistance 
of MDA-MB-231-R to DOX was evaluated by monitoring cell viabilities under DOX 
concentrations from 0.1 to 2.5 µg mL-1. Cell survival rate (%) against DOX shows increasing 
patterns as prolonging culture period with DOX over all DOX concentration ranges (Figure 
4.S7). In detail, cell survival rate with 2.5 µg mL-1 DOX in 0 week is 50.4 ± 3.8 % and becomes 
  Chapter 4 
148 
 
58.4 ± 8.9 %, 66.4 ± 5.1 % and 70.7 ± 7.9 % for 4 weeks,  8 weeks  and 12 weeks, clearly 
indicating the DOX resistance of the MDA-MB-231-R cells.  
4.3.6 Cellular uptake assays 
Surface HA coating is able to enhance selective endocytosis through HA receptors of CD44 
and/or RHAMM on the surface of metastatic cancer cells MDA-MB-231 [29]. To confirm the 
HA receptor mediated endocytosis of the PSeHD-SeSeP/miR-21i/HA delivery system, FAM 
labelled miRNA with a random sequence (FAM-miR) was loaded to the co-delivery system 
with DOX instead of miR-21i with their emission at 530 and 580 nm under the excitation at 
488 nm from CLSM. MDA-MB-231 cell membrane was also stained by CellMaskTM Deep 
Red to emit 666 nm under excitation at 640 nm. CLSM images those emission to evaluate 
cellular uptake of PSeHD-SeSeP/FAM-miR/HA. As a control, Figure 4.4A shows red colors 
for the cell membranes without other colors for load. In Figure 4.4B and 4.4C, the green from 
FAM-miR and the blue from DOX overlap with the red from the stained cells to give off purple 
color, indicating cell intake of PSeHD-SeSeP/FAM-miR/HA. To confirm ineffective 
endocytosis of the HA coated delivery systems to cells without HA receptors, HA pre-treated 
cells were prepared to block HA receptors. Figure 4.4D indicates that the PSeHD-SeSeP/FAM-
miR/HA systems are difficultly endocytosed in lieu of HA-receptor mediations as evident from 
few green and blue colors being observed on the red color for HA pre-treated cells. The 
qualitative results from the CLSM prove PSeHD-SeSeP/FAM-miR/HA HA can selectively 
enter metastatic cancer cells with HA receptors rather than cells without the receptors. 
The receptor-mediated endocytosis of PSeHD-SeSeP/FAM-miR/HA delivery systems was 
further quantitatively examined by flow cytometry. More than 97 % of control cells without 
the PSeHD-SeSeP/FAM-miR/HA are located on the down-left section of Figure 4.S8A. For 
the cells after administration of PSeHD-SeSeP/FAM-miR/HA, 92.7 % FAM and DOX 
fluorescent signals are located on the upper-right section of Figure 4.S8B, indicating highly 
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efficient cellular uptake of the delivery systems. However, after blocking HA receptors on cell 
surface, only 3.8 % FAM and DOX signals are positioned on the upper-right section of Figure 
4.S8C. The quantitative results from flow cytometric analysis also support HA receptor-













Figure 4.4 MDA-MB-231 cellular uptake assays of PSeHD-SeSeP/FAM-miR/HA system by 
confocal laser scanning microscopy (CLSM), (A) Cells only without the PSeHD-SeSeP/FAM-
miR/HA, (B) Cells with PSeHD-SeSeP/FAM-miR/HA system in low magnification and (C) in 
high magnification, and (D) HA pre-treated cells with the PSeHD-SeSeP/FAM-miR/HA. 
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Besides, HA receptors are not widely spread on the surface of healthy cells [29]. As HA 
receptors on the surface of HA pre-treated cells are blocked, HA pre-treated cells behave as 
healthy cells in the course of cell uptake. Therefore, it may conclude that PSeHD-SeSeP/miR-
21i/HA can be selectively endocytosed to metastatic cancer cells but not to healthy cells via 
HA receptor mediation. 
4.3.7 Evaluation on side effect of co-delivery system 
One of the targets of designing current delivery system is to minimize the side effects of 
anticancer chemotherapy. Biocompatibility of delivery carriers without DOX loading and with 
DOX loading was evaluated against human embryonic kidney cell line (HEK293T). For the 
delivery carriers without DOX loading, cell survival rates of 50 µg mL-1 PSeH, PSeSe, and 
microgel debris being treated by 20 mM of GSH for 48 h are 85.0 ± 2.4, 95.0 ± 1.4 and 97.2 ± 
0.92 % respectively (Figure 4.5A). These survival rates are similar to that of PEI800 (86.4 ± 
1.7) and Lipofectamine2000 (82.0 ± 1.3 %), and far higher than the 49.1 ± 1.4 % for PEI25k 
as a negative control. The high biocompatibility of the microgel carriers is introduced by the 
application of biocompatible PEI800 and consumption of primary amine groups during 
crosslinking. As the primary amine content of the microgels decreases, the decomposed 
fragments of the microgels are more biocompatible than PEI800 and provide the possibility of 
safe excretion. 
To further confirm minimal side-effect of our delivery system after loading DOX and miR-21i, 
HEK 293T cell survival rates against PSeHD-SeSeP/miR-21i/HA (10 N/P and 5-folds wt. of 
HA to miR-21i) with loaded DOX concentrations from 0.1 to 2.5 µg mL-1, were evaluated and 
compared with free DOX, PSeHD-SeSeP, and PSeHD-SeSeP/miR-21i at same concentrations 
after 48 h incubation (Figure 4.5B). The survival rate (%) of free DOX is 45.9 ± 10.7 at a 
concentration of 0.5 µg mL-1 and further drops to 35.5 ± 4.7. After DOX being loaded to PSeH 
microgel by hydrazone and diselenide bonds, PSeHD-SeSeP displays outstanding high cell 
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survival rate (%) of 94.0 ± 0.64 at the highest DOX concentration of 2.5 µg mL-1. This 
remarkable biocompatibility of PSeHD-SeSeP is due to the dual-linkers for DOX conjugation. 
In Chapter 3, a delivery system with DOX loading through a single-linker of hydrazone bond 
(PSeHD) shows HEK293T survival rate of 75 % at a DOX concentration of 2.5 µg mL-1. The 
addition of the diselenide bond for DOX conjugation can suppress the release of DOX to 
HEK293T. Suppression of DOX release from PSeHD-SeSeP can be observed in either 
hydrazone or diselenide bond being conjugating DOX, as seen in Figure 4.1. First, the 
physiological pH of 7.4 in the extracellular environment of normal cells and the rapid 
endosomal escape by proton sponge effect of less than 10 min may in part cleave the hydrazone 
bond [22]. In addition, the 2.8 fold lower level of GSH in normal cells than in cancer cells may 
partially cleave GSH concentration-dependent diselenide bond [36]. Partial cleavage of 
hydrazone and diselenide bonds can maintain DOX load and inhibit DOX release to HEK293T 
cells.  
Although miR-21i loaded PSeHD-SeSeP shows slightly lower survive rate of 81.1 ± 2.3 % at 
the DOX concentration of 2.5 µg mL-1, HA coated system of PSeHD-SeSeP/miR-21i/HA 
exhibits outstanding HEK293T survival rate of 95.1 ± 1.3 %. After miR-21i loading, inhibition 
of a few of miR-21 in HEK293T cells  by miR-21i may upregulate programmed cell death 4 
(PDCD4), and activate apoptosis [37]. However, surface HA coating makes PSeHD-
SeSeP/miR-21i/HA difficult to enter HEK293T cells via HA receptor mediation due to the lack 
of HA receptors on the surface of normal cells [29]. The high HEK293T cell viability of 
PSeHD-SeSeP/miR-21i/HA caused by dual-linker DOX binding and surface HA coating 
minimizes side-effects on normal cells associated with cancer therapeutic delivery. 
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(A)                                  (B)                                 (C) 
 
 
(D)                                  (E)                                 (F) 
 
 
Figure 4.5 Cell viability, (A) HEK293T survival rate against microgel carriers without loading 
DOX (PSeSe, PSeH and degraded microgel fracture products), PEI25k as a negative control 
and Lipofectamine2000/PEI800 as positive controls, (n = 4), (B) HEK293T survival rate 
against delivery carriers with DOX loading (PSeHD-SeSeP, PSeHD-SeSeP/miR-21i and 
PSeHD-SeSeP/miR-21i/HA) and free DOX as a negative control, (n = 12), (C) MDA-MB-
231-S survival rate against free DOX, PSeHD-SeSeP/HA and PSeHD-SeSeP/miR-21i/HA, (n 
= 12), (D) MDA-MB-231-R4w survival rate against free DOX, PSeHD-SeSeP/HA and 
PSeHD-SeSeP/miR-21i/HA, (n = 4), (E) MDA-MB-231-R12w survival rate against free DOX, 
PSeHD-SeSeP/HA and PSeHD-SeSeP/miR-21i/HA, (n = 8), and (F) IC50 value, DOX 
concentration for half cell death, of free DOX, PSeHD-SeSeP/HA and PSeHD-SeSeP/miR-
21i/HA against MDA-MB-231-S, MDA-MB-231-R4w, and MDA-MB-231-R12w cells, (n = 
4). 
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4.3.8 Comparison on viability of PSeHD-SeSeP/miR-21i/HA on DOX sensitive and 
resistant cancer cells 
Anticancer therapeutic synergy effects of DOX and miR-21i using the PSeHD-SeSeP/miR-
21i/HA on DOX sensitive and resistant metastatic breast cancer cells were examined in this 
study. The survival rates of DOX sensitive metastatic breast cancer cells (MDA-MB-231-S) 
and the cells with ascending level of DOX resistance (MDA-MB-231-R4w and MDA-MB-
231-R12w) were assayed after 48h incubation with free DOX, PSeHD-SeSeP/HA, and 
PSeHD-SeSeP/miR-21i/HA over a range of DOX concentrations from 0.1 to 2.5 µg mL-1. Two 
distinct patterns are observed in the analysis. First, the survival rate of all cells decreases with 
increasing DOX concentrations. Secondly, the anticancer effect of free DOX is enhanced using 
the delivery system of PSeHD-SeSeP/HA, and integrates with the miR-21i of PSeHD-
SeSeP/miR-21i/HA to create a more synergistic effect.   
In Figure 4.5C, DOX sensitive MDA-MB-231-S cell survival rate for DOX is 50.5 ± 3.8 % at 
a DOX concentration of 2.5 µg mL-1. The MDA-MB-231-S survival rate falls to 34.5 ± 2.5 % 
for PSeHD-SeSeP/HA and to 26.1 ± 1.6 % for PSeHD-SeSeP/miR-21i/HA at the same 
concentration of DOX. The pattern of decreasing MDA-MB-231-S cell survival rate after using 
delivery system and delivering miR-21i is the same for DOX-resistant MDA-MB-231-R4w 
and MDA-MB-231-R12w. In Figure 4.5D, the survival rate (%) of MDA-MB-231-R4w cells 
against free DOX, PSeHD-SeSeP/HA and PSeHD-SeSeP/miR-21i/HA is 58.4 ± 8.9, 38.4 ± 
14.2 and 26.3 ± 8.4 at a DOX concentration of 2.5 µg mL-1. Although there is more DOX 
resistance to MDA-MB-231-R4w, MDA-MB-231-R12w in Figure 4.5E shows the identical 
pattern of cell survival rate against free DOX (70.7 ± 7.9 %), PSeHD-SeSeP/HA (56.3 ± 7.9 %) 
and PSeHD-SeSeP/miR-21i/HA (36.3 ± 4.4 %) at a DOX concentration of 2.5 µg mL-1. 
The higher anticancer performance of PSeHD-SeSeP/HA than free DOX can be due to its 
higher cellular uptake than DOX. Although PSeHD-SeSeP/HA enters the metastatic cancer 
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cells through HA receptor-mediated endocytosis, free DOX (amine pKa of 7.55) penetrates 
across hydrophobic core of phospholipid cell membrane after being protonated at a weak acid 
(pH 6.5) of cancer extracellular environment [38-40]. As the binding of positively charged 
DOX to the hydrophobic membrane are unworkable, the permeation of the DOX to the cells 
can be limited. Unlike the HEK293T viability assay (Figure 4.5B), the high anticancer efficacy 
of PSeHD-SeSeP compared to free DOX is due to the complete cleavage of dual-linkers, 
hydrazone and diselenide bonds, for DOX conjugation. Hydrazone bonds can be completely 
hydrolyzed in the delivery course from weak acids in the cancer extracellular environment to 
strong acids in endosome/lysosome. In the following delivery course to cytosol, it is possible 
to reduce the diselenide bonds at the cancer cytosol levels of GSH to intensively release DOX 
and make the difference in survival rate between normal and cancer cells for PSeHD-SeSeP.  
Meanwhile, delivering miR-21i with DOX using PSeHD-SeSeP/miR-21i/HA produces a good 
anticancer synergy effect. Strengthening DOX resistance increases the cancer cell survival rate 
for free DOX and PSeHD-SeSeP/HA, but that for PSeHD-SeSeP/miR-21i/HA remains the 
lowest, and expands the difference between whether the presence of miR-21i. The involvement 
of miR-21i inhibit activity of miR-21 to upregulate PTEN and PDCD4, thereby restoring DOX 
sensitivity to multidrug resistant cancer cells and activating apoptosis [9, 11, 41].   
DOX concentration for 50 % of cell death, as referred to IC50, were calculated and shown in 
Figure 4.5F. The IC50 values for free DOX are 2.54, 3.27, and 4.93 µg mL-1 for MDA-MB-
231-S, MDA-MB-231-R4w and MDA-MB-231-R12w cells. The anticancer therapy of 
PSeHD-SeSeP/HA shows 2-folds higher effective than that of DOX, presenting IC50 values of 
1.19, 1.53, and 2.99 µg mL-1 on MDA-MB-231-S, MDA-MB-231-R4w, and MDA-MB-231-
R12w cells. The increasing dosage requirement for free DOX and PSeHD-SeSeP/HA on MDA-
MB-231-R4w and MDA-MB-231-R12w cells could be explained by the overexpression of 
ATP binding cassette (ABC) transporters to expel the intracellular localized DOX to 
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extracellular environment, reducing anticancer effects [42]. However, PSeHD-SeSeP/miR-
21i/HA systems prove anticancer synergy effects with a fixed IC50 value of 0.9 for MDA-MB-
231-S and MDA-MB-231-R4w cells. In addition, the IC50 value of PSeHD-SeSeP/miR-21i/HA 
for MDA-MD-231-R12w is 3.2 times lower than that of free DOX, indicating 3.2 times more 
effective for cancer.  
The synergistic anticancer effects on the above cell lines suggest that PSeHD-SeSeP/miR-
21i/HA can deliver DOX and miR-21i selectively and effectively to metastatic cancer cells and 
their multidrug resistant cells but not to normal cells. The proposed dual-lock co-delivery 




HA coated cationic microgels with a double-lock for anticancer drugs are synthesized for 
selective co-delivery of DOX and miR-21i to multidrug resistant cancer cells with exceptional 
anticancer synergetic effects and minimal side effects. The delivery systems of PSeHD-
SeSeP/miR-21i/HA are designed on the basis of diselenide crosslinked PEI800 for miR-21i 
loading and double-lock linkers of hydrazone and diselenide bonds for DOX conjugation, and 
finally HA surface coating for charge convert and cancer cell targeting. The microgel system 
is well maintained in structure and size without DOX leakage, allowing stable circulation 
during the delivery process. HA allows the system to selectively enter cancer cells through HA 
receptor mediation. Only under the situation of sequentially passing through the cancer 
extracellular environment and endo/lysosome with acidic pH and the cytosol with reductase 
enzyme GSH, hydrazone and diselenide bonds can be cleaved to release loaded DOX and miR-
21i. At the same time, microgel carriers are degraded into 1-2 nm fractures after releasing DOX 
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and miR-21i to target cells. 3.2 times higher therapeutic performance than free DOX on 
multidrug-resistant cells and minimal side effects on HEK293T cells prove this dual-lock 
cationic co-delivery system can contribute to future complex therapeutic applications.   
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Figure 4.S1 Raman spectrum of the diselenide bond crosslinker (-SeSe-).  
 
 
Figure 4.S2 FTIR spectra of diselenide crosslinker (-SeSe-), PEI800, and PEI800 microgels 
via crosslinking PEI800 with –SeSe-. 
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(A)                                                    (B)   
 
Figure 4.S3 Characterizations of diselenide bond (-SeSe-) crosslinked PEI800 microgels 
(PSeSe), (A) zeta potential to compare with that of PEI25k and PEI800 as a positive control 
and a negative control, and (B) size to confirm diselenide bond cleavage under various 




(A)                                                    (B)   
 
Figure 4.S4 Conductivity and pH titrations for (A) PSeSe (2.4 mg) and (B) PSeHD-SeSeP 
(2.65mg), measured at room temperature. 





















Figure 4.S6 Agarose gel retardation assay for miR-21i loading to PSeHD.  
 











Figure 4.S7 Survival rate against DOX concentrations from 0.1 to 2.5 µg mL-1 for DOX 
sensitive breast cancer cell, MDA-MB-231-S (0W), and DOX resistant metastatic breast cancer 
cells, MDA-MB-231-R4w (4W), MDA-MB-231-R8w (8W) and MDA-MB-231-R12w (12W), 





























Figure 4.S8 Quantitative MDA-MB-231 cellular uptake assays of PSeHD-SeSeP/FAM-
miR/HA system by flow cytometer, (A) cells only without PSeHD-SeSeP/FAM-miR/HA as a 
control, (B) cells with PSeHD-SeSeP/FAM-miR/HA, and (C) HA-pretreated cells with 
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Multidrug resistance (MDR) in invasive cancer with chronic chemotherapy leads to poor 
prognosis, high dosages and resultant severe side effects to patients. To exert effective 
therapeutic effect on multidrug-resistant cancers and minimize side effects of 
chemotherapeutic agents, biocompatible and fully-biodegradable microgels were prepared by 
crosslinking low molecular weight polyethyleneimine (PEI800) and doxorubicin (DOX) with 
diselenide-crosslinkers in a one-step process,  and a microRNA-21 inhibitor (miR-21i) and an 
ATP aptamer (Apt) were complexed with the microgels to construct novel nanomedicines able 
to release DOX intracellularly and mitigate MDR by inhibiting oncogenic microRNA-21 and 
ATP-binding cassette (ABC) transporters in cancer cells. Hyaluronic acid (HA) was finally 
introduced to nanomedicine surface for facilitating HA receptor-mediated endocytosis and 
eliminating serum protein adsorption. The nanomedicine is benign to normal cells with 99.2 % 
viable HEK293T cells after treatment. Biodegradation and drug release of this nanomedicine 
simultaneously occur in response to specific tumor microenvironment with a high 
concentration of GSH to cleave diselenide crosslinkers. This nanomedicine displays an 
enhanced and synergistic therapeutic efficacy: 29.1 ± 4.7 % of metastatic breast cancer cell 
survival and remarkably 8.9 % of multidrug-resistant cancer cells survive after treatment with 
this nanomedicine at a DOX concentration of 2.5 µg mL-1. This nanomedicine has 
demonstrated great potential in combating multidrug resistant cancer cells by tri-delivery of 
functional therapeutic agents (DOX, miR-21i inhibitor and Apt) into cells.  
Keywords: tri-delivery, nanomedicine, multidrug resistance, diselenide crosslinker, DOX, 
miR-21 inhibitor, ATP aptamer, hyaluronic acid, microgels 




Multidrug resistance (MDR) has posed a significant challenge in completely eradicating cancer 
cells since these cells have gradually gained tolerance to chemotherapeutic agents. The cancer 
cells possess inherent drug resistance via phosphatidylinositol-3-kinase (PI3K)/Akt and 
mammalian target of rapamycin (mTOR) signaling pathways to enhance cancer cell growth 
and survival, and expression of microRNA-21 (miR-21) to downregulate phosphatase and 
tensin homolog (PTEN), an inhibitor of PI3K, and programmed cell death 4 (PDCD4), a 
protector of tumor suppressor protein p53 [1-4]. Practically, doxorubicin (DOX), an 
anthracycline drug, is initially progressive in exerting its anticancer effect via intercalating 
adenosine triphosphate (ATP)-driven topoisomerase II and damaging DNA to activate p53, 
and downregulating B-cell lymphoma-2 (bcl-2) to induce apoptosis of cancer cells [5, 6]. 
However, chronic administration of DOX promotes MDR in cancer cells via detoxification 
with an increasing level in glutathione (GSH), mutation of topoisomerase II for reduced DOX 
intercalation, and inhibition of PTEN and PDCD4 with increasing expression of miR-21 after 
activation of nuclear factor kB (NF-kB) and signal transducer activator of transcription 3 
(STAT3) [7-10]. In addition, overexpression of ATP-binding cassette transporters (ABC 
transporters) in cancer cells after chronic chemotherapy reduces intracellular accumulation of 
DOX [11, 12]. Meanwhile, an increased dosage of DOX and cellular uptake of DOX by normal 
cells result in detrimental side-effects, such as heart failure, skeletal muscle dysfunction, 
chronic kidney function loss, and liver injury [13-17]. Introduction of a miR-21 inhibitor (miR-
21i) to multidrug-resistant cancer cells augments their sensitivity to administrated DOX [18, 
19]. In addition, ATP aptamers (Apt), short single-stranded oligonucleotides to bind ATP have 
been used for ATP depletion in drug resistant cells by preventing efflux of anticancer drugs 
[20-23]. Therefore, tri-delivery of DOX, miR-21i and Apt into cancer cells may mitigate MDR 
and maximize the anticancer efficacy of DOX. 
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To date, many drug delivery carriers have been developed to physically/chemically load 
chemotherapeutic or gene drugs, while these carriers may not be able to meet ideal criteria for 
delivery of drugs: minimized side effects due to systemic toxicity, great biocompatibility with 
no/low inherent toxicity, controlled release of drugs, prolonged circulation, selective 
endocytosis, traceable delivery and enhanced anticancer efficiency. In our recent studies, 
strong cations with effective gene condensation ability but high cytotoxicity (e.g., PEI25k, 
polyamidoamine dendrimers and poly-L-lysine) are replaced by low-toxic biodegradable 
vesicles of crosslinked biocompatible weak cations (e.g., PEI800) using redox cleavable 
disulfide or diselenide molecules to achieve high transfection efficiency and biocompatibility 
[24-27] (Chapter 3). On the other hand, premature leakage of physically loaded DOX from a 
delivery vesicle, including liposome, micelle, and inorganic nanoparticles, can be improved by 
chemical conjugation of drug to vesicles via cleavable linkers of hydrazone or/and diselenide 
moieties which are specifically responsive to the acidic pH and strongly expressed GSH in 
tumor microenvironment [28-30] (Chapters 3 and 4). To prolong the circulation time of drug-
loaded delivery systems, the hydrodynamic sizes of the systems is often controlled to be 
between 10 and 200 nm to improve the enhanced permeation and retention (EPR) effect and 
avoid renal and reticuloendothelial system (RES) clearance [31-33]. Surface modification with 
poly(ethylene glycol) (PEG) contributes to prolonged circulation by preventing serum protein 
adsorption, but increased PEGylated nanomedicines experience low efficiency in  endocytosis 
[31-33]. Although active cancer targeting of a delivery system is realizable by surface 
modification with ligands for specific receptors on cancer cells, such as antibodies, peptides 
and aptamers, these ligands have challenging issues, such as immunogenicity from interaction 
between antibodies and Fc receptors on normal cells, cytotoxicity from positively charged 
peptides, and less efficient targeting of aptamers in practice [20, 34-36]. Anionic hyaluronic 
acid (HA) is suggested to prevent delivery system from serum adsorption by electrostatic 
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repulsion and to be selectively endocytosed to cancer cells via overexpressing HA receptors, 
CD44 and RHAMM [37]. Moreover, inorganic molecules can be introduced to delivery 
systems for imaging technologies, including UV-vis absorbance, magnetic resonance (MR) 
imaging and photoluminescence, to track bio-distribution in diverse clinical applications 
although the inorganics exhibit potential toxicity due to their high accumulation in patient body 
[38-41]. Quenching effect on fluorophore (e.g., quantum dot and DOX) by a quencher within 
100 Å of distance can also be useful to image their intracellular localization in real-time when 
they are far apart from each other [42, 43].  
Herein, we prepared a multi-functional tri-delivery vesicle for DOX, miR-21i and Apt in order 
to enhance the therapeutic effect of DOX on invasive cancers with MDR and minimizing the 
side-effect from both DOX and vesicle itself. Biocompatible PEI800 and DOX were simply 
crosslinked with intracellular cytosol GSH-cleavable diselenide crosslinkers to yield 
biodegradable DOX-conjugated microgels, which then electrostatically bound to miR-21i and 
Apt. After HA coating on the surface of the formed polyplexes, a biodegradable nanomedicine 
was produced with an anionic surface and a hydrodynamic size of 100 - 200 nm for prolonged 
systemic circulation and HA receptor-mediated endocytosis. Fluorescence from DOX allowed 
monitoring cellular uptake of the nanomedicine (Scheme 5.1A), and the black hole quencher 
(BHQ) labeling of the nanomedicine confirmed intracellular release of DOX (Scheme 5.1B). 
Anticancer effect of DOX was significantly enhanced via mitigating MDR by inhibiting miR-
21 and DOX exporters with ATP depletion because of spontaneously release of miR-21i and 
Apt of the nanomedicine.  
 


























Scheme 5.1 (A) Scheme for entire process of the traceable tri-delivery system, PSeSeD/miR-
21i/Apt/HA: synthesis, HA receptor-mediated endocytosis, GSH-triggered nanomedicine 
degradation in cytosol to release loaded DOX, miR-21i and Apt, isolating ATP by Apt, and 
inhibiting miR-21 by miR-21i. (B) Scheme for tracing intracellular DOX localization by 
quenching the fluorescence in PSeSeDBHQ but emitting fluorescence in GSH-rich cytosol.  
 





Doxorubicin hydrochloride was purchased from Wuhan Wang Lianshang Biotechnology 
(China). MicroRNA-21 inhibitor (sequence 5’-GUCCACUCUUGUCCUCAAUG-3’) (miR-
21i) and FAM-labelled miRNA inhibitor with a single strand as a negative control (sequence 
5’-CAGUACUUUUGUGUAGUACAA-3’) (FAM-miR) were obtained from Shanghai Gene 
Pharma Co., Ltd. BHQ®-2 succinimidyl ester was obtained from LGC Biosearch Technologies. 
Adenosine 5’-triphosphate (ATP) aptamer (sequence 5’- 
ACCTGGGGGAGTATTGCGGAGGAAGGT-3’) was supplied from InvitrogenTM. Sodium 
hyaluronate 60 kDa (HA) was obtained from Lifecore Biomedical, LLC. Branched 
polyethyleneimine 800 (PEI800), selenium, sodium borohydride (NaBH4), 3-chloropropionic 
acid, 1-ethyl-3-(3-dimethyl-laminopropyl) carbodiimide (EDC), N-hydroxysulfosuccinimide 
(NHS), L-glutathione reduced (GSH), Leibovitz’s Medium (L-15), cell counting Kit-8 (CCK-
8), bis-benzimide H 33258, and ATP bioluminescent somatic cell assay kit were purchased 
from Sigma-Aldrich. Dulbecco modified eagle medium (DMEM), fetal bovine serum (FBS), 
penicillin-streptomycin (PS), Trypsin-EDTA (0.25%), and CellMaskTM Deep Red Plasma 
Membrane Stain were supplied from Life Technologies Australia Pty Ltd. HEK293T and 
MDA-MB-231 cell lines were from Australia Health and Medical Research Institute and 
School of Pharmacy at University of South Australia. Deionised water was produced from a 
Spectra/Por® Milli-Q water system (18.2 MΩ·cm, Spectrum Laboratories, Inc.). 
5.2.2 Synthesis of DOX loaded microgels (PSeSeD) 
5.2.2.1 Diselenide crosslinker (-SeSe-) 
3,3’-diselanediyldipropanoic acid, a diselenide crosslinker (-SeSe-), was synthesized from the 
same method being reported in our previous paper (Chapter 3). Briefly, selenium powder (1.18 
g, 15 mmol) was suspended in water (5 mL) in a flask with nitrogen protection and magnetic 
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stirring. Sodium borohydride (1.13 g, 30 mmol) dissolved in cold water (12.5 mL) was 
dropwise added to the flask in an ice bath for 10 min until the solution became colorless. 1.18 
g of selenium powder was then added to the solution and stirred at 105 °C under nitrogen 
environment for 20 min to turn the color into reddish-brown. 3-chloropropionic acid (3.26 g, 
30 mmol) in water (7.5 mL, pH 8.0 being adjusted with sodium carbonate) was injected to the 
flask at room temperature for overnight stirring with N2 gas protection. The mixture was further 
stirred under an open air environment to oxidize unreacted selenium for 12 h. After filtering 
with a 0.45 µm membrane filter, pH of the mixture was adjusted to 3.0 using 3 M hydrochloride. 
Coagulants were collected through extraction with ethyl acetate and subsequent water wash for 
3 times. After drying the product in ethyl acetate using magnesium sulphate and filtering, -
SeSe- with a pale yellow color was crystalized. Successful synthesis of diselenide crosslinker 
was confirmed by Raman spectroscopy.   
5.2.2.2 DOX conjugated PEI microgels of PSeSeD and PSeSeD2X 
For the synthesis of DOX conjugated PEI microgels (PSeSeD), mixture of –SeSe- (42.8 mg, 
140.9 µmol), EDC (162.1 mg, 845.7 µmol) and NHS (64.9 mg, 563.8 µmol) in DMSO (400 
µL) was magnetically stirred under nitrogen protection at ambient temperature for 45 min. 
DOX·HCl (16.35 mg, 28.2 µmol) in DMSO (200 µL) was injected to the mixture under light 
protection, and branched PEI800 (pH 8.0 being adjusted by 3M HCl, 90.2 mg, 112.7 µmol) in 
200 µL DMSO was injected after an interval of 5 min. The mixture was stirred for another 2 
days under dark and dialyzed with a tube of 7 kDa MWCO against deionized water at 4 °C 
under light protection for 32 h with water change at every 8 h. After lyophilization, PSeSeD 
was produced. The zeta potential and hydrodynamic size of PSeSeD in 10 mM NaCl solution 
at pH 7.4 were characterized with dynamic light scattering (DLS) measurement from a zeta 
sizer (Malvern Zetasizer Nano ZS ZEN 3600). FTIR was used to confirm the synthesis of 
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PSeSeD. The amine content in PSeSeD (µmol mg-1) was quantified with conductivity and pH 
titration. DOX loading (wt. %) was calculated from following Equation: 
DOX loading (%) =  
(total DOX−unloaded DOX)
DOX loaded microgels
 × 100                             (1) 
The amount of unloaded DOX was determined from a UV-vis spectroscopy (Figure 5.S3) at a 
wavelength of 479.5 nm.  
At the same time, PEI microgels with double DOX feed (PSeSeD2X) was synthesized using a 
similar method but with the feed of DOX (32.7 mg, 56.4 µmol), PEI800 (90.2 mg, 112.7 µmol) 
and –SeSe- (51.4 mg, 169.1 µmol). 
5.2.2.3 Black hole quencher conjugation (PSeSeDBHQ) 
Black hole quencher-2 (BHQ) was conjugated to PSeSeD (PSeSeDBHQ) by chemical bonding 
of succinimidyl ester and primary amine. PSeSeD (12.6 mg, 2.17 µmol of loaded DOX) and 
BHQ®-2 succinimidyl ester (1.6 mg, 2.65 µmol) were dissolved in DMSO (4 mL), and the 
mixture was magnetically stirred at room temperature under nitrogen and light protection for 
overnight. After 3-day dialysis in darkness at 4 °C with frequent water change and freeze drying, 
PSeSeDBHQ was produced. Successful interaction of BHQ and PSeSeD was confirmed from 
the absorbance spectrum of a UV-vis spectrophotometer and the color change in solution. 
5.2.2.4 Microgels without DOX (PSeSe) and degraded-PSeSe (Degrade-P)  
PEI microgel without DOX loading (PSeSe) was synthesized by the same method as PSeSeD 
but without DOX feed. –SeSe- (34.2 mg, 112.7 µmol) was used to crosslink PEI800 (90.2 mg, 
112.7 µmol) to produce PSeSe as being confirmed from FTIR. 
PSeSe degradation was handled in a mimicking cytosol condition: 20 mM glutathione (GSH), 
pH 7.4, and 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES) buffered glucose 
solution containing 20 mM HEPES and 5% glucose (HEPES buffer), producing Degrade-P. 
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The degradation process was monitored via the hydrodynamic size measurements in HEPES 
buffer (pH 7.4) with 20 mM GSH and without GSH at 37 °C and predetermined time intervals 
for 72 h. 
5.2.3 Ex vivo DOX release and biodegradation 
5.2.3.1 DOX release 
PSeSeD in pH 7.4 HEPES buffer (5 mL, 1 mg mL-1) was dialyzed using a tube (MWCO 3.5 
kDa) against HEPES buffer (95 mL) with various GSH concentrations of 0 M, 10 µM, and 20 
mM in a horizontal shaker (100 rpm) at 37 °C over 144 h. An aliquot outside the dialysis tube 
was withdrawn with its absorbance read at 479.5 nm via a UV-vis spectrophotometer at pre-
designed time intervals. Quantification of released DOX from PSeSeD was determined from 
the DOX calibration curve (Figure 5.S3). 
5.2.3.2 Biodegradability of PSeSeD 
Bio-stability and bio-degradability of PSeSeD complexes were evaluated via hydrodynamic 
size measurements in HEPES buffer (pH 7.4) at different mimicking conditions: 0 M GSH for 
a physiological condition, 10 µM GSH for an extracellular microenvironment, and 20 mM 
GSH for an intracellular cytosol environment. The hydrodynamic sizes of the PSeSeD in above 
solutions under shaking at 100 rpm at 37 °C were measured at a predetermined time for a 
duration of 120 h.  
5.2.4 miR-21i and Apt loading (PSeSeD/miR-21i/Apt) and release 
A mixture of miR-21i (0.5 µL, 0.42 nmol µL-1) and Apt (0.5 µL, 0.54 nmol µL-1) was incubated 
with PSeSeD at room temperature for 20 min at various mixing mole ratios of nitrogen (N) in 
PSeSeD (Figure S6) to phosphate (P) in the mixture of miR-21i and Apt (N/P), ranging from 1 
to 8. The mixture of miR-21i and Apt only without PSeSeD was employed as a control. Agarose 
gel (0.8 %) retardation assay was conducted at 100 volts for 1 h. The mixture migrated in the 
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gel was fluorescent under UV irradiation and photographed by a G-BOX. PEI25k and PEI800 
as a positive and a negative control were polyplexed with the mixture of miR-21i and Apt at a 
predetermined N/P ratio of 0.5, 1.0, 2.0, and 3.0 for PEI25k and 4.0, 6.0, 8.0, and 10.0 for 
PEI800, while PSeSeD2X and PSeSe were polyplexed with miR-21i and Apt at a N/P of 1.0 
to 10.0. The N/P ratio for full loading of these polyplexes was determined with agarose gel 
electrophoresis and G-BOX.  
Release of miR-21i and Apt from PSeSeD/miR-21i/Apt polyplexes at an N/P of 10.0 was ex 
vivo assayed via agarose gel electrophoresis. The polyplexes were incubated in HEPES buffer 
solution with 20 mM GSH at pH 7.4 at 37 °C for 72 h, and assayed in agarose gel at 100 volts 
for 1 h with subsequent photographing by a G-BOX.   
5.2.5 HA coating (PSeSeD/miR-21i/Apt/HA) and characterization 
5.2.5.1 HA coating  
Hyaluronic acid (HA) was coated to PSeSeD/miR-21i/Apt polyplexes in RNase free water 
(DEPC water).  PSeSeD was incubated with a mixture of miR-21i and Apt at an N/P ratio of 
10.0 at room temperature for 20 min and then incubated with HA at a weight ratio of HA to 
PSeSeD of 1.5 for 20 min to yield the PSeSeD/miR-21i/Apt/HA. 
5.2.5.2 Zeta potential and particle size 
Zeta-potential and hydrodynamic size of PSeSeD/miR-21i/Apt/HA were measured in 10 mM 
NaCl solution at pH 7.4 using a zetasizer (ZEN 3600) and compared to that of PSeSeD and 
PSeSeD/miR-21i/Apt. 
5.2.6 Cell culture 
Human embryonic kidney cell line (HEK293T), human metastatic breast cancer cell line 
(MDA-MB-231), and DOX resistant breast cancer cell line (MDA-MB-231-R) were cultured 
in a humidified incubator (Contherm Scientific Limited) at 5 % CO2 and 37 °C. HEK293T was 
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cultured with Dulbecco Modified Eagle Medium (DMEM), 10 vol. % of fetal bovine serum 
(FBS), and 1 vol. % of penicillin-streptomycin (PS). The culture medium including Leibovitz’s 
Medium (L-15), 10 % FBS, and 1 % PS was employed to culture MDA-MB-231. For MDA-
MB-231-R culture, a low concentration of DOX (0.01 µg for 8 weeks and 0.02 µg mL-1 from 
9th to 12th week) was included in the L-15 based medium.  
The viability assay for MDA-MB-231-R cells was executed via Cell Counting Kit-8 (CCK-8) 
at every 4 weeks while culturing over 12 weeks. MDA-MB-231-R was incubated in a 96-well 
plate with L-15 based medium without DOX for 24 h, and then further incubated with 
DOX·HCl (free-DOX) at an increasing concentration from 0.1 to 2.5 µg mL-1 for 48 h. The 
well plate with CCK-8 treatment for another 4 h in the incubator was inserted in a microplate 
reader (ELx808 BioTek) to read absorbance at 450 nm wavelength to determine the cell 
survival rate (%) using the following equation:  
Cell survival rate (%) =  
(S−B)
(C−B)
 × 100                                     (2) 
where S, C, and B represent the absorbance with DOX, without DOX, and a blank without 
cells.  
5.2.7 Intracellular uptake of PSeSeD/FAM-miR/Apt/HA and localization of DOX 
5.2.7.1 Tracing cellular uptake of PSeSeD/FAM-miR/Apt/HA  
Intracellular uptake of PSeSeD/FAM-miR/Apt/HA was qualitatively monitored via a confocal 
laser scanning microscopy (CLSM) (Olympus FV3000) with replicates. MDA-MB-231 cells 
were incubated on glass cover slips in 3 wells of a 12-well plate with L-15 based media, and 
HA (10 mg mL-1) was included in one well to block HA receptors to obtain HA pretreated cells. 
After 24 h incubation, PSeSeD/FAM-miR/HA (10.0 N/P of PSeSeD to FAM-labeled miRNA 
negative control with a random sequence (FAM-miR) and 1.5 weights of HA to PSeSeD) was 
applied to two wells of the plate: one well containing cells without HA pretreatment and the 
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other well with HA pretreated cell, while the third well with cells without HA pretreatment and 
PSeSeD/FAM-miR/HA was used as a control. After further 4 h incubation, cells in the 3 wells 
were treated with CellMaskTM Deep Red Plasma Membrane Stain for 5 min, and fixed with 
formaldehyde (4 %) for 10 min. Subsequently after washing with PBS 3 times, fluorescent 
images were obtained with blue for DOX, green for FAM-miR, and red for cells via a CLSM. 
 Quantification of intracellular uptake of PSeSeD/FAM-miR/HA was determined via detecting 
the fluorescent intensity from DOX and FAM-miR using filters, FL-2 (ex. 488, em. 585 nm) 
and FL-1 (ex. 488, em. 530 nm), of a flow cytometer (BD FACSCaliburTM) with replicates. 
MDA-MB-231 cells were cultured in two wells of a 24-well plate for 24 h. One well with 
PSeSeD/FAM-miR/HA and the other well without PSeSeD/FAM-miR/HA as a control were 
further incubated for another 4 h, and cells were then collected by trypsin-EDTA treatment and 
washed by PBS.  
5.2.7.2 Intracellular localization of DOX and FAM-miR 
Intracellular localization of DOX and FAM-miR was traced via a flow cytometer. DOX and 
FAM-miR loaded complexes with a quencher (BHQ), PSeSeDBHQ/FAM-miR/HA, were 
prepared in the same condition as PSeSeD/FAM-miR/HA, and applied to MDA-MB-231-R 
cells after 24 h incubation on a 24-well plate. The cells were further incubated for 4 h and 12 
h, and cells without PSeSeDBHQ/FAM-miR/HA were used as a control. After treatment with 
trypsin-EDTA and washing with PBS, the collected cells were excited at 488 nm wavelength 
with a flow cytometer to detect fluorescent intensity of DOX and FAM-miR using FL-2 and 
FL-1 filters. 
5.2.8 Biocompartibility of PSeSe microgels and PSeSeD/miR-21i/Apt/HA 
Biocompatibilities of PSeSe microgels and Degrade-P fragments were evaluated via HEK293T 
cell viability assay. HEK293T cells were incubated in a 96-well plate for 24 h, and then exposed 
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to PSeSe or Degrade-P at a concentration of 1.0, 10.0, and 50.0 µg mL-1, followed by further 
48 h incubation. After CCK-8 treatment for 4 h, cell survival rates were determined from 
Equation 2 with the absorbance reading at 450 nm from the well plate using a microplate reader. 
The cell survival rates for PEI25k and PEI800 were compared as controls.  
HEK293T viability assay against PSeSeD/miR-21i/Apt/HA (10 N/P and 1.5 wt. ratio of HA to 
PSeSeD) was carried out to confirm biosafety of PSeSeD/miR-21i/Apt/HA after systemic 
administration. HEK293T cells were incubated in a 96-well plate for 24 h. The cells were 
treated by PSeSeD/miR-21i/Apt/HA with an increase in DOX concentration from 0.1 to 2.5 µg 
mL-1, and incubated for another 48 h. After CCK-8 treatment for 4 h and absorbance reading 
at 450 nm in a microplate reader, the cell survival rate against PSeSeD/miR-21i/Apt/HA was 
calculated using Equation 2. The cell viability was also measured after cells were treated by 
free-DOX, PSeSeD, and PSeSeD/HA as controls.  
5.2.9 Anticancer efficacy PSeSeD/miR-21i/Apt/HA against MDA-MB-231 cell lines 
The anticancer efficacy of PSeSeD/miR-21i/Apt/HA (10.0 N/P, 1.5 wt. ratio HA) against 
MDA-MB-231 cells was evaluated by counting viable cells after treatment. MDA-MB-231 
cells were incubated in a 96-well plate for 24 h, and incubated for further 48 h in the presence 
of PSeSeD/miR-21i/Apt/HA with loaded DOX concentrations from 0.1 to 2.5 µg mL-1. MDA-
MB-231 cell survival ratio after exposure to PSeSeD/miR-21i/Apt/HA was obtained after 4 h 
CCK-8 treatment and absorbance reading in a microplate reader. For comparison, free-DOX, 
PSeSeD/HA (2.0 wt. ratio HA), PSeSeD/Apt/HA (20.0 N/P, 1.8 wt. ratio HA), and 
PSeSeD/miR-21i/HA (20.0 N/P, 1.8 wt. ratio HA) were also applied to MDA-MB-231 cells 
for measuring their viabilities.  
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5.2.10 ATP aptamer efficacy 
5.2.10.1 ATP quantification  
ATP contents in MDA-MB-231 and MDA-MB-231-R cells before and after treatment with 
Apt were determined via an ATP bioluminescent somatic cell assay kit and a fluorophotometer 
(Shimadzu, RF-5301PC) with replicates. MDA-MB-231 (231-S) and MDA-MB-231-R (231-
R) cells (300,000 cells per well) were seeded in a 6-well plate (2 wells for 231-S and 2 wells 
for 231-R) and incubated for 24 h. PSeSe (54.5 µL, 0.1 mg mL-1) was incubated with Apt (7.8 
µL, 0.54 nmol µL-1) for 20 min at room temperature, and coated by HA (8.2 µL, 1 mg mL-1) 
to produce PSeSe/Apt/HA. An equal amount of PSeSe was coated by HA (10.9 µL, 1 mg mL-
1) to produce PSeSe/HA without Apt. PSeSe/Apt/HA and PSeSe/HA without Apt were added 
into two types of cells for another 48 h incubation. Cells were collected by trypsin-EDTA 
treatment and counted in a hemocytometer. 1×104 cells in each well were suspended in the 
ATP assay dilution buffer at pH 7.8 (50 µL) and mixed with the somatic cell ATP releasing 
agent (100 µL) and deionized water (50 µL). The mixture (100 µL) was transferred to a 
fluorimeter cuvette in the presence of 25-folds diluted ATP assay working solution (including 
luciferin and luciferase) (100 µL) and additional ATP assay dilution buffer (2 mL). The signal 
of luciferin fluorescence was detected at a wavelength of 530 nm via a fluorophotometer (ex. 
350 nm) and ATP (pmol per cell) was quantified using a calibration curve of the fluorescence 
intensity to a range of ATP concentrations (nmol) (Figure 5.S9).  
5.2.10.2 Qualitative therapeutic effect induced by Apt on MDA-MB-231-R  
The therapeutic effect induced by Apt on multi-drug resistant MDA-MB-231-R cells was 
qualitatively evaluated via monitoring DOX intracellular localization after release from 
PSeSeDBHQ/Apt/HA and PSeSeDBHQ/HA under a CLSM. DOX and Apt loaded PSeSe with 
BHQ (PSeSeDBHQ/Apt/HA) was prepared. PSeSeDBHQ (60 µL, 0.1 mg mL-1) was mixed 
with Apt (7.8 µL, 0.54 nmol µL-1) for 20 min incubation at room temperature, and coated by 
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HA (6 µL, 1 mg mL-1). PSeSeDBHQ/HA without Apt was prepared by directly coating HA (9 
µL, 1 mg mL-1) to PSeSeDBHQ (60 µL, 0.1 mg mL-1). MDA-MB-231-R cells were incubated 
on glass slips of 4 wells in a 12-well plate for 24 h. Because tracing DOX intracellular 
localization was dependent on incubation time and the presence of Apt, two wells was 
incubated with PSeSeDBHQ/Apt/HA for 24 and 48 h, while the other two wells was treated 
with PSeSeDBHQ/HA for 24 and 48 h. Subsequently, membrane and nucleus of the cells were 
stained with CellMaskTM Deep Red for 5 min and bisBenzimide H 33258 for another 5 min, 
and fixed by formaldehyde (4%) for 10 min. After washing with PBS3 times, fluorescent 
images from DOX (blue), membrane (red), and nucleus (cyan) were captured via CLSM. 
5.2.11 Anticancer synergy of PSeSeD/miR-21i/Apt/HA on cancer cells with MDR 
The synergistic therapeutic efficacy of PSeSeD/miR-21i/Apt/HA on multi-drug resistant cell 
lines, MDA-MB-231-R, was quantified via the cell viability assay using CCK-8. The procedure 
was similar to that for MDA-MB-231 cells. Therapeutic effects induced by free-DOX, 
PSeSeD/HA, PSeSeD/Apt/HA, and PSeSeD/miR-21i/Apt/HA on MDA-MB-231-R were also 
evaluated. 
 
5.3 Results and Discussion 
5.3.1 Synthesis of PSeSeD microgels 
5.3.1.1 DOX conjugated biodegradable microgels (PSeSeD) 
Conjugation of doxorubicin (DOX) to a delivery carrier with cleavable linkers may protect 
DOX from pre-leakage before reaching tumor site, while DOX release is realized by cleaving 
the linker in response to specific tumor microenvironment. For delivery of miR-21i and Apt, 
strong positive charged polymers with a large molecular weight intrinsically show a high 
loading efficiency due to electrostatic interaction between anionic genes/Apt and cationic 
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polymers, but severe cytotoxicity and accumulation in a patient’s body are often associated 
with cationic polymers. In this study, biodegradable microgels with DOX conjugation were 
prepared by crosslinking low molecular weight PEI800 with DOX in the presence of -SeSe- in 
one reactor and miR-21i and Apt were complexed with DOX conjugated microgels by 
electrostatic interaction. 
The redox-sensitive diselenide crosslinker, 3.3’-diselanediyldipropanoic acid (-SeSe-), was 
prepared with a yield of 56.5 %, in which the Se-Se bond and the Se-C bond are observed in 
Raman shifts at 291 and 517 cm-1 (Figure 5.S1). DOX conjugated microgels (PSeSeD) were 
formed by crosslinking DOX and PEI800 at a feed mole ratio of 0.25:1 with –SeSe- in a reactor 
(Scheme 5.2) with a yield of 48 %. PSeSeD has a zeta potential of 58.3 ± 1.4 mV and a 
hydrodynamic size of 218.7 ± 13.4 nm from a Malvern zetasizer measurement. Successful 
synthesis of PSeSeD is confirmed from FTIR spectra of PEI800, PEI800 microgels without 
DOX (PSeSe) and PSeSeD (Figure 5.S2). Distinct PEI800 peaks at 3356, 3251 and 1541 cm-1 
for N-H stretching of primary amine and N-H bending are detected in the PSeSeD spectrum 
and peaks from crosslinking by –SeSe- at 1630 and 527 cm-1 for C=O stretching and Se-C 
stretching. Conjugated DOX is evident at 3078, 1408 and 985 cm-1 of the FTIR spectrum for 
aromatic C-H stretching and O-H bending from DOX. Conductivity and pH titration reveals 
the amine group of 4.2 µmol mg-1 in PSeSeD (Figure 5.S6A). DOX loading in PSeSeD 
determined by Equation 1 is found to be 9.35 wt. %.  
By doubling the feed molar ratio of DOX to PEI800 (0.5:1) in comparison with 0.25:1 for 
PSeSeD, PSeSeD2X was produced by crosslinking DOX and PEI800 with –SeSe- with a yield 
of 56 %. The zeta potential and the hydrodynamic size of PSeSeD2X reduce to 31.5 ± 4.5 mV 
and 136.8 ± 24.3 nm respectively, while DOX loading increases by 1.8 times (16.5 wt. %) in 
comparison with that in PSeSeD (9.35 wt.%) (Table 5.S1). The results indicate DOX loading 
in the microgels can be controlled by adjusting the feed ratio of DOX to PEI800. 





Scheme 5.2 Synthesis of PSeSeD by crosslinking PEI800 and DOX with –SeSe-  
 
5.3.1.2 Preparation of PSeSeDBHQ, PSeSe, and Degrade-P 
To trace intracellular localization of DOX and FAM-labelled miRNA with a random sequence 
(FAM-miR), black hole quencher-2 (BHQ) was conjugated to PSeSeD by covalently bonding 
succinimidyl ester in BHQ to the primary amine group in PSeSeD, producing PSeSeDBHQ. 
Emissions from DOX at a wavelength of 580 nm and FAM at 530 nm  can be quenched by 
BHQ in the integrated structure of PSeSeDBHQ, while the emissions from DOX and FAM can 
be switched on for fluorescence detection after they are release from PSeSeDBHQ with a 
quenching distance more than 10 nm between BHQ and DOX or FAM [42]. Successful 
synthesis of PSeSeDBHQ is confirmed by a UV-vis absorbance peak at 541.5 nm and a dark 
purple color of the product, comparing to an absorbance peak at 488 nm and a red color of 
PSeSeD (Figure 5.S4).      
To deliver Apt alone without DOX for the ATP assay, PEI800 was crosslinked by –SeSe- to 
produce PSeSe microgels with a zeta potential and a particle size of 68.3 ± 0.68 mV and 260.0 
± 22.9 nm (Table 5.S1). The amine content in PSeSe is determined via conductivity and pH 
titration to be 4.96 µmol mg-1 (Figure 5.S6B).  
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To evaluate in vitro biocompatibility of degraded microgels with normal kidney cell lines 
(HEK293T), PSeSe microgels were incubated with 20 mM glutathione (GSH) at pH 7.4 for 72 
h, producing Degrade-P with a zeta potential and a size of 0.96 ± 3.9 mV and 3.7 ± 1.9 nm. 
Figure 5.S5 shows the size of  PSeSe decreases in 20 mM GSH to mimic the cytosol reductase 
with extension of the incubation time up to 72 h, while the size of PSeSe is maintained in 0 M 
GSH during the entire experimental time, supporting the microgels are only biodegradable 
under a redox condition by cleaving the diselenide crosslinker, -SeSe-.  
5.3.2 Cytosol responsive DOX release and biodegradation of PSeSeD 
The drug delivery carrier is ideally designed to release drugs selectively in intracellular target 
sites to enhance therapeutic efficacy and to reduce pre-leakage during blood circulation for 
reducing side effects.  DOX and PEI800 were crosslinked by a diselenide crosslinker (-SeSe-) 
to form cationic PSeSeD which can interact with miR-21i and Apt by electrostatic interaction, 
and cleavage of redox-sensitive -SeSe- is able to release DOX and miR-21i/Apt. PSeSeD was 
incubated in a mimicking cellular microenvironment at pH 7.4 with 0 M, 10 µM, and 20 mM 
GSH, representing a physiological condition, an extracellular microenvironment, and a cytosol 
environment. Figure 5.1A displays a significant amount of loaded DOX is controllably released 
from PSeSeD at 20 mM GSH with 28.6 ± 1.3 % over 12 h and 55.7 ± 1.8 % over 144 h, whereas 
only 18% of DOX release at both 0 and 10 µM of GSH over 144 h. These data strongly support 
the release profiles are regulated by GSH, i.e., intensive cleavage of -SeSe- at cytosol condition 
but much less cleavage at a physiological or extracellular environment.  
Cytosol GSH-responsive cleavage of -SeSe- is also demonstrated in the biodegradability 
experiments (Figure 5.1B). The PSeSeD hydrodynamic size of 218.7 ± 13.4 nm reduces to 
150.3 ± 7.1 nm over 6 h exposing to 20 mM GSH, and further down to 2.08 ± 0.08 nm over 5 
days, whereas exposing to 0 µM GSH or 10 µM GSH, PSeSeD slightly decreases in size over 
first 6 h and then remains at 180.1 ± 7.4 nm and 131.7 ± 5.4 nm over 5 days. Therefore, PSeSeD 
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keeps its integral structure during the delivery course in a physiological condition and an 
extracellular environment but degrades into small fragments in the cytosol environment. 
 






(C)                                  (D)                                                 (E) 
                                                                                                                              
Figure 5.1 (A) DOX releasing profiles from PSeSeD at pH 7.4 and different concentrations of 
GSH over 144 h (n = 4). (B) Hydrodynamic size distributions of PSeSeD at pH 7.4 and various 
GSH concentrations (n = 4). Gene of miR-21i and Apt loading assay via agarose gel 
electrophoresis for (C) PSeSeD at N/P ratios of 1, 2, 4, 6 and 8 with naked gene as a control, 
and (D) PEI25kDa (P25k) at N/P ratios (0.5, 1, 2 and 3) and PEI800Da (P800) at N/P ratios (4, 
6, 8 and 10) as the references. (E) Gene of miR-21i and Apt releasing profiles of the 
PSeSeD/miR-21i/Apt (N/P 10) after incubation with 20 mM GSH at pH 7.4 for 72 h. 
 
5.3.3 miR-21i and Apt loading (PSeSeD/miR-21i/Apt) and release 
PSeSeD with a zeta potential of 58.3 ± 1.4 mV and its stability in the physiological condition 
may be a great candidate as a gene delivery vector to electrostatically interact with miR-21i 
and Apt. The miR-21i and Apt loading capability of PSeSeD was evaluated via agarose gel 
(0.8 %) electrophoresis and compared to that of PEI25k and PEI800. In Figure 5.1C, PSeSeD 
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is able to achieve full loading of miR-21i and Apt at an N/P of 6.0 to form the PSeSeD/miR-
21i/Apt polyplexes. The miR-21i and Apt loading capacity of PSeSeD is lower than that of 
PEI25k with full retardation of gene at an N/P ratio of 2.0, but far higher than that of PEI800 
with no retardation even at an N/P of over 10.0 in Figure 5.1D.  
The hypothesis on zeta potential dependent gene loading capacity of microgels was further 
confirmed in the other synthesized microgels. Gene of miR-21i and Apt is completely loaded 
to PSeSeD2X (a higher concentration of DOX than PSeSeD) with zeta potential of 31.5 ± 4.5 
mV at 10.0 N/P (Figure 5.S8A), whereas PSeSeDBHQ with a slightly higher zeta potential 
(39.3 ± 5.9 mV) than PSeSeD2X shows full loading at an N/P of 8.0 (Figure 5.S8B). In addition, 
PSeSe with the highest zeta potential (68.3 ± 0.7 mV) among synthesized microgels presents 
an outstanding loading capacity at an N/P of 3.0 (Figure 5.S8C). These results demonstrate the 
gene loading capacity of microgels by electrostatic interaction is directly proportional to the 
zeta potential of the microgels and the amount of gene is manipulatable through tuning the zeta 
potentials of delivery vectors. 
Release of miR-21i and Apt from PSeSeD/miR-21i/Apt polyplexes was evaluated via the 
agarose gel retardation after 72 h incubation in the mimicking cytosol condition of pH 7.4 and 
20 mM GSH. In Figure 5.1E, the gene band of PSeSeD/miR-21i/Apt polyplexes with full 
retardation at 10.0 N/P moves in the presence of GSH, indicating miR-21i and Apt releases in 
the mimicking cytosol. Reduction of diselenide crosslinkers in the mimicking cytosol allows 
PSeSeD microgels to be converted to Degrade-P with size of 3.7 ± 1.9 nm and zeta potential 
of 0.96 ± 3.9 mV (Table 5.S1), weakening electrostatic interaction with miR-21i and Apt to 
release them. Therefore, the smart nanomedicine of PSeSeD/miR-21i/Apt with effective 
loading and selective release of DOX, miR-21i and Apt being triggered by intracellular cytosol 
is achieved. 
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5.3.4 HA surface coating to produce PSeSeD/miR-21i/Apt/HA 
Drug conjugated or gene-complexed therapeutic products are often accumulated in tumor site 
by the enhanced permeability and retention (EPR) effect. Prolonging their systemic circulation 
may increase the accumulation efficiency in tumor site, and reduce undesired distribution in 
other organs as well as systemic toxicity. Drug or gene delivery products to prolong blood 
circulation are often designed to be in a size range of 10 to 200 nm to avoid renal and 
reticuloendothelial system (RES) clearance and have negative surface charges to prevent 
protein serum adsorption [32, 44]. In this study, anionic hyaluronic acid (HA) was coated on 
the cationic surface of PSeSeD/miR-21i/Apt at a weight ratio of HA to PSeSeD of 1.5 by 
electrostatic interaction to produce the PSeSeD/miR-21i/Apt/HA. Successful HA surface 
coating is confirmed by zeta potential measurement, i.e., the zeta potential of 58.3 ± 1.4 mV 
for PSeSeD; 51.3 ± 2.5 mV after miR-21i and Apt loading and -30.2 ± 0.23 mV after HA 
coating (Figure 5.S7). The negative charged nanomedicines after HA coating have been 
demonstrated to minimize protein adsorption during circulation (Chapter 3), and the 
hydrodynamic size of PSeSeD/miR-21i/Apt/HA was measured to be 140.9 ± 18.4 nm, falling 
into the range for EPR effect.  
5.3.5 Cellular uptake of PSeSeD/FAM-miR/Apt/HA and release of therapeutic agents 
5.3.5.1 Cellular uptake of PSeSeD/FAM-miR/Apt/HA 
Monitoring drug-conjugated and gene-complexed therapeutic products during administration 
provides great insights into intracellular transportation and mechanisms in a qualitative and 
quantitative manner. PSeSeD/miR-21i/Apt/HA possesses DOX fluorescence at 580 nm. On the 
other hand, FAM-miR was used instead of miR-21i to prepare the PSeSeD/FAM-miR/Apt/HA 
with fluorescence at 530 nm. The intracellular transportation of PSeSeD/FAM-miR/HA with 
two fluorescent emissions can be traced under a confocal laser scanning microscopy (CLSM) 
and a flow cytometer. HA coating is also operated to allow metastatic cancer cells uptake via 
  Chapter 5 
191 
 
HA receptor mediated endocytosis,  but the HA receptors of CD44 and RHAMM are not 
present on the surface of non-invasive cancer cells and normal cells [45]. All metastatic breast 
cancer MDA-MB-231 cell membrane was stained with CellMaskTM Deep Red. While only red 
color MDA-MB-231 cells without PSeSeD/FAM-miR/HA is seen in Figure 5.2A, green 
(FAM-miR), blue (DOX), and red (MDA-MB-231 cells) are overlapped to produce a pink color 
in the merged images in Figure 5.2B, indicating successful cellular uptake of PSeSeD/FAM-
miR/HA. To confirm whether HA receptor mediate endocytosis is the dominant pathway for 
cellular entry of PSeSeD/FAM-miR/HA, HA pretreated MDA-MB-231 cells by blocking all 
surface HA receptors prepared via incubation cells with HA for 24 h were exposed to 
PSeSeD/FAM-miR/HA. In Figure 5.2C, weak green and blue signals are seen to overlap with 
red color in HA pretreated cells. Therefore, PSeSeD/FAM-miR/Apt/HA is endocytosed via HA 
receptor mediation to selectively enter to metastatic cancer cells. 
Cellular uptake of PSeSeD/FAM-miR/HA to metastatic cancer cells was quantitatively traced 
via a flow cytometer. In Figure 5.2D, control cells without PSeSeD/FAM-miR/HA displays 
FAM (0.29%) and DOX (0.86%) fluorescence intensity, similar to background. After 4 h 
incubation of cells with PSeSeD/FAM-miR/HA, 99.53 and 100 % of cells have displayed 
bright fluorescence of FAM and DOX than the control, indicating cells have uptaken 
PSeSeD/FAM-miR/HA (Figure 5.2E). Such quantitative information demonstrates traceability 
of PSeSeD/FAM-miR/Apt/HA and is consistent with the qualitative CLSM results of HA 
receptor-mediated endocytosis. 
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Figure 5.2 Tracing cell intake of PSeSeD/FAM-miR/HA via CLSM imaging of (A) MDA-
MB-231 cells without PSeSeD/FAM-miR/HA (scale bar 20 µm), (B) MDA-MB-231 cells with 
PSeSeD/FAM-miR/HA (scale bar 15 µm), (C) HA pre-treated MDA-MB-231 cells with 
PSeSeD/FAM-miR/HA (scale bar 10 µm). Cellular uptake tracing via flow cytometer of (D) 
MDA-MB-231 cells without PSeSeD/FAM-miR/HA as a control and (E) MDA-MB-231 cells 
with PSeSeD/FAM-miR/HA. (F) Tracing DOX release from PSeSeDBHQ/FAM-miR/HA to 
MDA-MB-231 cells via flow cytometer over 4 and 12 h, (MDA-MB-231 cells without 
PSeSeDBHQ/FAM-miR/HA as a control). 




5.3.5.2 Release of DOX and FAM-miR 
Therapeutic agents exert their therapeutic effects in different intracellular locations after entry 
into cells. Identification of location of released drugs from delivery carriers allows rational 
design of the carrier for targeting release of drugs at specific organelles. To trace the released 
of DOX and FAM-miR from PSeSeD/FAM-miR/HA, PSeSeD was replaced by PSeSeDBHQ 
to quench the intrinsic fluorescence from DOX and FAM-miR due to the distance between 
BHQ (quencher) and DOX and/or FAM-miR (donor) within 10 nm [42]. After intracellular 
release of DOX and FAM-miR from PSeSeDBHQ /FAM-miR/HA, DOX and FAM-miR are 
far from BHQ conjugated delivery carriers so that their fluorescence can be detectable. The 
fluorescence signals from DOX and FAM-miR were quantified at a pre-determined time via a 
flow cytometer. In Figure 5.2F, control of MDA-MB-231 cells without PSeSeDBHQ /FAM-
miR/HA has a background intensity with 0.02 and 0.01 % of DOX and FAM-miR fluorescence 
signals. After cells were incubated with PSeSeDBHQ/FAM-miR/HA for 4 h, the percentage 
of cells with fluorescence from DOX and FAM-miR slightly increased to 0.13 and 0.06 % and 
further to 10.5 and 10.3 % over 12 h of incubation. Comparing to the cellular uptake of 
PSeSeD/FAM-miR/HA with 100 and 99.53 % of DOX and FAM-miR over 4 h incubation 
(Figure 5.2E), DOX and FAM-miR are gradually released from PSeSeDBHQ/FAM-miR/HA 
and traced since being away from the delivery carriers.  
5.3.6 Cytotoxicity of PSeSeD/miR-21i/Apt/HA with normal cells 
Inherent toxicity of drug delivery carriers to normal cells often hinders their clinical application. 
Ideal drug carrier should be biocompatible with normal cells before loading therapeutic agents. 
Often designed carriers with high molecular weight to increase systemic circulation time 
should be decomposed to fragments with size less than 10 nm for renal clearance to avoid its 
buildup in body. These fragments should be biocompatible to prevent damage to the kidney 
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during the clearance. In the absence of DOX, human kidney cell viability assays of PSeSe and 
Degrade-P (debris of PSeSe) were executed on HEK293T cells with PEI25k and PEI800 as 
negative and positive control. In Figure 5.3A, PEI25k shows its strong cytotoxicity with a 
significant drop in cell survival rate from 94.4 ± 4.6 % at a PEI25k concentration of 1.0 µg mL-
1 to less than half at a concentration of 50 µg mL-1. However, low molecular PEI800 displays 
excellent biocompatibility with a survival rate of 86.5 ± 5.01 % at a concentration of 50 µg mL-
1. For PSeSe and Degrade-P, HEK293T cells have exceptionally high survival rates of 95.0 ± 
1.4 % and 99.1 ± 3.8 % up to their concentrations of 50 µg mL-1, indicating their outstanding 
biocompatibility with insignificant inherent toxicity before and after degradation.  
In addition to the ideal drug carrier before loading therapeutics, the delivery carrier after 
loading the therapeutics should be non-toxic to normal cells. Delivery systems of PSeSeD/miR-
21i/Apt/HA was incubated with HEK293T cells for 48 h to evaluate its side effect to normal 
cells with free-DOX as a reference. After treatment with PSeSeD/miR-21i/Apt/HA, HEK293T 
cells exhibit a high survival rate of 99.2 ± 2.4 % at a DOX concentration of 2.5 µg mL-1, 
whereas free-DOX as a negative control, shows its severe cytotoxicity with more than half of 
HEK293T cell death at a DOX concentration of 0.5 µg mL-1 (Figure 5.3B). In PSeSeD/miR-
21i/Apt/HA, DOX releasing is highly dependent on the GSH concentration in the cytosol 
(Figure 5.1A) and the GSH concentration in HEK293T cells is not high enough to cleave the 
diselenide crosslinker for releasing DOX, as the GSH concentration in normal cells is normally 
2.8 folds lower than that in cancer cells [46, 47].  
Besides, HA surface coating may impede cellular uptake of PSeSeD/miR-21i/Apt/HA to 
HEK293T cells. To confirm the effect of HA surface coating on the HEK293T cell survivals, 
PSeSeD and HA surface coated PSeSeD/HA were in vitro evaluated. The cell survival rate of 
96.8 ± 2.1 % is found for HEK 293T cells after exposure to PSeSeD/HA, higher than that of 
89.4 ± 1.3 % for PSeSeD at an equivalent DOX concentration of 50 µg mL-1 (Figure 5.3B). 
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This demonstrates the effects of HA surface coating reduces cellular uptake to HEK293T with 
lack of HA receptors. Therefore, minimal side effects of PSeSeD/miR-21i/Apt/HA to healthy 
cells are an outstanding impact of our nanomedicines. 
(A)                                 (B)                                 (C) 
 
Figure 5.3 (A) Cell viability assays of  PEI25k as negative control, PEI800 as positive control, 
PSeSe and Degrade-P on HEK293T cells after administration for 48 h (n = 4). (B) Cell viability 
assays of PSeSeD/miR-21i/Apt/HA on HEK293T after 48 h administration (n = 8) with free-
DOX as negative control. (C) Anticancer effects of PSeSeD/miR-21i/Apt/HA on MDA-MB-
231 after 48 h administration (n = 12) 
 
5.3.7 Therapeutic effect of PSeSeD/miR-21i/Apt/HA on metastatic breast cancer cells  
The synergistic therapeutic function of PSeSeD/miR-21i/Apt/HA was evaluated on a 
metastatic breast cancer cell line, MDA-MB-231, via the cell viability assay after 48 h 
incubation. The cell viability after treatment with PSeSeD/HA, PSeSeD/miR-21i/HA and 
PSeSeD/Apt/HA was also measured to compare with that of PSeSeD/miR-21i/Apt/HA. The 
cell survival rate after treatment with free-DOX, as a native control, and all four PSeSe derived 
nanomedicines displays a decreasing pattern as DOX concentration increases from 0.1 to 2.5 
µg mL-1. However, the degree of such decreases varies, and a significant drop in cell survival 
rate after PSeSeD/HA is incorporated with miR-21i and Apt indicates the synergistic effects 
(Figure 5.3C). PSeSeD/HA without miR-21i compared to free-DOX shows slightly lower 
performance. That is, at a DOX concentration of 2.5 µg mL-1, the cell survival rate is 57.9 ± 
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4.2 % for PSeSeD/HA and 50.5 ± 3.8 % for free-DOX. Lower than a half amount of the loaded 
DOX released from PSeSeD/HA over 48 h (Figure 5.1A) to cytosol may be less than the 
amount of free-DOX localized within the cells. For the PSeSeD/miR-21i/HA, the anticancer 
effect is enhanced with a drop in the survival rate to 36.6 ± 4.0% at the same DOX 
concentration of 2.5 µg mL-1. Blocking the miR-21 activity by miR-21i can upregulate PDCD4 
which activates apoptosis [48]. To isolate ATP by Apt, the PSeSeD/Apt/HA also shows good 
anticancer effect with a cell survival rate of 35.3 ± 4.1 %. ATP depletion by Apt can activate 
adenosine monophosphate-activated protein kinase (AMPK) which leads to cancer cell cycle 
arrest via p27 and apoptosis via p53 [49]. The anticancer synergy effect is amplified when 
DOX is delivered together with miR-21i and Apt via PSeSeD/miR-21i/Apt/HA with a 
minimum cell survival rate of 29.1 ± 4.7 % at a DOX concentration of 2.5 µg mL-1.  
5.3.8 Effect of ATP on therapeutic effects on multidrug resistant cancer cells  
5.3.8.1 DOX resistance of MDA-MB-231-R 
Multidrug resistance of cancer cells enables exporting DOX from intracellular to extracellular 
environment using ABC transporters with consumption of ATP. Delivery of Apt into cancer 
cells allows inactivation of the ABC transporters by depletion of ATP with Apt. PSeSeD/miR-
21i/Apt/HA was designed to enhance the anticancer effect on cancer cells with multidrug 
resistance. We cultured MDA-MB-231 cells in the presence of DOX for 12 weeks to produce 
the drug-resistance MDA-MB-231 cells (MDA-MB-231-R). DOX resistance of MDA-MB-
231-R was evaluated via the cell viability assay at DOX concentrations from 0.1 to 2.5 µg mL-
1 in every four weeks for 12 weeks, and indicated 4 weeks (4 W), 8 weeks (8 W), and 12 weeks 
(12 W) with DOX-sensitive MDA-MB-231 (0 W) as a control. In Figure 5.4A, the survival 
rate of cells displays an ascending pattern as increasing the incubation time from 0 to 12 W, 
while viable cells decrease as DOX concentration increases. Half of the MDA-MB-231 cells 
are viable at 0 W at a DOX concentration of 2.5 µg mL-1, the number of viable cells rises up to 
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two third at 8 W and further climbs to 70.7 ± 7.9 % at 12 W, confirming that cells become more 
resistant to DOX. The resistance of MDA-MB-231-R cells to DOX may be caused by 
upregulated expression of ABC transporters on the cell membrane due to an increasing efflux 
of DOX, supported by Saxena et al. via reverse transcription-polymerase chain reaction (RT-
PCR) and by Dordal et.al via kinetic analysis of DOX efflux by the exporters [11, 50]. In 
addition to upregulated expression of ABC transporters, DNA damage of the breast cancer cells 
by DOX induces NF-kB activation to upregulate oncogenic microRNA-21 expression which 
can helps the cancer cells avoiding DNA-damage-derived apoptosis by DOX, increasing DOX 
resistance to the cells [9]. 
5.3.8.2 ATP assay depending on Apt treatment  
ATP directly influences cancer cell survival and MDR via activation of AMPK and ABC 
transporters [49, 51]. To clarify ATP creation and depletion by MDR and Apt treatment, ATP 
in MDA-MB-231 (231-S) and MDA-MB-231-R (231-R) cells was quantified depending on 
Apt treatment with PSeSe/Apt/HA as Apt presence and PSeSe/HA as Apt absence.  
The ATP contents in these cells was determined using an ATP bioluminescent somatic cell 
assay kit and a fluorophotometer (ex. 350 nm wavelength) with a correlation of the intensity 
of luciferin fluorescence at 530 nm with the mole of ATP from a calibration curve (Figure 
5.S9). In the presence of ATP in the mixture of luciferin and luciferase, the intensity of luciferin 
fluorescence is decreased (Figure 5.S10) as ATP reacts with luciferin via luciferase to produce 
adenyl-luciferin and reduce the amount of luciferin associated with fluorescence [52]. In the 
absence of Apt, the ATP quantity of 0.418 ± 0.021 pmol in a 231-S cell increases to 0.555 ± 
0.019 pmol in a 231-R (Figure 5.4B), indicating that cells with MDR requires 33 % more ATP 
than cells without MDR, and the ATP may be consumed for ABC transporters. On the other 
hand, 231-R after Apt treatment display ATP depletion by more than 36 % to an ATP amount 
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of 0.353 ± 0.027 pmol per cell (Figure 5.4B). Therefore, the Apt treatment from PSeSe/Apt/HA 
depletes ATP inside cells. 



















Figure 5.4 (A) Cell viability assay of DOX with diverse concentrations on multidrug-resistant 
MDA-MB-231-R cells with various culturing periods of 4 weeks (4 W), 8 weeks (8 W) and 12 
weeks (12 W), and DOX-sensitive MDA-MB-231 cells (0 W) as a control (n = 4), (B) APT 
content assays on DOX-sensitive MDA-MB-231 (231-S) cells, DOX-resistant MDA-MB-231-
R (231-R) cells and those cells with ATP aptamer treatment (231-S/Apt and 231-R/Apt), via a 
spectrofluorophotometer, (n = 3). Tracing MDA-MB-231-R cell localization of DOX released 
from (C) PSeSeDBHQ/HA for 24 h (scale bar 30 µm), (D) PSeSeDBHQ/HA for 48 h (scale 
bar 20 µm), (E) PSeSeDBHQ/Apt/HA for 24 h (scale bar 50 µm), (F) PSeSeDBHQ/Apt/HA 
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for 48 h (scale bar 20 µm). Colors of red, cyan, blue and overlaps in the low from 1 to 4 of 
CLSM images are cell membrane, cell nucleus, DOX and the merged. 
 
5.3.8.3 Apt effects on MDA-MB-231-R via tracing DOX intracellular localization 
To confirm whether delivery of Apt into cancer cells affects the ABC transporters of MDA-
MB-231-R cells, intracellular localization of DOX released from PSeSeDBHQ/Apt/HA (in the 
presence of Apt) and PSeSeDBHQ/HA (in the absence of Apt) were traced via detecting 
fluorescence of DOX (blue), membrane (red) and nucleus (cyan) under a CLSM after 
incubation of cells with two therapeutics for 24 and 48 h. As loaded DOX is quenched by BHQ 
of both therapeutics (Figure 5.2F), a blue color appearing in the images is associated with 
released DOX from the therapeutics. In the absence of Apt, a strong blue color is located 
between red and cyan in Figure 5.4C at 24 h after incubation of cells with PSeSeDBHQ/HA, 
indicating DOX is released intracellularly into cytosol. However, the blue color becomes dim 
in cells after 24-h incubation in Figure 5.4D, which may be due to expulsion of intracellularly 
localized DOX into an extracellular environment via ABC transporters. However, in the 
presence of Apt, strong blue color overlaps red and cyan colors in both Figures 5.4E and 5.4F 
for 24 and 48 h incubation, indicating DOX is localized inside nuclei and sustainably released 
from PSeSeDBHQ/Apt/HA for 48 h. Therefore, MDA-MB-231-R cells consumes more ATP 
for activation of ABC transporters to expel intracellularly localized DOX to an extracellular 
environment, however, Apt treatment by PSeSeDBHQ/Apt/HA depletes ATP in the multidrug 
resistant cells and inhibits the DOX exporters, thereby enhancing localization of DOX in nuclei 
to trigger DNA damage and apoptosis.  
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5.3.9 Therapeutic synergy on multidrug resistance cancer cells by PSeSeD/miR-
21i/Apt/HA 
PSeSeD/miR-21i/Apt/HA was designed to maximize therapeutic effects on multidrug resistant 
cancer cells. The therapeutic efficacy of PSeSeD/miR-21i/Apt/HA was evaluated by the cell 
viability of MDA-MB-231-R at DOX concentrations from 0.1 to 2.5 µg mL-1 in comparison 
with free-DOX, PSeSeD/HA, PSeSeD/Apt/HA, and PSeSeD/miR-21i/HA.  
Figure 5.5A shows the survival rate of MDA-MB-231-R cells has a descending trend as 
increasing DOX concentration for all samples. The anticancer effect of DOX-incorporated 
therapeutic products on the cells with MDR outweighs that of free-DOX for the entire DOX 
concentrations investigated. The cell survival rate of more than 70 % treated by free-DOX at a 
DOX concentration of 2.5 µg mL-1 is decreased by around 30 % to 41.5 ± 6.8 % after treatment 
with PSeSeD/HA. DOX sustainably released from PSeSeD/HA in cytosol is expelled by ABC 
transporters in the transmembrane of multidrug resistant cells [11], while the amount of DOX 
from PSeSeD/HA may be far lower than that from free-DOX which is permeated in the cells 
through their transmembrane. More DOX from PSeSeD/HA remains in cells than free-DOX, 
leading to a higher anticancer effect on the cells.  
Comparing to PSeSeD/HA, PSeSeD/Apt/HA, co-delivery of Apt with DOX, has an improved 
therapeutic efficacy with two-third of the cell death at a DOX concentration of 2.5 µg mL-1. 
Apt depletes ATP in the MDA-MB-231-R (Figure 5.4B), inhibiting ABC transporters to expel 
the released DOX from inside of the cells, and thereby prolonging intracellular localization of 
the released DOX (Figure 5.4F). In addition, ATP depletion can induce the cell cycle arrest 
and apoptosis by upregulating AMPK [49]. Beside, treatment with MDA-MB-231-R cells with 
PSeSeD/miR-21i/HA, co-delivery of miR-21i with DOX, significantly reduces the amount of 
viable multidrug resistant cells to 20.6 ± 3.2 % at a DOX concentration of 2.5 µg mL-1. 
Inhibition of miR-21 activity by miR-21i from PSeSeD/miR-21i/HA may re-sensitize the 
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cancer cells with MDR to DOX with upregulation of PTEN and activate apoptosis with 
upregulation of PDCD4 [18, 53, 54].  










Figure 5.5 Cell viability assay on anticancer effects of free-DOX, PSeSeD/HA, 
PSeSeD/Apt/HA, PSeSeD/miR-21i/HA and PSeSeD/miR-21i/Apt/HA on multidrug resistant 
MDA-MB-231-R cells with (A) the cell survival rate to DOX loaded concentrations (n = 12) 
and (B) DOX concentration for one half cell death, IC50 value. 
 
The most effective therapeutic treatment on MDA-MB-231-R cells is achieved by 
administration of DOX, miR-21i, and Apt using PSeSeD/miR-21i/Apt/HA, as 8.9 ± 2.6 % of 
the cell survival is detected at a DOX concentration of 2.5 µg mL-1. The DOX concentration at 
which one half of MDA-MB-231-R cells are viable, IC50, is 4.93 µg mL
-1 for free-DOX and it 
remarkably reduces to 1.17 µg mL-1 for PSeSeD/miR-21i/Apt/HA (Figure 5.5B). 
PSeSeD/miR-21i/Apt/HA displays its therapeutic effects on the cancer cells with MDR 4.2-
times higher than free-DOX, which means the dose of DOX from PSeSeD/miR-21i/Apt/HA 
required to achieve the identical anti-cancer effect 4.2-folds less than that from free-DOX. The 
IC50 values of PSeSeD/Apt/HA and PSeSeD/miR-21i/HA (co-delivery of DOX with Apt or 
miR-21i) and PSeSeD/HA (mono-delivery of DOX) are 1.1 to 1.6 times higher than that of 
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PSeSeD/miR-21i/Apt/HA. Therefore, administration of PSeSeD/miR-21i/Apt/HA enhances 
the therapeutic efficacy of DOX on multidrug resistant cancer cells than nanomedicines with 
mono-drug or co-drug. PSeSeD/miR-21i/Apt/HA with significantly improved anticancer 
effects on both DOX sensitive and resistant cells has great promise in therapeutic applications 
to patients with a multidrug resistant cancer. 
 
5.4 Conclusion 
We have successfully demonstrated a nanomedicine for tri-delivery of DOX, miR-21i, and Apt 
with significantly improved anticancer effect on metastatic cancer cells with multidrug 
resistance but minimized side effects. The nanomedicine was produced via crosslinking 
PEI800 and DOX by diselenide crosslinkers, electrostatically interacting with miR-21i and Apt, 
and finally surface coating with HA. Great biocompatibility of the nanomedicine is achieved 
from benign PEI800 PSeSeD microgels and their degraded-products, as well as minimal 
leakage during blood circulation due to its stability in the physiological environment and 
reduced accumulation in normal cells due to HA coating. Its therapeutic efficacy of the 
nanomedicine on multidrug resistant cancer cells is realized through structure features with 
negative charges and a size of 140 nm for reduced systemic clearance and the EPR effect in 
the tumor site, HA receptor-mediated endocytosis for accurate target on cancer cells, inhibition 
of miR-21 by miR-21i for re-sensitizing the multidrug resistant cells to DOX, inactivation of 
ABC transporters via depleting ATP by Apt, and control release of DOX intracellularly due to 
its specific response to intracellular tumor microenvironment. This nanomedicine will be 
explored for its therapeutic application in eradicating multidrug resistant cancer cells in the 
animal model as well as patients. 
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Table 5.S1 Characterizations of synthesized microgels of PSeSeD, PSeSeD2X, PSeSeDBHQ, 
















PSeSeD 218.7 ± 13.4 58.3 ± 1.4 488.0 9.35 6 
PSeSeD2X 136.8 ± 24.3 31.5 ± 4.5 482.0 16.5 10 
PSeSeDBHQ 249.6 ± 18.3 39.3 ± 5.9 541.5 N/A 8 
PSeSe 260.0 ± 22.9 68.3 ± 0.68 N/A N/A 3 





























Figure 5.S2 FTIR spectra of PEI800, synthesized microgels of PSeSe and PSeSeD  













Figure 5.S4 Absorbance spectra of PSeSeD and PSeSeDBHQ from 400 to 800 nm wavelength, 
and their aqueous solution colors. 
 




Figure 5.S5 Hydrodynamic size profiles of PSeSe microgels in pH 7.4 and 20 mM GSH over 








(A)                                                        (B) 
 
Figure 5.S6 Amine content assays via conductivity and pH titration of (A) PSeSeD microgels 
(2.5 mg) and (B) PSeSe microgels (2.4 mg) 




Figure 5.S7 Zeta potentials of PSeSeD, PSeSeD/miR-21i/Apt (N/P 10) and PSeSeD/miR-
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Figure 5.S8 miR-21i and Apt loading assay via agarose gel electrophoresis for (A) PSeSeD2X 
at N/P ratios from 1 to 10, (B) PSeSeDBHQ at N/P ratios (1, 2, 4, 6 and 8) with PEI25k at N/P 
1 as positive control, (C) PSeSe microgels at N/P ratios (1, 2 and 3). Naked gene (miR-21i) in 
the left-end lane as a control. 




Figure 5.S9 Calibration curve of fluorescence intensity of luciferin (ex. 350 and em. 530 nm 








Figure 5.S10 Fluorescence spectra of luciferin with/without ATP in presence of luciferase, 
measuring a spectrofluorophotometer with excitation at 350 nm wavelength. 
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Doxorubicin (DOX) chemotherapy can actively suppress cancers, but simultaneously develop 
multidrug resistance (MDR) by upregulating miRNA-21 and DOX exporters, causing serious 
dose-dependent side-effects. Herein, we introduce a fully degradable microgel-based 
nanomedicine with the ability of initial releasing miRNA-21 inhibitor (miR-21i) to multidrug-
resistant cancer cells and sequential DOX release to these re-sensitized cells for enhancing 
therapeutic efficiency. Glutathione (GSH)-cleavable polyethyleneimine (PEI) microgel 
carriers were prepared, DOX was loaded to the carriers via a caspase-3-cleavable DEVDC 
peptide linker through click chemistry, miR-21i was then loaded through electrostatic 
interaction with PEI moieties, and finally hyaluronic acid (HA) surface coating was applied to 
promote HA receptor-mediated endocytosis to target cancer cells. The diselenide crosslinker 
of PEI microgel carriers can be cleaved in GSH-concentrated cytosol to release miR-21i, 
followed by miR-21 inhibition, MDR reverse, caspase-3 activation, DEVDC cleavage and 
cysteine-tailed DOX release. The intracellular microenvironment triggered sequential release 
profiles can be visually traced using the black hole quencher2 (BHQ2)-labeled microgels 
together with fluorescence quenching technique. Such a system minimizes DOX efflux to 
healthy cells and achieves 7.3-folds higher anticancer efficiency to cancer cells than free DOX. 
Obviously, our reported nanomedicines enable sequential release of miR-21i and DOX to 
multidrug resistant cells with maximal anticancer efficacy and minimal side-effects. 
 
Keywords: sequential release, DEVDC, caspase-3, DOX, miR-21 inhibitor, multidrug 
resistance, co-delivery 
  




Doxorubicin as an anthracycline is one of the most effective anticancer chemo-drugs with two 
apoptotic pathways of topoisomerase II (Topo II) intercalation and reactive oxygen species 
(ROS) production [1, 2]. On the one hand, DNA replication damage by the isolation of the 
Topo II activates a tumor suppressor nuclear p53, which initiates apoptotic signaling pathway 
via upregulating Bcl-2-associated X protein (Bax), releasing cytochrome c from mitochondria, 
activating caspase-9 and caspase-3 and generating apoptosis [1, 3]. The DNA damage can 
activate inhibitors in the apoptotic pathway. One of the inhibitors is B-cell lymphoma 2 (Bcl-
2) that represses Bax activation in mitochondria [2]. In addition, the phosphoinositide 3-kinase 
(PI3K) pathway, including protein kinase B (Akt) and mammalian target of rapamycin (mTOR) 
(PI3K/Akt/mTOR), promotes tumor progression and survivals [4]. Moreover, nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) expresses its downstream gene of 
microRNA-21 (miR-21) as an inhibitor of phosphatase and tensin homolog (PTEN), which 
restricts the PI3K pathway [5, 6]. At the same time, oxidative stress by the induction of the 
ROS from DOX triggers tumor necrosis factor alpha (TNFα)-induced apoptotic pathway via 
activating caspase-8 and caspase-3 [3]. However, the external apoptotic pathway executes N-
terminal phosphorylation of Jun (JNK) signaling pathway including c-Jun [7]. JNK/c-Jun 
pathway promotes cell survivals by expressing vascular endothelial growth factor (VEGF) for 
angiogenesis and executing epithelial to mesenchymal transition (EMT) for metastasis [8, 9]. 
In addition, JNK/c-Jun pathway downregulates p53 for inhibition of mitochondrial apoptosis 
[10]. The oxidative stress upregulates NF-κB and VEGF-related signal transducer and activator 
of transcription 3 (STAT3) for overexpression of miR-21, which inhibits programmed cell 
death 4 (PDCD4), as an inhibitor of the JNK/c-Jun pathway [2, 9, 11]. Taken together, 
administration of DOX for anticancer chemotherapy leads to apoptosis by activating caspase-
3, but simultaneously enhances resistance to the chemotherapy by overexpressing miR-21. 
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Such simultaneous resistance of cancer cells to chemotherapeutic agents is referred to as 
multidrug resistance (MDR) [12]. MDR includes inhibition of apoptosis by miR-21 
upregulation, ROS detoxification by GSH cytosol level enhancement and reduction of 
intracellular DOX accumulation by a hydrophobic drug exporter of ATP-binding cassette 
(ABC) transporter overexpression [13-15]. MDR requires high dose of DOX for high efficacy, 
which directly induces dose-dependent side effects, such as cardiotoxicity, nephrotoxicity and 
hepatotoxicity, due to higher cellular uptake of free DOX by normal cells than tumors [16-21]. 
To overcome MDR and significant side effects, co-drug therapy with DOX and miRNA-21 
inhibitor (miR-21i) is required for selective and secure delivery to target cancer cells.  
Co-delivery carriers for DOX and supplementary gene drugs, including pDNA, siRNA and 
miRNA, have been developed with diverse mechanisms of DOX loading and release, while a 
fixed method of electrostatic interaction of anionic genes with cationic polymer moieties in the 
systems. Physical adsorption has been utilized to load DOX to co-delivery carriers, such as 
polymer micelles, polymeric core-shell nanoparticles, hyaluronic acid (HA)-chitosan 
nanoparticles and polymer modified mesoporous silica nanoparticles, while expressing less 
controlled releasing of DOX [22-25]. For better controlled release, DOX has been conjugated 
to polyethyleneimine 25 kDa (PEI25k) via acidic-cleavable hydrazone bond, and gene drugs 
electrostatically interacted with PEI25k [26, 27]. The formed polyplexes were additionally 
assembled with polyethylene glycol (PEG) and active target ligands (e.g., folate or Asn-Gly-
Arg (NGR) peptide) to prevent serum adsorption and deliver selectively to cancer cells. 
However, these polyplexes are therapeutically less effective than free DOX without showing 
clear release mechanism of genes from PEI25k. Polymer-based gene vectors have conventional 
issues of cytotoxicity and accumulation in patient body due to their strong positive charge and 
non-degradability although the properties allow effective polyplex formation, durable structure 
in systemic circulation and active endosomal-escape [28]. To achieve the merits of polymer-
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based vectors and eliminate their weakness, our team has introduced fully biodegradable 
microgels by crosslinking low molecular weight of PEI800 with cytosol level glutathione 
(GSH)-cleavable diselenide crosslinkers (Chapters 3, 4 and 5). DOX conjugation to the PEI 
microgels via hydrazone or/and diselenide bonds enables selective release into 
endosome/lysosome or cytosol of cancer cells regardless of releasing sequence of DOX and 
miR-21i. Ren et al. employed an external stimulus of near infrared-pulsed (NIR) laser to release 
DOX at predetermined time, and found that sequential release of DOX following miR-21i 
amplifies anticancer performance than simultaneous release [29].  
In this study, we developed an intracellular microenvironment-triggered system with the ability 
of sequential release of miR-21i and DOX using fully biodegradable microgels as co-delivery 
carriers to aim remarkably efficient and effective therapeutic performance in targeting 
multidrug resistant cells with negligible side effects to healthy cells. DOX was covalently 
bonded to cysteine through an alkyne-ended peptide linker containing caspase-3-cleavable 
DEVDC moiety for copper-catalyzed azide-alkyne cycloaddition with azide-conjugated 
microgels consisting of PEI800 and GSH-cleavable diselenide crosslinkers (Scheme 6.1A), and 
miR-21i and HA were electrostatically interacted with the microgel carriers. Suppression of 
DOX release in the absence of caspase-3 and HA surface coating for selective delivery to target 
cancer cells via HA receptor-mediated endocytosis give rise to negligible side effect to healthy 
cells. BHQ2-labeled co-delivery system (Scheme 6.1B) can be used to confirm the sequential 












Scheme 6.1 (A) Scheme on the synthesis of PSeDEVDCD as a co-delivery carrier of DOX and 
miR-21i and the release of cysteine-DOX in the presence of caspase-3, (B) Scheme on the 
synthesis of PSeBHQDEVDCD as a traceable co-delivery carrier before and after releasing 
cysteine-DOX, where DOX fluorescence is quenched before release and is recovered after 
release.   
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The co-delivery system can be fully degraded by cleavage of diselenide crosslinkers in 
multidrug-resistant cancer cytosol level GSH and release loaded miR-21i, followed by 
inhibiting miR-21 and reversing MDR (Scheme 6.2). For the re-sensitized cells, part of DOX 
can be released by ROS-triggered caspase-3, followed by an accelerated burst DOX release via 
nucleus p53-induced caspase-3 after cleaving DEVDC moieties in the peptides. As a result, 
remarkable anticancer effect over simultaneous co-drug release and free DOX are achieved, 
and the reported sequential release system should have great potentials as effective anticancer 
nanomedicines in therapeutically complicated applications.  
 
Scheme 6.2 Schematic representation of PSeDEVDCD/miR-21i/HA as effective 
nanomedicines for intracellular sequential release of miR-21i being triggered by the cytosol 
GSH of MDR cells and DOX release to re-sensitized MDR cells with activated caspase-3. 
MDR cell is reversed to re-sensitized cells through the inhibition of miR-21 by miR-21i.  
 





Branched polyethylenimine Mw 800 (PEI800), 1-ethyl-3-(3-dimethyl-laminopropyl) 
carbodiimide (EDC) and N-hydroxysulfosuccinimide (NHS) were purchased from Sigma-
Aldrich. Doxorubicin hydrochloride (DOX) was obtained from Wuhan Wang Lianshang 
Biotechnology. (5-Hexynoic acid)-K(Dde)SGSGDEVDC Mw 1254.27 and (5-Hexynoic acid)-
K(BHQ2)SGSGDEVDC Mw 1593.58 were synthesized in ChinaPeptides. Azidobutyric acid 
NHS ester (N3-NHS) was provided from Lumiprobe. N-Succinimidyl-6-maleimidohexanoate 
(EMCS) was purchased from Tokyo Chemical Industry. MicroRNA-21 inhibitor (sequence 5’-
GUCCACUCUUGUCCUCAAUG-3’) (miR-21i) and FAM-labelled miRNA inhibitor single 
stranded negative control (sequence 5’-CAGUACUUUUGUGUAGUACAA-3’) (FAM-miR) 
were prepared by Shanghai GenePharma. Sodium Hyaluronate Mw 60k (HA) was purchased 
from Lifecore Biomedical. L-glutathione reduced (GSH), human caspase-3 enzyme, 
triethylenetetramine technical grade (Trien), 1,4-dithiothreitol (DTT), 4-(2-
hydroxyethyl)piperazine-1-ethanesulfonic acid (HEPES), ethylenediaminetetraacetic acid 
(EDTA), 3-[(3-Cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS) hydrate, 
glycerol, tetrakis(acetonitrile)copper(I) hexafluorophosphate ((Cu(CH3CN)4)PF6), 2,5-
dihydroxybenzoic (gentisic) acid, Leibovitz’s Medium (L-15), and cell counting Kit-8 (CCK-
8) were all purchased from Sigma-Aldrich. Dulbecco modified eagle medium (DMEM), fetal 
bovine serum (FBS), penicillin-streptomycin (PS), trypsin-EDTA 0.25%, and CellMaskTM 
Deep Red Plasma membrane stain were obtained from Life Technologies. HEK293T and 
MDA-MB-231 cell lines were kindly gifted by Professor Andrew Zannettino from South 
Australia Health and Medical Research Institute (SAHMRI) and Dr. Qian Tang from School 
of Pharmacy at University of South Australia. Deionised water was obtained from a Milli-Q 
water purification system (18.2 MΩ·cm. Spectra/Por®, Spectrum Laboratories, Inc.) 
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6.2.2 Synthesis of PSeDEVDCD complexes 
6.2.2.1 Synthesis of PSeN3 microgels 
Diselenide crosslinker of 3,3’-diselanediyldipropanoic acid (-SeSe-) and diselenide bond 
crosslinked PEI microgels (PSeSe) were prepared based on our previous study (Chapter 3). 
Dried -SeSe- (112.9 mg, 0.37 mmol) was dissolved in 0.8 mL of DMSO with NHS (170.9 mg, 
1.48 mmol) and EDC (427 mg, 2.23 mmol) under nitrogen protection and the mixture was 
stirred at room temperature for 45 min. PEI800 (297 mg, 0.37 mmol), after pH being adjusted 
to 8.0 by 3 M HCl and freeze dried, was dissolved in 0.6 mL DMSO and injected to the mixture 
for further 2 days stirring. The black color mixture was transferred to a dialysis tube with the 
MWCO of 7 kDa and dialyzed against deionized water for 1 week with daily changing water. 
After filtration and freeze drying, PSeSe microgels were produced.   
PSeSe (300 mg, 1488 µmol amine) dissolved in 4 mL of DMSO was mixed with N3-NHS (13.6 
mg, 60 µmol) and stirred under nitrogen protection at room temperature for 24 h. After dialysis 
and freeze drying, PSeN3 microgel was obtained, and characterized on its zeta potential and 
hydrodynamic size with a zeta sizer (Malvern Nano ZS ZEN 3600). Fourier-transform infrared 
spectroscopy (FTIR) was used to confirm azide conjugation. 
6.2.2.2 Synthesis of DEVDCDOX and BHQDEVDCDOX 
DOX was covalently bonded to alkyne-ended DEVDC peptide to produce the DEVDCDOX  
via a modified method from previous work [30]. DOX (75 mg, 129.31 µmol) dissolved in 5 
mL of dimethylformamide (DMF) was stirred with 50 µL of triethylamine (TEA) under 
darkness for 30 min. EMCS (31.7 mg, 103.45 µmol) was added to the mixture for further 2 h 
stirring under nitrogen protection at room temperature. The mixture was diluted in 10 volumes 
of dichloromethane (DCM) and filtered to remove precipitated DOX. The filtrate was diluted 
with 10 times in diethyl ether to precipitate the product of DOX-EMCS. 
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Dried DOX-EMCS was re-dissolved in 5 mL DMF with (5-hexynoic acid)-
K(Dde)SGSGDEVDC (59.7 mg, 86.2 µmol) and stirred at 4 °C under light protection for 16 h. 
The mixture was diluted in 10 volumes of DCM and kept at -20 °C for overnight. After 
centrifuge and 3 times washing with cold DCM, precipitates of alkyne-
K(Dde)SGSGDEVDCDOX (DEVDCDOX) were collected with the presence of alkyne and 
aromatic groups being confirmed from FTIR.  
DOX calibration curve was constructed via a UV-vis spectrophotometer by measuring 
absorbance at 479.5 nm against DOX concentrations (mg L-1). DEVDCDOX calibration curve 
was constructed with same method as the DOX calibration curve.  
For BHQDEVDCDOX preparation, DOX-EMCS (2.0 mg, 2.71 µmol) and (5-hexynoic acid)-
K(BHQ2)SGSGDEVDC (2.9 mg, 1.82 µmol) were dissolved in 2 mL of DMF and stirred at 
4 °C under darkness for 16 h. Black hole quencher2 (BHQ2)-labeled DEVDCDOX 
(BHQDEVDCDOX) was precipitated in cold DCM with centrifuge and obtained after 
washing.  
6.2.2.3 Click chemistry for PSeDEVDCD and PSeBHQDEVDCD 
Alkyne-ended peptides with DOX (DEVDCDOX and BHQDEVDCDOX) were covalently 
bonded to azide-conjugated microgels (PSeN3) via click reaction of azide-alkyne cycloaddition 
[31]. Cu(CH3CN)4PF6 (75 mg, 200 µmol) was dissolved in 2.5 mL of acetonitrile (CH3CN) in 
a three-necked flask at 60 °C under nitrogen protection with gentle stirring. DEVDCDOX (9.94 
mg, 5.0 µmol of alkyne) dissolved in the mixed solvent of 3 mL of DMSO and 0.5 mL of 
ethanol was instantly injected to the flask. At the same time, gentisic acid (250 mg, 2.0 mmol) 
in 12.5 mL of sodium phosphate buffer solution (100 mM, pH 7.0) with gentle heating and 
neutralization by 2 M NaOH, was injected to the flask. Then, PSeN3 (25.52 mg, 5.0 µmol of 
azide) dissolved in a solvent of 3 mL of DMSO and 0.5 mL of ethanol was added to the flask. 
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The mixture in the flask was stirred in an oil bath at 60 °C under nitrogen and light protection 
for 10 min and further stirred at room temperature overnight. The green-colored mixture in the 
flask was moved to a cool room at 4 °C for cooling down with gentle stirring under light 
protection. Trien after pH 7.0 adjustment by 6 volumes of 3 M HCl (1.05 mL, 1mmol) was 
injected to the flask and the darkish purple-colored mixture was ultrasonicated in an ice bath 
for 3 min with following overnight stirring at 4 °C under darkness. After filtration to remove 
copper precipitates, the darkish purple-colored mixture was transferred to a dialysis tube 
(MWCO 3.5 kDa) with another 1.05 ml of Trien at pH 7.0 inside the tube for dialysis against 
deionized water at 4 °C for 3 days with daily change of water. After filtration and lyophilization, 
DOX-conjugated microgels via DEVDC peptide linker (PSeDEVDCD) was produced. 
Successful synthesis of PSeDEVDCD was confirmed via FTIR and UV-Vis 
spectrophotometric measurement. Zeta potential and hydrodynamic size of PSeDEVDCD were 
measured via a zeta sizer. DOX loading to PSeDEVDCD (wt. %) was determined with DOX 
calibration curve (Figure 6.S2A) at 479.5 nm from a UV-vis spectrophotometer. Amine content 
in PSeDEVDCD (µmol mg-1) was measured via conductivity and pH titration (Figure 6.S6). 
To produce BHQ2-labeled complex of PSeBHQDEVDCD, BHQDEVDCDOX (11.64 mg, 5.0 
µmol of Alkyne) was fed instead of DEVDCDOX and the other methods were identical as the 
PSeDEVDCD production. 
6.2.3 Ex vivo release of DOX and miR-21i 
6.2.3.1 DOX releasing 
PSeDEVDCD complex in 1 mL deionized water (2 mg mL-1) was mixed with caspase-3 
enzyme (1µg, 0.031 nmol) in 1 mL of the caspase assay buffer (10 % (w/v) glycerol containing 
50 mM HEPES, pH 7.4, 100 mM NaCl, 10 mM DTT, 1 mM EDTA, and 0.1 % CHAPS). The 
mixture of PSeDEVDCD and 15.6 nM caspase-3 was transferred to a dialysis tube (MWCO 
3.5) and dialyzed against 13 mL of the caspase assay buffer in a horizontal shaker with a speed 
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of 100 rpm at room temperature over 48 h. 1 mL of the assay buffer was collected to measure 
absorbance at 479.5 nm via a UV-vis spectrophotometer at pre-determined time intervals and 
1 mL of the fresh buffer was refilled. The released DOX from PSeDEVDCD was quantified 
with a DOX calibration curve. Dialysis experiment of PSeDEVDCD aqueous solution mixing 
with 1 mL of the caspase assay buffer but without presence caspase-3 enzyme was chosen as a 
control.  
6.2.3.2 miR-21i loading  
PSeDEVDCD complex was incubated with miRNA-21 inhibitor (miR-21i) in RNase free 
(DEPC) water at room temperature for 20 min to form the PSeDEVDCD/miR-21i polyplex. 
The miR-21i loading capability of PSeDEVDCD was evaluated at various N/P molar ratios (1, 
2, 4, 6 and 8), nitrogen (N) in the complex (3.0 µmol mg-1) and phosphate (P) in 1 µL of miR-
21i (0.42 nmol µL-1), via agarose gel (0.8 %) retardation assay at 100 volts for 1 h. Naked miR-
21i and the polyplex of PEI25k and miR-21i at 1 N/P were used as negative and positive 
controls. The migrated gene images in the gel were fluorescent imaged under UV excitation 
and captured with a Gene-BOX.  
6.2.3.3 Biodegradability 
Biodegradability of PSeDEVDCD was ex vivo evaluated via measuring its hydrodynamic sizes 
in 50 mM HEPES buffer solution at pH 7.4 with various GSH concentrations of 0 M, 10 µM 
and 20 mM. The size changes of PSeDEVDCD in those solutions with stirring at 100 rpm and 
37 °C were monitored with dynamic light scattering (DLS) from a zeta sizer at pre-designed 
time over 120 h.  
6.2.3.4 miR-21i releasing 
Releasing of miR-21i from the PSeDEVDCD/miR-21i polyplex at 10 N/P was evaluated via 
agarose gel electrophoresis. The polyplex was incubated in HEPES buffer solution at pH 7.4 
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and 37 °C with 20 mM GSH for 72 h, and then run in an agarose gel (0.8 %) at 100 volts for 1 
h with following photographs in a Gene-BOX. Naked miR-21i and the polyplex at 10 N/P 
before incubation with GSH were run as negative and positive controls.   
6.2.4 HA receptor mediated endocytosis 
6.2.4.1 HA surface coating and characterizations 
Hyaluronic acid (HA) was coated on the surface of PSeDEVDCD/miR-21i polyplex (10 N/P) 
at 4 weights of HA to miR-21i in DEPC water at room temperature for 20 min, producing the 
PSeDEVDCD/miR-21i/HA nanomedicines. Zeta potential of PSeDEVDCD/miR-21i/HA in 
10 mM NaCl solution at pH 7.4 was measured via a zeta sizer. Hydrodynamic size of 
PSeDEVDCD/miR-21i/HA in HEPES buffer solution at pH 7.4 was obtained via DLS 
measurements. 
6.2.4.2 Cell culture  
Kidney cell line (HEK293T), breast cancer cell line (MDA-MB-231), and multidrug resistant 
breast cancer cell line (MDA-MB-231-R) were cultured in an incubator (Contherm Scientific) 
under 5 % CO2 and a moisturized environment at 37 °C with correspondent culture media. 
Mixture of Dulbecco modified eagle medium (DMEM), 10 (vol. %) of fetal bovine serum (FBS) 
and 1 (vol. %) of penicillin-streptomycin (PS) (DMEM-based medium) was consumed by 
HEK293T, while Leibovitz’s medium (L-15) supplemented with 10 % FBS and 1 % PS (L-15-
based medium) was used for MDA-MB-231. To culture the MDA-MB-231-R from MDA-MB-
231, DOX was incorporated in the L-15-based medium with stepwise increasing DOX 
concentrations (µg mL-1), such as 0.01 for the first 8 weeks, 0.02 for further 8 weeks, and 0.03 
for week 17th to 24th. DOX resistance to MDA-MB-231-R cells was evaluated with cell 
viability assay during the cell culture in 0 week (W), 4 W, 8 W, 12 W and 24 W against DOX 
concentrations from 0.1 to 2.5 (µg mL-1). MDA-MB-231-R cells in the certain week were 
recovered using trypsin-EDTA (0.25 %) in a 96-well plate for 24 h incubation with L-15-based 
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medium without DOX. Subsequently, varied concentrations of DOX were administrated to the 
cells with fresh L-15-based medium. After another incubation for 48 h, the cells with fresh 
DMEM-based medium were incubated in the presence of Cell Counting Kit-8 (CCK-8) for 
further 4 h. Absorbance from the well plate was read at 450 nm wavelength in a microplate 
reader (ELx808 BioTek) and cell survival rate (%) was calculated with following equation: 
𝐶𝑒𝑙𝑙 𝑠𝑢𝑟𝑣𝑖𝑣𝑎𝑙 𝑟𝑎𝑡𝑒 (%) =  
𝑆𝑎𝑚𝑝𝑙𝑒 − 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
𝐶𝑜𝑛𝑡𝑟𝑜𝑙 − 𝐵𝑎𝑐𝑘𝑔𝑟𝑜𝑢𝑛𝑑
 × 100                      (1) 
where sample, control and background indicate the absorbance from the well with toxicant-
incorporated cells, only cells, and neither cells nor toxicants respectively. 
6.2.4.3 Cellular uptake 
HA receptor-mediated endocytosis of PSeDEVDCD/miR-21i/HA into MDA-MB-231 cells 
was qualitatively monitored via a confocal laser scanning microscope (CLSM), Olympus 
FV3000. MDA-MB-231 cells were seeded on each glass cover slip in 3 wells of a 6-well plate. 
The cells in each well were incubated with L-15-based culture medium for 24 h, while the cells 
in one well were incubated with additional HA (10 mg mL-1) to block HA receptors. FAM-
labeled miRNA negative control with a random sequence (FAM-miR) was loaded to 
PSeDEVDCD at a 10 N/P, and 4 weights of HA to the FAM-miR were coated on the surface 
of polyplex to produce the PSeDEVDCD/FAM-miR/HA for cellular uptake assays. 
PSeDEVDCD/FAM-miR/HA was applied to two wells: one with MDA-MB-231 cells and the 
other with HA receptor-blocked MDA-MB-231 cells, and further incubated for 4 h. At the 
same time, MDA-MB-231 cells without PSeDEVDCD/FAM-miR/HA in the third well were 
used as a control. After staining cell membrane with CellMaskTM Deep Red for 5 min, fixing 
with formaldehyde (4 %) for 10 min, and washing 3 times with PBS, fluorescence from DOX, 
FAM-miR, and cell membrane in different wells was imaged with colors of blue, green and red 
via the CLSM.   
  Chapter 6 
231 
 
6.2.5 In vitro cell viability assays on normal and cancer cells 
6.2.5.1 Biocompatibility of PSeDEVDCD/miR-21i/HA on HEK293T cells 
Biocompatibility of the PSeDEVDCD/miR-21i/HA was evaluated via viability assays on a 
kidney cell line of HEK293T with CCK-8 treatment. HEK293T cells were seeded in a 96-well 
plate with DMEM-based medium for 24 h incubation. PSeDEVDCD/miR-21i/HA were 
prepared at various DOX concentrations, 0.1, 0.5, 1.0 and 2.5 (µg mL-1), at 10 N/P and 4 times 
of HA to miR-21i (w/w). With subsequent administration of PSeDEVDCD/miR-21i/HA to the 
HEK293T cells with fresh culture medium and incubation for 48 h, the cells were treated with 
CCK-8 for 4 h for absorbance reading at 450 nm via a microplate reader. HEK293T cell 
survival rates (%) against PSeDEVDCD/miR-21i/HA were obtained from Equation 1. 
PSeDEVDCD/HA and free DOX at equivalent DOX concentrations were chosen as references. 
6.2.5.2 Anticancer effect of PSeDEVDCD/miR-21i/HA on MDA-MB-231cancer cells  
Therapeutic effect of the PSeDEVDCD/miR-21i/HA on a model breast cancer cell line (MDA-
MB-231) was evaluated via viability assays together with CCK-8 treatment. The anticancer 
effects of PSeDEVDCD/miR-21i/HA (10 N/P, 4 weights of HA to miR-21i) with different 
concentrations of loaded DOX (0.1, 0.5, 1.0 and 2.5 (µg mL-1) were compared to 
PSeDEVDCD/HA and free DOX at equivalent DOX concentrations as references. Pre-cultured 
MDA-MB-231 cells in a 96-well plate with L-15-based medium for 24 h were further incubated 
with those delivery systems for 48 h.  After CCK-8 treatment for 4 h in DMEM-based medium, 
cell survival rates (%) were obtained via absorbance measurement at 450 nm from a microplate 
reader.  
6.2.6 In vitro trace of miR-21i and DOX sequential release  
To trace releasing patterns of miR-21i and DOX in a multidrug-resistant breast cancer cell line 
(MDA-MB-231-R), an equivalent amount of FAM-miR and miR-21i mixture was 
electrostatically interacted with PSeBHQDEVDCD instead of PSeDEVDCD at a 10 N/P. 4 
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weight of HA to the mixture of FAM-miR and miR-21i was further coated to prepare the 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA.  
The release profiles of quenched fluorescence from FAM-miR and DOX in the 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA were observed via the CLSM. 24 h pre-incubated 
MDA-MB-231-R cells in glass slips in a 6-well plate were further incubated with 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA for 4 h, 8h and 12 h. Fluorescent signals from 
FAM-miR, DOX and cell membrane were monitored via a CLSM after cell membrane being 
stained with CellMaskTM Deep Red and fixed with 4 % formaldehyde.  
Releasing of FAM-miR and DOX from the PSeBHQDEVDCD/FAM-miR/miR-21i/HA was 
further quantified via a flow cytometer (BD FACSCaliburTM). Pre-cultured MDA-MB-231-R 
cells in a 24-well plate for 24 h were further incubated with PSeBHQDEVDCD/FAM-
miR/miR-21i/HA for different time intervals of 4, 8, 12 and 24 h, and the cells without the 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA were used as a control. Cells in each well at the 
pre-determined incubation time were collected after trypsin-EDTA treatment, and the 
fluorescent intensity of DOX and FAM-miR being released from the 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA was quantified via a flow cytometer with FL-2 
(excitation at 488, emission at 585 nm) and FL-1 (excitation at 488, emission at 530 nm).  
6.2.7 Therapeutic effect of PSeDEVDCD/miR-21i/HA on multidrug-resistant MDA-MB-
231-R cancer cells  
Anticancer effect of sequentially releasable PSeDEVDCD/miR-21i/HA on a multidrug-
resistant cancer cell line (MDA-MB-231-R) was evaluated via cell viability assays with 
identical method as previous MDA-MB-231. Survival rates of MDA-MB-231-R cells against 
the PSeDEVDCD/miR-21i/HA were compared to PSeDEVDCD/HA and free DOX at the 
equivalent DOX concentrations (0.1, 0.5, 1.0 and 2.5 µg mL-1).  




6.3 Results and Discussion 
6.3.1 Synthesis of PSeDEVDCD 
PEI microgels by crosslinking PEI800 by GSH-cleavable diselenide crosslinkers were prepared 
to load DOX and miR-21i (Chapters 3, 4 and 5). The biocompatible PEI microgels are 
positively charged and be able to be smartly decomposed with intracellular microenvironment 
for effective miR-21i loading and release. However, our previous co-delivery systems, which 
simultaneously release miR-21i and DOX, motivate us the development of novel systems with 
intracellular microenvironment responsive sequential release of miR-21i and DOX to 
maximize therapeutic efficiency and efficacy to multidrug resistant cancer cells. To achieve 
sequential release of miR-21i and DOX, it is considered to conjugate DOX to PEI microgels 
via a peptide linker containing DEVDC that could be cleaved by caspase-3 enzyme of 
intracellular stimuli produced after the release of miR-21i (Scheme 6.1A). The activation of 
caspase-3 enzyme in apoptotic pathways can be inhibited under conditions of anti-apoptotic 
miR-21 overexpression [3]. However, mitigation of miR-21 activity by miR-21i can facilitate 
caspase-3 enzyme activation [32].  
6.3.1.1 PSeN3 microgel 
PEI microgels with azide groups (PSeN3) were synthesized to electrostatically interact with 
miR-21i and conjugate DOX via the cycloaddition with alkyne-ended caspase-3 enzyme-
cleavable DEVDC peptide linkers (Scheme 6.1A) for sequential release of miR-21i and DOX 
to multidrug-resistant cancer cells. After producing PEI microgel (PSeSe), azidobutyric acid 
NHS ester (N3-NHS) was introduced to the amine of PSeSe to produce PSeN3 microgels with 
a yield of 73.7 %. Successful synthesis of PSeN3 can be identified by shifts in zeta potentials 
and hydrodynamic sizes, which decrease from 68.3 ± 0.7 mV and 260.0 ± 1.9 nm of PSeSe 
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(Chapter 5) to 42.7 ± 1.6 mV (Figure 6.S7) and 242.5 ± 20.8 nm due to the consumption of 
primary amines of PEI. As further evidence for successful synthesis, FTIR peak of PSeN3 at 
2096 in Figure 6.S1 represents the N3 stretching.   
6.3.1.2 Pro-drugs of caspase-3 enzyme cleavable DEVDCDOX and BHQDEVDCDOX 
To produce DOX-bound pro-drug of DEVDCDOX, DOX was chemically bonded to the thiol 
group in cysteine of the peptides containing DEVDC using a linker of the EMCS containing 
NHS ester and maleimide ends. The use of cysteine, C, moiety in peptide to conjugate DOX is 
to protect the functions of amide and carboxylic acid groups in the DEVD moiety of the peptide 
linker as hydrolysis target sites by caspase-3. Also, the reason for using cysteine moiety in 
DOX conjugation is to release cysteine-tailed DOX through hydrolysis of DEVD moiety in the 
peptide (Scheme 6.1A). Cysteine-tailed DOX containing carboxylic acid can reduce the 
probability of export from cancer cells as it can minimize the affinity to hydrophobic sites of 
ABC transporters of a DOX exporter in multidrug resistant cells [15].  
FTIR spectrum (Figure 6.S1) confirms that the DEVDCDOX pro-drug is successfully 
produced with peaks at 3255, 3068, 984 and 621 cm-1, representing C≡C-H stretching, aromatic 
C-H stretching, O-H bending and C≡C-H bending. UV-vis spectrum of DEVDCDOX further 
reinforces the successful DOX integration due to the absorbance peaks at wavelengths of 292.0 
and 479.5 nm identical to DOX (Figure 6.S3A and 6.S3B). DOX ratio (wt.) of the 
DEVDCDOX pro-drug can be obtained via a UV-vis calibration curve of DOX (Figure 6.S2A) 
and DEVDCDOX adsorption (Figure 6.S2B) at 479.5 nm, indicating 25 wt. %.  
Since we use static fluorescence quenching technique to trace intracellular release of DOX, 
DOX was covalently bonded to BHQ2-labeled DEVDC peptide (BHQDEVDC) via an EMCS 
linker to produce the pro-drug of BHQDEVDCDOX containing the fluorophore of DOX and 
the quencher of BHQ2. BHQDEVDC with a broad band absorption from 500 to 600 nm (Figure 
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6.S4) can effectively quench the fluorescence of DOX emitted at 580 nm by forming the 
BHQDEVDCDOX as a ground-state non-fluorescent quencher-fluorophore complex. Ground-
state quencher-fluorophore complex formation can quench fluorescence intensity of 
fluorophore and can be confirmed by shifts in the absorption spectrum of the fluorophore by 
adding quencher [33]. The shift in UV-vis absorbance peak from DOX (479.5 nm) to 
BHQDEVDCDOX (536 nm) (Figure 6.S4) indicates that BHQDEVDCDOX pro-drug is a 
quencher-fluorophore complex with DOX fluorescence quenching function.  
6.3.1.3 Production of PSeDEVDCD and PSeBHQDEVDCD  
To react azide-containing PSeN3 microgels and alkyne end-capped DOX-containing pro-drug 
of DEVDCDOX, copper (I) catalyzed azide-alkyne cycloaddition was operated to produce the 
PSeDEVDCD (Scheme 6.1A). After the click chemistry reaction and dialysis against deionized 
water, the product solution with UV-vis absorbance peaks of 543.5 and 577.5 nm (Figure 
6.S3H) due to incomplete copper removal [34]. Triethylenetetramine (Trien) is used for copper 
(I) removal since it shows 108 times higher chelation capability with copper (I) than branched 
PEI [35]. After dialysis against deionized water, the color of mixture changes to orange 
associated with an UV-vis absorbance peak at 491.0 nm (Figure 6.S3O), which is well matched 
with DOX (Figure 6.S3A). Besides, successful production of PSeDEVDCD can be further 
confirmed by the FTIR peaks at 3068 and 984 cm-1 for aromatic C-H stretching and O-H 
bending (Figure 6.S1). In addition, zeta potential and hydrodynamic size of the PSeDEVDCD 
are changed to 30.9 ± 2.3 mV (Figure 6.S7) and 261.2 ± 24.8 nm compared to PSeN3 microgels 
by conjugating the DEVDCDOX pro-drug containing carboxylic group. From UV-vis 
measurement, the DOX loading in PSeDEVDCD is found to be 3.1 wt. %. 
At the same time, PSeBHQDEVDCD was also prepared to trace in vitro sequential release of 
FAM-miR and DOX. PSeBHQDEVDCD can be produced using similar azide-alkyne 
cycloaddition between PSeN3 and BHQDEVDCDOX (Scheme 6.1B). After azide-alkyne 
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reaction, the UV-vis absorbance peak of PSeBHQDEVDCD (544.5 nm) shifts from 
BHQDEVDCDOX pro-drug (536 nm) (Figure 6.S4) and also differs from DOX (479.5 nm). 
These indicate DOX fluorescence quenching in the PSeBHQDEVDCD is protected in the 
azide-alkyne reaction. 
6.3.2 Ex vivo releasing of DOX and miR-21i 
6.3.2.1 DOX releasing 
DOX was conjugated to the PSeN3 microgels via a caspase-3 cleavable peptide linker 
containing DEVDC. Active caspase-3 hydrolyzes the amide bonds between aspartic acid (D) 
and cysteine (C) of the peptide and release cysteine-DOX (Scheme 6.1A) [30]. To verify ex 
vivo DOX release in the presence of active caspase-3, PSeDEVDCD was mixed with 15.6 nM 
caspase-3 enzyme and dialyzed against the caspase assay buffer at pH 7.4 over 48 h, while that 
without caspase-3 was evaluated as a control. Figure 6.1A confirms the apoptotic enzyme-
driven controlled release of loaded DOX from PSeDEVDCD with 40.2 ± 2.2 % over 48 h in 
the presence of caspase-3, while 12.2 ± 0.87 % in the control. DOX releasing from the 
PSeDEVDCD is due to the cleavage of DEVDC moieties of the peptide linkers by caspase-3 
[36]. Caspase-3 can be activated by caspase-8 or caspase-9 in the condition of mitigation of 
apoptotic pathway inhibitors, such as microRNA-21 (miR-21), and can indiscriminately 
generate apoptosis [3]. Based on the ex vivo DOX releasing assessment, it can be inferred that 
PSeDEVDCD releases DOX to multidrug resistant cancer cells after activity of miR-21 is 
inhibited and MDR reverses.  
6.3.2.2 miR-21i loading 
The strategy to reverse the MDR is to impede the activity of miR-21 in cancer cells with its 
inhibitor miR-21i [37]. Therefore, it is important to co-deliver DOX and mi-21i together. The 
miR-21i loading capability to positively charged PSeDEVDCD by electrostatic interaction was 
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evaluated via agarose gel (0.8 %) retardation assays. At a N/P of 6 (Figure 6.1C), miR-21i can 
be fully loaded to the PSeDEVDCD.  
(A)                                                    (B)                                             
 







Figure 6.1 (A) DOX release from the PSeDEVDCD in the presence/absence of caspase-3 (n = 
3), (B) ex vivo degradation of PSeDEVDCD via hydrodynamic size measurement in HEPES 
buffer at pH 7.4 and 0 M GSH, 10 µM and 20 mM GSH (n = 3), (C) miR-21i loading to 
PSeDEVDCD at various N/P ratios (1, 2, 4, 6 and 8), PEI25k (P25k) N/P of 1 as a positive 
control and naked miR-21i as a negative control, (D) miR-21i release from the 
PSeDEVDCD/miR-21i at a 10 N/P in 20 mM GSH after 72 h incubation (right), 
PSeDEVDCD/miR-21i at a 10 N/P without GSH as positive control (middle) and naked miR-
21i as negative control (left). 
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6.3.2.3 Biodegradability and miR-21i releasing 
The loaded miR-21i in the PSeDEVDCD/miR-21i might be released in cancer cytosol due to 
the presence of high level GSH. GSH can degrade the PSeDEVDCD via cleaving diselenide 
crosslinkers, and these low charged PSeDEVDCD fragments cannot interact with miR-21i. The 
PSeDEVDCD biodegradation was ex vivo evaluated in a mimicking cancer cytosol (20 mM 
GSH) through size measurement and compared to imitated extracellular environment (10 µM 
GSH) and physiological state (0 M GSH) in an equivalent 50 mM HEPES buffer at pH 7.4  
(Figure 6.1B). In 20 mM GSH, the size of PSeDEVDCD at 261.2 ± 24.8 nm drops to 100 nm 
over 8 h, and further decreases to less than 10 nm over 72 h and 6.5 ± 1.2 nm over 120 h. 
However, the PSeDEVDCD show structural stability in 0 M and 10 µM GSH with slight size 
decreasing to 187.6 ± 2.7 and 170.8 ± 7.0 nm over 5 days. Such study not only strongly 
confirms the fully decomposition of PSeDEVDCD in mimicking cytosol condition for 
potential release of pre-loaded miR-21i, but also identifies the structural stability of 
PSeDEVDCD in simulated physiological and extracellular environment.  
To further verify the release of pre-loaded miR-21i in mimicking cytosol condition, the 
migration image of miR-21i from PSeDEVDCD/miR-21i (10 N/P) in the presence of 20 mM 
GSH for 72 h was monitored via agarose gel electrophoresis, while the PSeDEVDCD/miR-21i 
without GSH was run as a control. Figure 6.1D shows that the miR-21i in the 
PSeDEVDCD/miR-21i with full retardation at 10 N/P is stable in the absence of GSH, but 
migrates in the presence of GSH. That confirms the release of miR-21i in the simulated cancer 
cytosol condition. From ex vivo study, we can conclude that PSeDEVDCD can fully load miR-
21i at a 10 N/P and stably pass through mimicking physiological and extracellular environment 
conditions with limited pre-leakage of DOX and miR-21i. PSeDEVDCD/miR-21i can be 
degraded to small fragments in a mimicking cancer cytosol and release the pre-loaded miR-21i. 
As miR-21 consequently impairs the activity of intracellular caspase-3, the released miR-21i 
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can assist caspase-3 activation by inhibiting miR-21 [38]. The activated caspase-3 enzymes 
will then cleave the DEVDC moieties in the peptide linkers of PSeDEVDCD/miR-21i, and 
subsequently facilitate the release of the conjugated DOX. The reported PSeDEVDCD/miR-
21i with functions of sequential release of pre-loaded miR-21 and DOX can minimize DOX 
side-effects and increase therapeutic efficiency.  
6.3.3 HA receptor mediated endocytosis 
6.3.3.1 HA surface coating and characterization 
Positive charged PSeDEVDCD/miR-21i (zeta potential of 16.8 ± 1.5 mV in Figure 6.S7) trends 
to interact with serum proteins in the delivery course. To avoid serum protein adsorption, 
anionic hyaluronic acid (HA) was coated on the surface of PSeDEVDCD/miR-21i (10 N/P) 
via electrostatic interaction at a 4 weight ratio of HA to miR-21i to produce the 
PSeDEVDCD/miR-21i/HA. Zeta potential and hydrodynamic size of the PSeDEVDCD/miR-
21i/HA are -30.1 ± 1.9 mV (Figure 6.S7) and 190.5 ± 26.1 nm, and negative charged systems 
show negligible protein adsorption in our previous study (Chapter 3). In addition, the particle 
size of PSeDEVDCD/miR-21i/HA between 10 and 200 nm is ideal for enhanced tumor 
accumulation without renal and reticuloendothelial system clearance [39].  
6.3.3.2 HA receptor-mediated endocytosis 
HA coating on the surface of PSeDEVDCD/miR-21i also allows HA receptor-mediated 
endocytosis to metastatic cancer cells due to the over-expression of HA receptors, CD44 and 
RHAMM [40]. HA receptor-mediated endocytosis of PSeDEVDCD/miR-21i/HA to a 
metastatic cancer cell line of MDA-MB-231 was qualitatively evaluated via a CLSM. To 
monitor fluorescence of FAM-miR (green), DOX (blue), cell membrane (red) and merged 
images (purple) via CLSM, PSeDEVDCD/FAM-miR/HA was prepared and MDA-MB-231 
cells were stained. Control cells without PSeDEVDCD/FAM-miR/HA are shown in only red 
in Figure 6.2A, but MDA-MB-231 cells with PSeDEVDCD/FAM-miR/HA are displayed in 
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all four colors in Figure 6.2B to indicate excellent cellular uptake. To determine whether the 
pathway of PSeDEVDCD/FAM-miR/HA endocytosis to MDA-MB-231 is via HA receptors, 
the HA receptors on the surface of the MDA-MB-231 cells were first blocked before the 
cellular uptake evaluation. Figure 6.2C shows limited green and blue colors on the red of 
merged images, indicating that HA receptor-blocked MDA-MB-231 cells are impaired to 
uptake PSeDEVDCD/FAM-miR/HA. These results confirm PSeDEVDCD/FAM-miR/HA 














Figure 6.2 Cellular uptake images from a CLSM: (A) MDA-MB-231 cells without 
PSeDEVDCD/FAM-miR/HA (scale bar 30 µm), (B) MDA-MB-231 cells with 
PSeDEVDCD/FAM-miR/HA (scale bar 20 µm), (C) HA receptor-blocked MDA-MB-231 cells 
with PSeDEVDCD/FAM-miR/HA (scale bar 20 µm). The low from 1 to 4 are FAM-miR, cell 
membrane, DOX and the merged. 
 
Besides, HA receptors of CD44 and RHAMM are rarely expressed on normal cells [40]. Due 
to the lack of HA receptors of normal cells, in vitro cellular uptake evaluation confirms that 
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the HA coated PSeDEVDCD/FAM-miR/HA selectively enter metastatic cancer cells but not 
normal cells.  
6.3.4 In vitro cell viability assays on normal and DOX sensitive cancer cells 
6.3.4.1 Biocompatibility 
Key advantage of the PSeDEVDCD/miR-21i/HA is the function of targeting sequential release 
together with minimal side effects to healthy cells. To verify its low toxicity to normal cells, 
viability of human kidney cell line HEK293T in the presence of PSeDEVDCD/miR-21i/HA 
(10 N/P and 4 weights of HA to miR-21i) was in vitro evaluated at various loaded DOX 
concentrations from 0.1 to 2.5 µg mL-1. For comparison, HEK293T cell viability in the 
presence of PSeDEVDCD/HA and free DOX was also evaluated at the equivalent DOX 
concentrations. PSeDEVDCD/miR-21i/HA and PSeDEVDCD/HA show exceptionally high 
cell survival rates of 94.8 ± 1.9 and 99.6 ± 3.9 % at a DOX concentration of 2.5 µg mL-1, 
whereas free DOX as a negative control presents 35.5 ± 4.6 % of cell survival at the same DOX 
concentration (Figure 6.3A). The cell viability difference between free DOX and 
PSeDEVDCD/miR-21i/HA or PSeDEVDCD/HA is due to DOX accumulation in the 
HEK293T cells. By penetrating cell membrane, free DOX can accumulate enough to induce 
such severe apoptosis in HEK293T cells where anti-apoptotic gene of miR-21 is rarely 
expressed [41, 42]. However, HA surface coated PSeDEVDCD/miR-21i/HA and 
PSeDEVDCD/HA have negligible side-effects due to their ineffective HA receptor-mediated 
endocytosis to HEK293T cells where HA receptors are limitedly expressed [40]. In addition, 
DOX releasing from the delivery systems of PSeDEVDCD/miR-21i/HA and 
PSeDEVDCD/HA is suppressed in the absence of active caspase-3 enzyme (Figure 6.1A). 
Lack of ROS production or DNA damage in HEK293T cells by ineffective cellular uptake of 
PSeDEVDCD/miR-21i/HA and PSeDEVDCD/HA cannot trigger to activate caspase-3 and 
release DOX, resulting in such high survival rate of the cells.  
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(A)                                                   (B)                                             
 
Figure 6.3 Cell viability against free DOX, PSeDEVDCD/HA and PSeDEVDCD/miR-21i/HA 
(10 N/P) (A) HEK293T survival rates (n = 12) and (B) MDA-MB-231 survival rates (n = 8).  
 
6.3.4.2 Anticancer effect on DOX sensitive cancer cells 
Anticancer effect of the PSeDEVDCD/miR-21i/HA was evaluated via viability assay on a 
DOX sensitive metastatic breast cancer cell line (MDA-MB-231) after 48 h incubation at 
various loaded DOX concentrations from 0.1 to 2.5 µg mL-1. Cell viability assays of 
PSeDEVDCD/HA and free DOX were also in vitro conducted on MDA-MB-231 cells for 
comparison. Figure 6.3B shows descendent profiles of cell survival rates for all 
PSeDEVDCD/miR-21i/HA, PSeDEVDCD/HA and free DOX as increasing DOX 
concentrations. However, the anticancer efficacy of PSeDEVDCD/miR-21i/HA outweighs 
PSeDEVDCD/HA and free DOX. The cell survival rate for PSeDEVDCD/HA at a DOX 
concentration of 2.5 µg mL-1 is 61.4 ± 4.2 %, while that for free DOX is 50.5 ± 9.8 %. The 
lesser anticancer effect of PSeDEVDCD/HA than free DOX can be explained with the 
limitedly released DOX from the PSeDEVDCD/HA in the absence of caspase-3 (Figure 6.1A). 
Highly expressed in the metastatic cancer cells, miR-21 can suppress the release of DOX from 
the PSeDEVDCD/HA by down-regulating PTEN and inhibiting caspase-3 activation [3, 43]. 
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The PSeDEVDCD/miR-21i/HA show 35.3 ± 7.7 % cancer cell survival. The accompanying 
miR-21i can inhibit the activity of the apoptosis path suppressor miR-21 so that caspase-3 is 
activated to release DOX (Figure 6.1A) [3, 44]. In addition, the impeding miR-21 activity by 
miR-21i can upregulate PDCD4, as an inhibitor of JNK/c-Jun pathway, which protects p53 and 
accelerates apoptosis [9, 10]. Therefore, synergistic anticancer effects on the metastatic cancer 
cells is achieved by using PSeDEVDCD/miR-21i/HA.                                                            
6.3.5 MDR reverse-triggered sequential releasing 
6.3.5.1 Multidrug resistance of MDA-MB-231-R 
PSeDEVDCD/miR-21i/HA is prepared to sequentially deliver miR-21i and DOX to MDR 
metastatic cancer cells to enhance anticancer efficacy. For the evaluation of in vitro sequential 
releasing and therapeutic efficacy, MDA-MB-231 cells were cultured into multidrug resistant 
metastatic cancer cells of MDA-MB-231-R in the presence of DOX for 24 weeks. During the 
MDA-MB-231-R cell culture period at pre-determined time, 0, 4, 8, 12, and 24 weeks (W), the 
resistance of the cells to DOX was evaluated via cell viability assay at various free DOX 
concentrations from 0.1 to 2.5 µg mL-1. Figure 6.S8 shows ascending profiles of cell survival 
rate with prolonging culture time. The fact that initial cell survival of 50.4 ± 3.8 % at a DOX 
concentration of 2.5 µg mL-1 increases continuously to 77.3 ± 6.4 % after culturing over 24 W 
proves the successful incubation process of multidrug resistant cancer cell line, MDA-MB-
231-R. 
6.3.5.2 Tracing of sequential release of miR-21i and DOX in vitro 
The sequential release of miR-21i and DOX from PSeDEVDCD/miR-21i/HA has been ex vivo 
evaluated in pH 7.4 buffers under various caspase-3 and 20 mM GSH levels.  To verify the 
ability of PSeDEVDCD/miR-21i/HA to sequentially release miR-21i and DOX in order to 
maximize therapeutic efficiency and efficacy to multidrug resistant cancer cells, its 
intracellular release profiles should be tracked, where FAM-miR with its emission at 530 nm 
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is used together with miR-21i and DOX can emit fluorescence at 580 nm. As FAM-miR has 
the function of fluorescence but no miR-21 suppression, miR-21i is co-loaded to inhibit the 
activity of miR-21 for MDR reverse and caspase-3 activation. In addition,  the fluorescence of 
FAM-miR and DOX in PSeBHQDEVDCD is  quenched (Figure 6.S4) since the FAM-miR 
and DOX are close to the BHQ2 moiety within 10 nm [45]. After FAM-miR and DOX being 
released from the microgel carriers, their fluorescence will be visible.  
Prior to FAM-miR and DOX release, BHQ2 quenching the intrinsic fluorescence of FAM-miR 
and DOX is observed via a CLSM after incubating MDA-MB-231-R cells with 
PSeBHQDEVDCD/FAM-miR/HA for 4 h, where Figure 6.4A shows overlap of little green 
(FAM-miR) and no blue (DOX) in the merged image in contrast to the Figure 6.2B for cellular 
uptake of PSeDEVDCD/FAM-miR/HA. Although MDA-MB-231-R cells can uptake 
PSeBHQDEVDCD/FAM-miR/HA, quenching of DOX and FAM-miR makes them almost 
invisible via a CLSM. Besides, the intensity of green from FAM-miR monitored in Figure 6.4B 
for 8h incubation of MDA-MB-231-R cells with PSeBHQDEVDCD/FAM-miR/HA is further 
strengthened after incubating for 12 h (Figure 6.4C), where the blue color of DOX is also 
observed to confirm the sequential release of FAM-miR and DOX.  
At the same time, intracellular release of the FAM-miR (FL-1) and DOX (FL-2) from 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA to MDA-MB-231-R cells was further quantified 
via flow cytometer at different incubation intervals of 4, 8, 12, and 24 h. Figure 6.4D shows 
the fluorescence intensity in the sections of upper/left for FAM only, lower/right for DOX only 
and upper/right for FAM and DOX. The fluorescence intensity of 0.2 % for control MDA-MB-
231-R cells without delivery systems of PSeBHQDEVDCD/FAM-miR/miR-21i/HA in those 
sections displays 4.0, 3.1 and 2.9 % for the cells with the delivery system at incubation time of 
4 h. The fluorescence intensity for FAM only, DOX only and both FAM and DOX is further 
increased to 13.5, 4.0 and 9.7% over 24 h incubation. These indicate that the release of FAM-
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miR and DOX from their delivery system of PSeBHQDEVDCD/FAM-miR/miR-21i/HA are 
traced and continuously increased in volume.  
The fluorescence of FAM and DOX quenched by BHQ can be recovered after the FAM-miR 
and DOX are released from PSeBHQDEVDCD/FAM-miR/miR-21i/HA. Thus, the quantified 
fluorescence intensity of FAM and DOX through flow cytometer is expressed as the cumulative 
release of FAM-miR, miR-21i and DOX from PSeBHQDEVDCD/FAM-miR/miR-21i/HA 
over 24 h, at Figure 6.4E. The releasing amount of FAM-miR and miR-21i increases 
straightforwardly to 37.8 % over 12 h and further inclines to 45.6 % over 24 h. Such cumulative 
releasing profile of FAM-miR and miR-21i from PSeBHQDEVDCD/FAM-miR/miR-21i/HA 
can be explained when the PSeBHQDEVDCD is decomposed in GSH-intensive MDA-MB-
231-R cells and loses interaction with FAM-miR and miR-21i, as similar to Figure 6.1B and 
6.1D. Therefore, it is confirmed that FAM-miR and miR-21i are released as prolonging time 
of PSeBHQDEVDCD/FAM-miR/miR-21i/HA positioned in cancer cytosol. However, the 
cumulative release of DOX shows an unexpected profile to the ex vivo DOX releasing assay in 
0 M caspase-3 (Figure 6.1A). The cumulative release of DOX from PSeBHQDEVDCD/FAM-
miR/miR-21i/HA in MDA-MD-231-R cells increases moderately to 7.1 % over 8 h, but 
suddenly escalates to 10.8 % over 12 h and further to 13.3 % over 24 h (Figure 6.4E). The 
sudden increase in the speed of DOX release at the incubation time from 8 to 12 h is 
distinguished from the continuous decrease of DOX releasing speed over 24 h in Figure 6.1A. 
It can be inferred that the burst release of DOX from PSeBHQDEVDCD/FAM-miR/miR-
21i/HA in MDA-MD-231-R cells over 8 - 12 h is triggered by cleaving DEVDC moieties of 
the peptide linkers in the presence of an active caspase-3. Caspase-3 activation in multidrug 
resistant cells is hindered by overexpressed miR-21 as an inhibitor of apoptotic pathway [29].                                                                                         
 
 

























Figure 6.4 Tracing release of quenched FAM-miR and DOX from PSeBHQDEVDCD/FAM-
miR/miR-21i/HA to MDA-MB-231-R cells: (A) CLSM images after 4 h incubation (scale bar 
10 µm), (B) CLSM images after 8 h incubation (scale bar 30 µm), and (C) CLSM images after 
12 h incubation (scale bar 20 µm). The low from 1 to 4 are FAM-miR, cell membrane, DOX 
and the merged. (D) quantitative release via flow cytometer, MDA-MB-231-R without 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA as a control, and MDA-MB-231-R incubated with 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA for 4, 8, 12 and 24h (FL1 for FAM and FL2 for 
DOX), (E) graphic presentation of cumulative release of FAM-miR, miR-21i and DOX from 
PSeBHQDEVDCD/FAM-miR/miR-21i/HA to MDA-MB-231-R cells for 24 h incubation (n = 
3).  
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However, the steeply released miR-21i from PSeBHQDEVDCD/FAM-miR/miR-21i/HA over 
12 h can inhibit the activity of miR-21 to reverse MDR and activate caspase-3 for DOX burst 
release. Therefore, it is found that PSeBHQDEVDCD/FAM-miR/miR-21i/HA releases FAM-
miR and miR-21i first in GSH-enriched MDA-MB-231 cells, and intensively releases DOX 
sequentially in the presence of active caspase-3.  
6.3.6 Therapeutic effects on multidrug-resistant cancer cells 
Sequential releasing of miR-21i and DOX using PSeDEVDCD/miR-21i/HA is able to enhance 
therapeutic efficiency and efficacy to metastatic cancer cells with MDR. The anticancer effect 
was evaluated via viability assays to MDA-MB-231-R cells after incubation with 
PSeDEVDCD/miR-21i/HA, PSeDEVDCD/HA or free DOX with equivalent loaded DOX 
concentrations from 0.1 to 2.5 µg mL-1 for 48 h. Figure 6.5A shows a dose-dependent but 
remarkably different therapeutic effects of those systems to cells.  
Free DOX is ineffective to treat multidrug-resistant cancer cells since these multidrug resistant 
cells have self-defensive functions, such as overexpressed ABC transporters to reduce 
intracellular DOX accumulation, increased GSH levels to detoxify ROS from the remained 
DOX, and over-activated miR-21 to inhibit apoptosis [13, 14, 46]. The undermined anticancer 
performance of free DOX can be relatively enhanced by using the PSeDEVDCD/HA system 
with a cell survival rate of 45.8 ± 3.8 % at a loaded DOX concentration of 2.5 µg mL-1. The 
better therapeutic effect of the PSeDEVDCD/HA than free DOX can be due to its higher 
intracellular accumulation. HA surface coating of PSeDEVDCD/HA promotes selective 
endocytosis to MDA-MB-231-R cells through HA receptor mediation. Although DOX 
releasing from the PSeDEVDCD/HA in the absence of activated caspase-3 is limited (Figure 
6.1A), the amount of DOX from PSeDEVDCD/HA in cytoplasm is still larger than that of 
permeated free DOX crossover cell transmembrane, in which ABC transporters are installed 
[46, 47]. DOX loaded in the PSeDEVDCD can generate ROS via the quinone moieties of DOX 
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in a metabolic process of the cells [48]. The resulting ROS can initiate apoptosis signaling 
pathways that activate caspase-3 to release DOX from PSeDEVDCD/HA [1]. In addition, the 
released cysteine-DOX with carboxylic moiety that improves hydrophilicity than free DOX  
can reduce affinity with a pair of transmembrane domains (TMDs) of the ABC transporters, 
which hydrophobic materials can bind to [15]. Thus, the released cysteine-DOX from 
PSeDEVDCD/HA can accumulates in the cytoplasm rather than being exported out, leading to 
apoptosis in MDA-MB-231-R24w cells. However, the anticancer effect of PSeDEVDCD/HA 
on the multidrug resistant MDA-MB-231-R24w cells is moderately limited as DOX-induced 
oxidative stress activates apoptosis signals as well as anti-apoptotic factors of c-Jun and NF-
κB [2, 7]. The apoptotic inhibition of MDA-MB-231-R24w occurs by suppressing the pro-
apoptotic gene of p53 by c-Jun and expressing the anti-apoptotic gene of miR-21 by NF-κB [5, 
10].   
On the other hand, PSeDEVDCD/miR-21i/HA is more effective in killing cancer cells as 
evident from a low cell surviving of 1.6 ± 1.1 % at a DOX concentration of 2.5 µg mL-1. The 
released miR-21i from PSeDEVDCD/miR-21i/HA impedes miR-21, which targets tumor 
suppresser genes of PTEN and PDCD4 [37]. Upregulation of PTEN can downregulate PI3K, 
as an inhibitor of apoptotic pathway, and reverse MDR [44]. The reversing MDR allows to 
transmit successfully the apoptosis signals initiating from the DOX-induced oxidative stress to 
activate the caspase-3 [2]. The activated caspase-3 brings cell rupture and apoptotic body 
formation followed by cell death, as well as stimulating burst DOX-releasing to the re-
sensitized MDA-MB-231-R24w cells to accelerate apoptosis [2]. In addition, the upregulated 
PDCD4 can protect a DNA damage-induced tumor suppresser protein, p53, via downregulating 
oxidative stress-induced c-Jun, to successively signal to caspase-3 activation for the 
accelerating DOX release and apoptosis [10, 49]. Besides, the therapeutic efficacy of the 
PSeDEVDCD/miR-21i/HA to multidrug-resistant MDA-MB-231-R24w cells is even higher 
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than that to DOX-sensitive MDA-MB-231 cells (Figure 6.3B). As GSH is more enriched in 
multidrug-resistant cells than DOX-sensitive cells [14], more diselenide crosslinkers of 
PSeDEVDCD/miR-21i/HA can be cleaved in the GSH-intensive MDA-MB-231-R24w to 
release extra miR-21i (Figure 6.1B). The amount of miR-21i released from 
PSeDEVDCD/miR-21i/HA in the multidrug-resistant cells leads to better therapeutic efficacy 
to DOX-sensitive MDA-MB-231 cells, as well as to the other therapeutics of 
PSeDEVDCD/HA and free DOX.  






Figure 6.5 Viability of multidrug resistant cancer cells MDA-MB-231-R24w in the presence 
of free DOX, PSeDEVDCD/HA and PSeDEVDCD/miR/HA: (A) cell survival rate (n = 12) (B) 
IC50 values (n = 12). 
 
To easily compare therapeutic efficiency, DOX concentration for half cell death IC50 is 
depicted in Figure 6.5B, where PSeDEVDCD/miR-21i/HA requires 3 times lesser DOX than 
PSeDEVDCD/HA and 7.3 times lesser than free DOX for half cell death. . In addition, high 
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therapeutic efficiency can also be achieved by controlling DOX release time to minimize the 
amount of DOX that ABC transporter can expel. The PSeDEVDCD/miR-21i/HA release DOX 
at the most appropriate time when caspase-3 is activated and MDR is reversed for high 
therapeutic efficiency. The therapeutic efficiency for sequential releases of miR-21i and DOX 
from PSeDEVDCD/miR-21i/HA is compared with those simultaneous release of miR-21i and 
DOX in our previous studies and traditional therapeutic systems (Tables 6.S1 and 6.S2). Taking 
the IC50 value of free DOX as a reference, the relative IC50 values for sequential release of 
miR-21 and DOX to multidrug resistant cells represent notably higher than concurrent release 
and conventional therapeutic systems. That suggests the GSH and caspase-3-cleavable 
PSeDEVDCD/miR-21i/HA system for sequential releasing of miR-21i and DOX has a great 
potential in effective multidrug resistance cancer therapeutic applications. 
 
6.4 Conclusion 
A smart PSeDEVDCD/miR-21i/HA nanomedicine system with the ability of sequential release 
of miR-21i and DOX to multidrug resistant cancer cells was developed and evaluated to 
provide maximal therapeutic efficacy together with minimal side-effects. Biodegradable 
microgels of PSeN3 by crosslinking PEI800 with diselenide crosslinkers enable to release miR-
21i to cancer cytoplasm at a high GSH level. DOX is conjugated to the microgels through a 
DEVDC-containing peptide linker through azide-alkyne cycloaddition to control DOX release 
in the presence of active caspase-3. HA surface coating prevents serum protein adsorption and 
promotes HA receptor-mediated endocytosis to metastatic cancer cells. The intensive release 
of miR-21i to MDR cancer cells promotes the sequential DOX release of associated with the 
activation of caspase-3 and re-sensitizing MDR cancer cells. The PSeDEVDCD/miR-21i/HA 
is fully biodegradable in intracellular microenvironment of cancer cells and low toxic to normal 
cells. In vitro cell viability assays demonstrate the targeting sequential release of miR-21i and 
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DOX from PSeDEVDCD/miR-21i/HA, giving rise to high therapeutic efficacy and efficiency 
to multidrug resistant MDA-MB-231-R cells. The presence of this smart PSeDEVDCD/miR-
21i/HA nanomedicine system possesses a bright promise for the treatment of final stage cancers.   
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Table 6.S1 Comparison on the therapeutic efficiency of sequential and simultaneous release 
of miR-21i and DOX in various co-drug delivery systems via relative IC50 value of free DOX 
to co-delivery system on MDA-MB-231-R cells.  
Co-delivery 
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Table 6.S2 Comparison on the anticancer efficiency of various therapeutic systems via relative 
IC50 value of free DOX to therapeutic system on MDA-MB-231-R cells 
Therapeutic system Relative IC50                                Reference 
Free DOX 1 Control 
PSeDEVDCD/miR-21i/HA 7.3 This Chapter 
DOX/Ac-aCD NP 3.5 [1] 
ALN-MA-hyd-DOX 2.5 [2] 
LPNs-1 5.4 [3] 
DOX-S-S-PTX 6.7 [4] 
  




Figure 6.S1 FTIR spectra of diselenide crosslinked PEI microgels (PSeSe), azide group 
modified PEI microgels (PSeN3), DOX conjugated alkyne-ended peptide linker 
(DEVDCDOX), and DOX conjugated to microgels via DEVDC peptide linker (PSeDEVDCD) 
 
(A)                                                     (B)                                           
 
Figure 6.S2 UV-vis calibration curve of (A) DOX and (B) DEVDCDOX in aqueous solution 
at the wavelength of 479.5 nm and room temperature 
  








Figure 6.S3 UV-vis spectra and aqueous solution colors of (A) DOX·HCl, (B) DEVDCDOX, 
(C) PSeN3 microgels, (D) Triethylenetetramine (Trien), (E) mixture of Trien and DEVDCDOX, 
(F) mixture of Trien and PSeN3, (G) copper, (H) mixture of copper and PSeDEVDCD, (I) 
mixture of copper and Trien, (J) mixture of copper, Trien and DEVDCDOX, (K) mixture of 
copper, Trien and PSeN3, (L) mixture of copper, Trien and PSeDEVDCD, (M) gentisic acid, 








Figure 6.S4 UV-vis spectra of DOX·HCl, BHQ2 conjugated peptide (BHQDEVDC), DOX 
and BHQ2 conjugated peptide linker (BHQDEVDCDOX), and DOX and BHQ2 conjugated 















Figure 6.S5 Colors of the aqueous solutions of (A) PSeDEVDCD and (B) PSeBHQDEVDCD. 
(1) after copper catalyzed click reaction, (2) after adding Trien, and (3) after purification   
  
A1 A2 A3 
B1 B2 B3 













Figure 6.S7 Zeta potentials of PSeN3, PSeDEVDCD, PSeDEVDCD/miR-21i at a 10 N/P and 
PSeDEVDCD/miR-21i/HA with a 4-folds weight of HA to miR-21i (n = 3) 
  




Figure 6.S8 DOX resistance of various MDA-MB-231-R cells as evident from their cell 
viabilities against free DOX concentrations, where MDA-MB-231 cells were pre-cultured in 
DOX-incorporated culture medium for 0, 4, 8, 12 and 24 weeks to produce these MDA-MB-
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Chapter 7. Conclusion and Recommendation 
 
7.1 Conclusion 
The aim of this thesis is to develop novel multifunctional co-delivery systems of doxorubicin 
(DOX) and miRNA-21 inhibitor (miR-21i) to achieve both maximal anticancer performance 
and minimal side effects. Based on the understating of DOX as an active anticancer drug in the 
apoptotic signaling pathways, accompanied by serious multidrug resistance (MDR) and side 
effects, we developed a series of novel synergetic co-drug therapy protocols of DOX with miR-
21i on mitigation MDR by impeding the activity of miRNA-21 (miR-21) and investigated 
rational design of co-delivery systems to satisfy essentially required factors in the delivery 
course. Key conclusions are outlined below: 
Multifunctional PEI microgel-based co-delivery system (PSeHD/miR-21i/HA) was firstly 
prepared to meet all the essential factors in the delivery course in lieu of conflicts to achieve 
high anticancer effects and low side effects. The functions of PSeHD/miR-21i/HA include 
hydrazone for DOX conjugation and release in acidic cancer environment, diselenide 
crosslinking for microgel formation and degradation in reductant cytosol condition, size control 
from 161 nm for prolonged blood circulation to 10 nm for miR-21i release and complete 
urinary excretion, surface charge conversion from + 30 mV for miR-21i loading and HA 
coating to – 26.1 mV for the prevention of serum protein adsorption, HA surface coating for 
HA receptor-mediated endocytosis, positive charged PEI moieties for rapid endosomal escape, 
and DOX chemical conjugation for tracing the delivery course. This nano-drug system results 
in 4.4-fold higher anticancer effects on breast cancer cell line MDA-MB-231 than free DOX. 
It also demonstrates biocompatibility with kidney cell line HEK293T, as opposed to severe 
cytotoxic free DOX.   
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Biocompatible co-delivery systems was further developed by improving DOX loading by 
conjugation through a dual hydrazone and diselenide lock together with miR-21i and HA 
loading through electrostatic interaction (PSeHD-SeSeP/miR-21i/HA). The dual-lock for DOX 
conjugation fully suppresses premature leakage under physiological conditions and promotes 
intensive DOX release in reductant cytosol of cancer cells. The PSeHD-SeSeP/miR-21i/HA 
also demonstrates a remarkable biocompatibility with HEK293T cells and a 3.2-fold increase 
in anticancer effects on the MDR cell line of MDA-MB-231-R12w compared with free DOX. 
We further enhanced the anticancer effects on cancer cells with MDR together with real-time 
monitoring of DOX release by synthesizing traceable nanomedicines incorporated with DOX, 
miR-21i, HA, and ATP aptamer (Apt) (PSeSeD/miR-21i/Apt/HA). The microgels are 
synthesized in one pot with PEI800, DOX and diselenide crosslinkers to ensure microgel fully 
degraded and release all cargoes (DOX, miR-21i, and Apt) to cytosol. Apt administration in 
MDA-MB-231-R12w cells demonstrates ATP depletion, which hinders the role of ATP-
binding cassette (ABC) transporters in exporting DOX across the cell membrane. The use of 
BHQ2 quenching technology enables the visualization of DOX release profiles. As opposed to 
the lack of intracellular DOX accumulation in the absence of Apt, the amount of DOX in the 
nucleus of the cells is monitored in the presence of Apt. With the aid of ABC transporter 
inhibition, PSeSeD/miR-21i/Apt/HA demonstrates a 4.2-fold higher anticancer effect on 
MDA-MB-231-R12w compared with free DOX and minimal side effects on an HEK293T cells. 
Finally, we developed the strategy of sequential therapy of miR-21i and DOX by synthesizing 
intracellular stimuli-triggered co-delivery systems (PSeDEVDCD/miR-21i/HA) for maximal 
its anticancer effects. DOX conjugation to the systems via peptide linkers containing DEVDC 
moieties is cleaved by activated caspase-3 enzyme. miR-21i being loaded to the diselenide-
crosslinked PEI microgels will be initially released into the cytosol by reducing crosslinkers, 
and thus reverses MDR of cancer cells. The ROS production from DOX can stimulate apoptotic 
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pathways for the activation of caspase-3 that cleaves DEVDC moieties of the peptide linker 
and triggers a burst release of DOX in the re-sensitized cells. PSeDEVDCD/miR-21i/HA 
resultantly demonstrates a 7.3-fold increase in anticancer effects on multidrug-resistant breast 
cancer cell line MDA-MB-231-R24w compared with free DOX and minimal adverse side 
effects on HEK293T cells. 
In summary, combination therapy of DOX and sub-drugs (miR-21i or Apt) together with their 
sequential release protocol can effectively enhance therapeutic efficacy against multidrug-
resistant cancer cells via the MDR reversal by inhibiting miR-21 or ABC transporters. The 
advent of smart intercellular microenvironment responsive crosslinkers or linkers renders to 
achieve controlled release drugs together with decreasing cytotoxicity and premature release.   
On the other hand, targeting delivery through surface HA coating further improves therapeutic 
efficiency and circulate stability.  
 
7.2 Future directions 
In this thesis, a series of novel multifunctional microgel-based delivery systems with multi-
drugs of DOX, miR-21i and Apt have achieved DOX’s maximal anticancer effects and minimal 
side effects, contributing to advanced design. The following guidelines may be potential to 
explore in the future: 
Although the performance of the proposed co-delivery systems for anticancer effects and 
adverse side effects has been demonstrated in vitro, but furthermore, in vivo assessments of the 
delivery systems will provide more feasibility in clinical applications.  
The proposed co-delivery systems selectively targets metastatic cancer cells to induce 
apoptosis, but the cancer cells can spread through cancer vasculature to other organs and 
interfere with comprehensive chemotherapy. The use of extracellular tumor enzyme-cleavable 
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peptide linkers will facilitate the connecting of different types of carriers in one system to 
deliver multiple drugs to different cancer targets, such as solid cancer and cancer vasculature 
for integrated cancer treatment.  
 
 
 
